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Cleft lip, cleft palate or both are among the most common human
congenital malformations with a reported birth prevalence of around 1.5
per 1000 total births in Caucasian populations. In a minority of cases
chromosomal aberrations, single gene defects or environmental causes
can be identified, but for the majority multifactorial inheritance is
suspected although the number and nature of these genes is unknown.
Identification of the genes involved in craniofacial morphogenesis can be
achieved either directly by detection of stage- and site-specific
expression of candidate gene mRNA in the embryo or indirectly by
patient linkage or association studies.
In the first part of the study complete ascertainment of facial clefts born
in the West of Scotland between 1st January 1980 and 31st December
1984 was attempted. In ibis five year period 286 cases were identified
giving a birth prevalence of 1.53 per 1000 total births. Of these 17.8%
had cleft lip only, 51.4% had cleft palate only and 30.8% had both.
Of the 139 patients with cleft lip with or without cleft palate (CL(P)), the
lip defect was unilateral in 86/139 (61.9%), midline in 2/139 (1.4%) and
bilateral in 41/139 (29.5%), in the remaining 10 cases details of the lip
defect were not recorded. There was a statisically significant excess of
left- sided cleft lip (55/86) among the unilateral defects (x2=6.7 p<0.05).
There was a statistically significant excess of males in the CL(P) group,
with a maleifemale ratio of 1.84:1 (YM x2=8.36 p<0.01). 48/139
(34.5%) of the CL(P) group had congenital abnormalities associated with
the facial cleft, 5 of these 48 had a chromosomal aberration, 8/48 a single
gene defect, and 8/139 a recognisable malformation syndrome. In the
remaining 27 cases no specific aetiology was recognised.
In the cleft palate only group (CP) the maleifemale ratio was 0.81:1.




(57.7%) cases in this group had congenital anomalies associated with
their facial cleft. 8/86 had chromosomal anomalies, 12/86 had single
gene defects, 30/86 had recognised malformation defects and in 1/86
teratogen induced anomalies. In the remaining 35 cases no
specific aetiology was recognised.
Data from the present study are in broad agreement with previous studies
from Northern European populations. This study provides an unbiased
cohort of patients that can be used in future haplotype association studies
and to calculate empiric recurrence risks for use in counselling parents of
affected children. It also confirms the remarkable degree of clinical
heterogeneity within orofacial clefts group.
In the second part of the study was an attempt to identify the function of
a group of 'candidate' genes in normal palatogenesis. To this end the in
situ hybridisation technique was employed to study the role of
transforming growth factors type beta (TGFB) isoforms in murine
palatogenesis. Embryos from NIH/Parkes crossed mice were obtained at
the critical stages in development of the secondary palate (gestation day
(GD) 11.5, 12.5, 13.5, 14.0, 14.5 and 15.0) and hybridised with
35
S -labelled antisense riboprobes to TGFB1, 62 and B3 gene transcripts.
A differential expression pattern for all three of these growth factors was
established during palate development.
No specific pattern of hybridisation was found until GD 13.5 when
TGFB3 RNA was detected in the medial edge epithelia (MEE) of the
vertical palatal shelves and in the epithelia of the nasal septum that will
go on to fuse with the shelves. After elevation of the shelves TGFB3
expression continued to be specific to the MEE and could be detected in
the cells of the midline epithelial seam immeditely after fusion. The
TGFB3 hybridisation signal in MEE at this stage is the most easily visible
of any in the whole embryo, it is however almost completely absent from
the medial edge palatal mesenchyme. As the epithelial seam disrupts by
epithelial-mesenchymal transformation the specific pattern of TGFB3
expression is lost. TGF61 expression followed a similar pattern of
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expression to TGFB3 but was not detectable in the MEE until GD 14.0,
with an apparently much less abundant transcript. Specific hybridisation
of TGF81 was also lost with disruption of the epithelial seam. TGFB2
expression followed a different pattern first detectable in discrete areas of
hyperplasia in the oral epithelium of the vertical palatal shelves, these
probably represent the developing palatal rugae. With elevation of the
shelves TGF62 hybridises specifically to the medial edge palatal
mesenchyme. As fusion occurs expression is also seen in the
mesenchyme underlying the nasal epithelium. No hybridisation of
TGF82 is seen in the midline epithelial seam.
This pattern of site- and stage- specific hybridisation inferred an
important role for these isoforms in the normal processes of palatal
fusion. To test this hypothesis the experiments were repeated in retinoic
acid treated embryos that would develop cleft palate. Pregnant C57/B
mice were treated with either lOOmg/Kg or 200mg/Kg of all-trans
retinoic acid at 12.0gd or 14.0gd. Although the palatal shelves of all the
treated embryos were obviously hypoplastic and had delayed shelf
elevation there was no alteration in the expression patterns of TGFBl,
132 or 83.
Knowledge of the in vitro properties of the TGFBs and the RNA
localisation data argue an important role for TGFfil, 82 and 83 in
mammalian palatogenesis. It is however interesting that failure of fusion
can occur with apparently normal expression patterns. It seems likely
that these growth factors act via an alteration in the extracellular matrix
of the medial edge palatal mesenchyme thus providing a suitable
microenvironment for epithelial transformation and mesenchymal
migration. Although further work will be necessary to elucidate the role
of the TGFBs in palatogenesis this will be greatly helped by transgenic
techniques that offer ihe possibility of stage and site specific modulation
of gene action during morphogenetic processes. It must be hoped that by
understanding the molecular mechanisms involved in all developmental
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Cleft lip, cleft palate or both are among the most common congenital
malformations in man (de Wals & Lechat 1986) and although they are
generally considered treatable conditions, therapy often involves complex
surgical procedures carried out in specialist centres with the necessity of long
term follow-up by a multidisciplinary team. It would seem reasonable,
therefore, to describe these malformations as major congenital anomalies
(Czeizel & Tusnady 1984).
Most facial clefts are either cleft lip with or without cleft palate (CL(P)) or
isolated cleft palate (CP). In addition, however, there is a smaller group of
unusual facial clefts such as oblique and lateral facial clefts. These are much
rarer and, almost certainly, aetiologically distinct, this subgroup will
therefore not be discussed further (for review see Gorlin et al. 1990).
The two major subgroups of facial cleft malformations, CL(P) and CP, have
generally been considered as separate genetic and developmental entities
(Fogh-Andersen, 1942; Fraser, 1970; Gorlin et al. 1990). The basis of this
distinction has been from both embryological studies (see section 1.2.3) and
family recurrence data. Poul Fogh-Andersen (1942) was the first to
recognise these genetic differences in a study of a large number of Danish
families with one member or more affected with cleft lip, cleft palate or both.
He reported that siblings of patients with CL(P) have a higher incidence of
cleft lip (CL) and cleft lip and palate (CL+P) but not of CP and that this
homogeneity of defect recurrence also occurred in the siblings of CP patients.
Subsequent reports have confirmed these findings (Fujino et al. 1963;
Woolfe, 1971; Bonaiti et al. 1982; Czeizel & Tusnady 1984). Although
these data have been generally accepted, it is interesting to note that
exceptions exist to this recurrence phenomenon. Families with Van der
Woude syndrome, an autosomal dominant condition, can have both types of
facial cleft defect associated with lip pits, segregating with the gene (Woolf,
1971). Woolf (1971) has also shown a small but convincing increase in the
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incidence of CP occurring in the families of a large cohort of patients with
CL(P).
1.1.1 The epidemiology of facial clefts
Facial clefts are predominantly non-lethal malformations that are usually
obvious at birth or in early neonatal life with surgical treatment as the only
therapeutic option. These anomalies would, therefore, seem to present
investigators with few problems in the estimation of accurate birth
prevalence figures. This has prompted many CL(P) and CP birth prevalence
studies which have used either birth certificates (Woolf & Woolf, 1963;
Tenconi et al. 1988) or hospital records (Fogh-Andersen 1942; Bear 1976;
Bonaiti et al. 1982) as their main sources of ascertaining the affected
individuals. This single-source approach to ascertainment has, however,
been criticised on two accounts. Firstly, it has been estimated that in up to
one third of cases the presence of the facial cleft will not be recorded on birth
records or neonatal discharge forms (Shapiro, 1976). Secondly, Drillien et
al. (1966) have shown that up to 20% of infants with facial clefts will die
before operation or before the cleft is recognised. It must be assumed,
therefore, that using either of the above methods alone would lead to
significant under-ascertainment of facial cleft cases.
From published reports the average birth prevalence of facial clefting in
Caucasian populations is 1 per 1000 total births for CL(P) and 1 per 2000
total births for CP (for reviews see; Shapiro, 1976; Gorlin et al. 1990). Cleft
lip accounts for 20-30% of the whole group, cleft palate 30-45% and both
35-50% (Drillien et al. 1966). As more studies have been published,
significant racial differences in birth prevalence for all facial clefts have
become apparent, with a higher birth prevalence in peoples of oriental origin:
2.64 per 1000 total births in Japanese (Neel, 1958) and 3.17 per 1000 total
births in North American Indians (Tretsven, 1963) and a lower birth
prevalence in African Americans, at between 0.59-0.82 per 1000 total births
(Longnecker et al. 1965; Chung & Myrianthopoulos 1968). The majority of
these inter-racial variations in the facial clefts group are, however, accounted
for by differences in the CL(P) birth prevalence which range from 0.42 per
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1000 total births in African Americans, to 2.7 per 1000 total births in
Canadian Indians. Racial differences are not so apparent in the CP group
(Chung & Mirianthopoulus, 1968; Neel, 1958) with an incidence of 0.41 per
1000 total births in Black Americans(Chung & Myrianthopoulos, 1968), 0.44
per 1000 total births in Canadian Indians (Lowry & Renwick, 1969) and an
average birth prevalence of 0.5 per 1000 total births in European populations
(Shapiro, 1976).
Ching & Chung (1974) have shown that the racial differences in CL(P) birth
prevalence are likely to have a genetic basis. In an extensive study from
Hawaii, they have shown that Japanese immigrants continue to have
increased birth prevalence of CL(P) and by studying inter-racial crosses have
shown that Caucasian-Japanese matings have intermediate birth prevalence,
thus suggesting that the racial differences are independant of environment.
Support for this theory is provided by Leek (1972) who has shown that the
variation in the birth prevalence of CL(P) between different ethnic groups
living in the same areas is eight-times greater than that among
geographically scattered populations of the same ethnic origin.
The differences in sex ratios within the facial cleft groups have proven to be
more complicated, varying with severity of the cleft, the number of affected
sibling in a family and racial origin. In all studies of Caucasian populations
CL(P) occurs more frequently in males than females with an average male to
female ratio of 2:1 (Shapiro, 1976). In Japanese populations there is a
significant male excess in the cleft lip and palate group but not in the cleft lip
only group (Fujino et al. 1963). In Caucasians the male excess in
the CL(P) group becomes more apparent with increasing severity of cleft
(Fogh-Andersen, 1942) and less apparent when more than one sibling is
affected in the family (Niswander et al. 1972). In both races there would
appear to be a slight excess of affected females in the CP group (Fraser,
1970; Shapiro, 1976). In African Americans there is no overall significant
sex difference in either group (Shapiro, 1976), although isolated cleft lip
would appear to be more common in females (Green et al. 1964). No
generally accepted explanation for these gender differences exists, although
sex differences in the timing of critical developmental stages in craniofacial
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development are thought to have an as yet undefined role in their aetiology
(Burdi & Silvey, 1969)(see section 4.1).
The differences in laterality of the cleft lip group has also proved to be a
consistent and puzzling finding. Of unilateral CL (85% of all CL) two thirds
have left sided defects regardless of sex, race and severity of defect
(Fogh-Anderson, 1942; Fraser & Calnan, 1961). No convincing explanation
for these differences has been advanced (see section 4.1).
1.1.2 Family studies
Poul Fogh-Andersons' (1942) classic study of 703 probands with CL, CP or
both showed a six-fold increase in the incidence of facial clefting in their
third degree relatives or closer. All subsequent studies have confirmed this
familial clustering (for review see Fraser, 1970; Shapiro, 1976). Twin
studies have shown a significantly higher concordance of clefts in
monozygous than dizygous pairs, the heritability (h") has been estimated at
0.35 (i.e. 35% of the difference between those with clefts and those without
may be attributable to genetic factors) (Hay & Wehrung, 1970).
The analyses of family data in non-mendelian diseases have improved
greatly over the last thirty years helped by the improvement in computer
hardware capabilities, the work of the so-called English School (Edwards
1960; Carter 1965) and the group working at the University of Hawaii
(Morton, 1959; Morton & MacLean, 1974; Lalouel et al. 1983). Edwards
(1960) and Carter (1965) championed the multifactorial ( quasicontinuous )
model of inheritance in facial clefting that has been supported by several
extensive studies of family data (Woolf, 1971; Czeizel & Tusnady 1972;
Dan-ning et al. 1982). This model postulates that the cumulative effect of
numerous weak, independent factors, genetic or environmental, determines
liability to clefting, which occurs when liability exceeds a threshold. More
recent analyses and reanalyses of family data have been performed under
mixed (Morton & McLean, 1974) or unified (Lalouel et al. 1983) models of
inheritance, which combine two conceptually different models, the
multifactorial and generalised single locus model (Demenais et al. 1984;
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Chung et al. 1986). These analyses have failed to discriminate between
polygenic and monogenic inheritance within the whole group. Chung et al.
(1986), however, suggested that both modes of inheritance were operating in
CL(P) after studying 2,998 nuclear families from Denmark, with a single
recessive locus accounting for about one third of cases. Interestingly the
major locus effect was not seen in the Japanese families studied.
1.1.3 Aetiology of Facial clefts
Both CL(P) and CP are anomalies with remarkably heterogeneous
aetiologies. Within both of these groups there are well recognised
unifactorial aetiologies (chromosomal, single gene and teratogenic), the
majority of cases have, however, no specific cause that can be identified
(Gorlin et al. 1990). Due to the complex nature of the mechanical and
biochemical events involved in palatogenesis (see section 1.3), it would seem
likely that the processes of palate development could be interrupted at many
different stages by a wide variety of factors with cleft lip, cleft palate or both
as a consequence. The number and nature of these disruptive factors is not
known, though our understanding of the normal developmental processes
and the causation of facial clefts may be greatly advanced by the study of the
inborn errors of morphogenesis (Opitz et al. 1979).
1.1.3.1 Environmental factors
Many specific environmental factors have been implicated in facial clefting
(for review see Gorlin et al. 1990). Some of these, such as hyperemesis
(Drillien et al. 1966) and pre-eclampsia (Fraser, 1970) have, however, not
been confirmed by subsequent studies (Saxen 1974). Shprintzen et al.'s
(1985) attempted to quantify the load of environmental disease in the facial
cleft population by studying 1000 cases of orofacial clefts. They found 4%
of these were due to specific teratogenic agents, of which fetal alcohol
syndrome was the most common (75%) entity. The known teratogenic
syndromes associated with orofacial clefts in humans are shown in Table 1.
In contrast to the relative paucity of information of teratogenesis as a cause
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of facial clefts in human subjects, attempts at chemical manipulation of
palate development in animal models have provided large amounts of in vivo
teratogenic data (Shah, 1984). Retinoic acid (RA) is one of the most widely
studied of these agents and is often used as a tool in the study of normal and
abnormal palate development. As RA was used as a teratogen in the present
study, its in vivo effects will be reviewed in detail.











Mental retardation, poor growth and cleft palate
Cleft palate only
Unusual facies, digital anomalies, congenital
heart defects (CHD) and cleft palate
CHD, CP and limb defects
Unusual facies, mesomelia and other limb
defects
Mental retardation, CHD, unusual facies and
CP
Ear abnormalities and CNS anomalies (see
section 1.1.3.2)
Neural tube defects and craniofacial
abnormalities
Microcephaly, mental retardation and cleft
palate.
1.1.3.2 Retinoic acid
The retinoid group of molecules consist of retinol (Vitamin A) which is an
alcohol form that is metabolised to retinal (aldehyde form) and retinoic acid
(acid form). The in vivo effects of these substances are thought to be mediated
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through three groups of molecules, the cellular retinoic acid-binding protein
(CRABP), the cellular retinol-binding protein (CRBP)(Ong et al. 1982) and
the nuclear retinoic acid receptors (RARs)(Zelent et al. 1989). Although the
retinoids are considered teratogenic at supraphysiological levels, their in
vitro effects (Glick et al. 1989) and the in vivo localisation patterns of RA
(Thaller & Eichele, 1987), the binding proteins (Perez-Castro et al. 1989)
and the RARs (Zelent et al. 1989) argue an important role for these
molecules as morphogens. Retinoic acid in particular, has proven a very
useful tool in the study of orofacial development. Cohlan (1953) first
reported a specific pattern of craniofacial and limb anomalies in rats exposed
to Vitamin A in embryonic life. Subsequently many other studies have
catalogued these anomalies in the chick (Tamarin et al. 1984), the mouse
(Newall & Edwards 1981), simian species (Fantel et al. 1977) and humans
(Rosa et al. 1986). Following marketing of the 13-cis form of retinoic acid
for the treatment of severe acne, Rosa et al. (1986) reported 44 outcomes of
pregnancies from women taking this drug during the first trimester. The
commonest defects in this group were, malformations of the central nervous
system (37/44), ear abnormalities (30/44), congenital heart defects (22/44),
micrognathia (13/44), cleft palate (5/44) and microphthalmia (5/44). These
abnormalities are similar to those seen in animal studies.
The pathogenesis of retinoic acid-induced cleft palate has been the subject of
much study. Newall and Edwards (1981) have shown that it is possible to
induce cleft palate in C57B1 mice by giving large doses only twelve hours
prior to fusion. Abbott et al. (1989) have suggested that the aetiology of the
retinoid-induced cleft varies with the embryonic stage. Those mice treated at
gestation day (GD) 10 developed small palatal shelves that did not make
midline contact (see section 1.3). The medial edge epithelia (MEE) of these
hypoplastic palatal shelves failed to undergo peridermal cell death and
differentiated into oral type palatal epithelium. Those embryos treated on
GD 12 showed no palatal growth inhibition with the palatal shelves making
contact above the tongue. The MEE of these shelves, however, developed a
nasal epithelial phenotype with subsequent failure of fusion. It is of interest
that the distribution of the epidermal growth factor (EGF) receptor is altered
in the palates of retinoic acid exposed embryos (Abbott et al. 1988) (see
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section 1.4.4). Although the mechanism of retinoid action in the palate is
still far from clear, knowledge of their complex actions on mesenchyme
proliferation and epithelial differentiation and concommitant changes in
growth factor expression pattern may allow informed hypotheses.
1.1.3.3 Chromosomal anomalies causing clefts
Both CL(P) and CP are common in trisomies 13 and 18. In published case
reports CL(P) is also frequently associated with abberations involving
chromosomes lq, 3,4, 7q, 9p, lOp, lip, 13q and 22q (Schinzel, 1984). CP is
also common in many" different chromosomal aberrations with those
involving lq, 3, 4, 5q, 6q, 7q, 8q, 10, 13, 14, 17, 18, 22 and X being the most
common (De Grouchy, 1984; Schinzel, 1984). The present incomplete
understanding of the pathogenesis of abnormalities associated with
chromosomal aneuploidy has, however, made interpretation or application of
these data very difficult.
1.1.3.4 Single gene defects
Appendix A summarises the conditions with facial clefting as a feature that
are listed in McKusicks' catalogue 'Mendelian Inheritance in Man' (1990)
and the London Dysmorphology Database (Winter & Barraitser, 1988).
There are 53 autosomal dominant, 67 autosomal recessive and 13 X-linked
conditions listed in the catalogue. Many of these syndromes have only been
reported in one family and may represent so-called 'private' recessive
syndromes. In spite of the large number of single gene defects described, as
a group they are thought to represent a relatively small proportion of the
facial cleft population (Gorlin et al. 1976). Recently, Shprintzen et al.
(1985) have challenged this assumption by suggesting that single gene
defects account for a significant proportion of the facial clefts. In a
comprehensive hospital based survey of facial clefts they found that four
autosomal dominant conditions accounted for 15.2% of the whole group,
velo-cardio-facial syndrome (4.7%), Van der Woude syndrome (4.5%),
Marshall-Stickler syndrome (3.8%) and Treacher Collins syndrome (2.2%).
Other surveys have supported these conditions as important causes of facial
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clefts (particularly CP) in hospital populations (McDonald et al. 1989;
Rollnick & Pruznansky et al. 1981).
Attempts at molecular characterisation of the genes involved in the four
common genetic causes of facial clefting have, as yet, been unsuccessful.
Velo-cardio-facial (VCF) syndrome is an autosomal dominant condition
recognised by the characteristic facies, ventricular septal defects and overt or
submucous cleft palate (Shprintzen et al. 1981). There is no chromosomal
localisation for the VCF gene. Van der Woude syndrome is characterised by
facial clefting and lower lip pits (Cervenka et al. 1967). It has been localised
to chromosome 1 (lq25-41) by linkage to the renin gene (Murray et al.
1988), although no 'candidate' gene in this area has been recognised.
Marshall-Stickler syndrome or hereditary ophthalmoarthropathy, is a
pleotropic condition, characterised by wide joints/ myopia, deafness and cleft
palate (Opitz et al. 1972). Francomano et al. (1987) demonstrated genetic
linkage to the COL2A1 locus (12ql3) in two large families with
Marshall-Stickler syndrome, however no mutations of this gene have been
demonstrated in affected individuals. Treacher Collins syndrome is
characterised by lower lid coloboma, hypoplasia of the zygoma, microtia and
macrostomia (Fazen et al. 1967), it has been the subject of much recent
interest as it has striking similarities to retinoic acid embryopathy (Sulik et al.
1987) and the malformations in transgenic mice with ectopic expression of
the Hox 1.1 gene (Balling et al. 1989). Balestrazzi et al. (1983) described a
girl with Treacher Collins syndrome with a de novo apparently balanced
translocation t(5;13); there are no genetic linkage data as yet.
1.1.3.5 Malformation syndromes
Appendix B summarises the currently recognised malformation syndromes
of unknown aetiology associated with orofacial clefting (Winter &
Barraitster 1988). In two recent studies of abnormalies associated with cleft
lip, cleft palate or both, unrecognised malformation compounds accounted
for almost a quarter of the cases (Shprintzen et al. 1985; Rollnick &
Pruzansky, 1981). The recognised malformation syndromes accounted for
approximately 10% of the total groups. Isolated Pierre Robin sequence
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(micrognathia, U-shaped CP and glossoptosis) is the most common of these,
identified in around 4% of the whole group. The primary defect in Pierre
Robin sequence (PRS) is thought to be mandibular hypoplasia, with glossal
obstruction of palate closure ( Clarke etal. 1988). The holoprosencephaly,
facio-auriculo-vertebral and amniotic band sequences accounted for about
2% each.
1.2 CRANIOFACIAL MORPHOGENESIS
Most studies of vertebrate craniofacial development use non-human species
with species-specific embryonic size and gestational periods. To allow
comparison between vertebrate species, corresponding developmental stages
are assessed using the Carnegie System. This system, developed by Streeter
in his classic series of articles on human embryonic development (Streeter,
1942; Streeter, 1945; Streeter, 1948), is summarised in Table II.
As the embryological studies in sections 1.2 and 1.3 describe experimental
work on several different mammalian species, the animal model used will be
indicated in each case. Although extrapolation of these data to the human
must remain speculative, the limited data available on human embryos has
yielded no major discrepancies in the anatomical (Andersen & Mathiessen,
1967) or histochemical (Abbott & Pratt, 1987) aspects of secondary palate
development with that available from non-human mammalian species.
Studies of craniofacial development of avian (Wedden et al. 1986) and
reptilian (Sharpe & Ferguson, 1988) species have provided much fascinating
information of great interest to anyone studying developmental systems.
The development of the palate in chicks (having naturally cleft palates) and
alligators (palates fuse by epithelial migration) would, however, appear to be
fundamentally different from that in mammalian species (for review see
Ferguson, 1988) and will, therefore, not be discussed further.
1.2.1 The pharyngeal arches
The pharyngeal arches are bars of tissue that arise ventral to the hindbrain in
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TABLE II The Carnegie System of Staging Development
Carnegie Size (mm) Age Features
stage (human) (days)
1 0.1 1 Fertilisation
2 0.1-0.2 1.5-3.0 From 2-16 cells
3 0.1-0.2 4 Free blastocyst
4 0.1-0.2 5-6 Attaching blastocyst
5 0.1-0.2 7-12 Implanted although previllous
6 0.2 13 Chorionic villi; primitive streak
7 0.4 16 Notochordal process
8 1.0-1.5 18 Primitive pit
9 1.5-2.5 20 Somites first appear
10 2.0-3.5 22 Neural fold begin to fuse; 2 pharyngeal bars
11 2.5-4.5 24 Rostral neuropore closes
12 3-5 26 Caudal neuropore closes;
3-4 pharyngeal bars; upper limb buds appear
13 4-6 28 Four limb buds; lens disc; otic vesicle
14 5-7 32 Lens pit and optic cup
15 7-9 33 Lens vesicle; nasal pit; antitragus beginning;
hand plate
16 8-11 37 Nasal pit faces ventrally; foot plates;
auricular hillocks begin
17 11-14 41 Head relatively larger, nasofrontal groove;
finger rays
18 13-17 44 Tip of nose distinct; eyelid folds
19 16-18 47.5 Trunk elongating and straightening
20 18-22 50.5 Upper limbs longer and bent at elbows
21 22-24 52 Fingers longer; hands approach each other
22 23-28 54 Eyelids and external ear more developed
23 27-31 56.5 Head more rounded; limbs longer and more
developed
Adapted from O'Rahilly & Muller (1987)
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human embryos at stages 10-12 (Bartelmez & Evans, 1926). Each consists
of a mesenchymal core partly derived from migratory cranial neural crest
cells, covered externally by surface ectoderm and internally by epithelia of
endodermal origin (Sulik & Schoenwolf, 1985). Although 3-4 pharyngeal
arches appear in a rostrocaudal sequence in human embryos (O'Rahilly &
Muller, 1987) only the first and second arch contribute directly to facial
structures (Table III). The first arch, although initially linear, with
differential growth forms the shape of an 'c\ The dorsal part of the arch
(maxillary process) forms the rostral arm of the 'c' and the ventral part
(mandibular process) forms the caudal arm (Fig.lA) (Streeter, 1945).
In early stage 12 the primitive mouth or stomodeum has been formed,
bordered superiorly by the frontal process, laterally by the maxillary
processes and interiorly by the mandibular processes (Fig.lA) (Sulik &
Schoenwolf 1985). In stage 13 the mandibular processes enlarge, grow
medially and merge in the midline to form the lower lip and mandible.
Although facial development involves the formation of many structures only
the formation of the nose and upper lip will be dealt with in detail here.
The paired maxillary and mandibular processes together with the frontal
process will form the facial structures. In addition to these 5 major
processes, the maxillary and frontal components contribute another 3 paired
mesenchymal growth centres (medial and lateral nasal ridges and the
intermaxillary processes) which will form the structures of the central face
(Fig.lA-D). These growth centres are areas of condensed mesenchyme with
detatched foci of growth separated from each other by a common underlying
matrix of loose connective tissue (O'Rahilly & Muller, 1987). Merging of
these prominences involves no ectodermal adsorption but rather 'filling-in' of
the furrows between them by mesenchymal proliferation (Peter 1913).
1.2.2 Formation of the nose and nasal cavities
Warbrick (1960) recognised four stages in the formation of the nasal cavities
in human embryos. (1) Formation of the nasal placodes at stage 14 as
thickenings of the surface ectoderm on either side of the frontal process. (2)
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FIGURE 1
DEVELOPMENT OF THE CENTRAL FACE
FIGURE 1. Develpment of the central face. Diagraming-representation of
central face development from the frontal process and the paired
maxillary and mandibular processes. (A) Represents a human embryo at
early Stage 12 with the primitive mouth bordered rostrally by the
frontal process, laterally by the maxillary processes and caudally by
the mandibular processes. (B) Late in Stage- 12 the mandibular processes
enlarge until the growth centres are adjacent in the midline. (C) In
Stage 13 the mandibular processes fuse and the frontonasal mass becomes
more distinct. (D) In Stage 16-17 the medial nasal ridge and the
intermaxillary processes (i) can be distinguished as separate growth
centres, the intermaxillary centres will fuse with the premaxillary
centres (p) late in Stage 17.
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Formation of the nasal grooves. (3) Deepening of these grooves to form the
nasal pits. (4) Formation of the nasal sacs as the nasal pits deepen and grow
towards each other. The ventral sac epithelium (nasal fin) maintains
epithelial continuity between the nasal cavity and the roof of the mouth,
separating the maxillary and intermaxillary growth centres (Streeter, 1948).
The nasal sacs are separated from the primitive mouth by the oronasal
membrane, this ruptures to form the primitive choanae (England, 1983). The
paranasal air sinuses develop as diverticulae of the lateral nasal wall and
extend into the maxilla, frontal, ethmoid and sphenoid bones (Sadler, 1989).
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Three paired facial processes form from the nasal ridges that surround the
nasal pits. The lateral portions of the nasal ridges form the lateral nasal
processes, most oi the medial portion becomes the medial nasal process and
the ventral ends of which form the premaxillary centres. The nose proper is
thus formed from seven processes, the frontal process gives rise to the
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bridge, the merged medial processes form the nasal septum, the premaxillary
centres form the median philtrum, columella and tip and the lateral
processes form the alae.
1.2.3 The primary palate and upper lip
With continued growth the premaxillary centres merge in the midline to form
the intermaxillary segment (Fig. ID). This segment consists of a labial
component, which will form the philtrum of the upper lip, an upper jaw
component, which carries the four incisor teeth and a palate component,
which forms the triangular primary palate. In the first half of this century
many embryologists, most notably Fraser (1931), believed that the upper lip
was formed in the human embryo by fusion of the maxillary processes in the
midline, more recently Warbrick (1960), using wax plate reconstruction, and
Sulik and Schoenwolf (1985), using scanning electron micrography, have
convincingly demonstrated that the upper lip is formed by merging of the
maxillary processes with the intermaxillary segment at stage 17 (Fig.ID).
More detailed studies of the histological processes involved in the fusion of
the upper lip have shown that the intermaxillary segment forms an isthmus of
mesenchyme that is isolated from the maxillary processes by the epithelial
wall of the nasal fins. This mesenchymal mass then expands through the
proliferation of neural crest cells with fusion occurring after autolysis of the
nasal fin by coalescence of the intermaxillary and maxillary mesenchyme
(Andersen & Mathiessen 1967; Trasler, 1968).
1.3 FORMATION OF THE SECONDARY PALATE
After closure of the primary palate at stage 17 the oral cavity is roofed by the
frontal process, wailed by two lateral maxillary processes, floored by the
merged first arches and occupied by the enlarging tongue and the developing
nasal septum. It communicates dorsally with the foregut and ventrally with
the amniotic cavity via the mouth and the nares. Development of the
secondary palate is phenotypically similar in all mammalian species
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studied (for review see Ferguson, 1988) and can be summarised as; initiation
of the palate primordia, initially vertical growth of the palatal shelves,
subsequent elevation and approximation of the shelves, fusion of the medial
edge epithelia to form an epithelial seam followed by disruption of the seam
establishing mesenchymal continuity (Fig.2A-D).
In stage 18 the palatal shelves arise from the bilateral maxillary processes as
distinct ridges of mesenchymal cells associated with craniopharyngeal
ectoderm (Greene & Pratt'1976). Shah (1984) carried out an ultrastructural
study of shelf initiation in hamster embryos, and showed a change in
epithelial phenotype from simple cuboidal before the appearance of palatal
1.3.1 The palatal primordia and vertical growth
FIGURE 2 Normal mammalian palatogenesis
A B
Stage 18 Stage 21
C D
Stage 22 Stage 23
FIGURE 2. Normal stages of mammalian palatogenesis. Diagram •vVv.tJt-
representation of the normal stages of mammalian palatogenesis. (A) At
Stage 18 the palatal shelves (ps) become visible as ridges on the
maxillary processes. (B) The palatal shelves grow vertically down the
side of the tongue (to), reaching their full length by Stage 21. (C) In
Stage 22 reorientation of the palatal shelves brings them into
apposition above the tongue. (D) The palatal shelves fuse in the midline
in Stage 21
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shelves to a bilayer with flattened cells covering a layer of irregularly shaped
cells in early palatal shelves. It would seem likely that the initiation of
palatal shelf growth, at least in part, is controlled by epitheliomesenchymal
tissue interaction, although the physiochemical nature of these signals is
unknown. Drugs known to interfere with the early periods of palate
development in vitro (6-mercaptopurine & Hadacidin) are inhibitors of
nucleic acid synthesis (Shah 1984) and are, therefore, likely to act in a
non-specific way. Other studies of initial palatal shelf growth using
indicators of DNA synthesis have shown two periods of rapid mesenchymal
proliferation one during initial shelf outgrowth and the other during the
period immediately prior to shelf elevation (Burdett et al. 1988).
With rapid vertical growth, the shelves achieve their full length prior to
elevation. This growth on either side of the tongue is the result of
proliferation of mesenchyme (Fig.2B) (Ferguson, 1987). It is often stated
that the palatal shelf mesenchyme is of cranial neural crest origin (Greene &
Pratt 1976; Ferguson 1987) there is, however, no direct evidence for this
in mammalian species. The cranial neural crest does, however, contribute
significantly to the cell population of chick maxillary processes (Johnston &
Listgarten, 1972) and several cranial neural crest-derived ectomesenchymal
phenotypes appear during human palatogenesis (Slavkin, 1984).
1.3.2 Mechanisms of shelf elevation
In the stage 20 embryo a remarkable reorientation of the palatal shelves
occurs, as both shelves rapidly elevate they come into apposition above the
tongue. The origin of the intrinsic force of elevation has been the subject of
much debate and is almost certainly multifactorial (Ferguson, 1987).
Coleman (1965), using rat embryos, and Brinkley and Morris-Wiman (1984),
using mouse embryos, demonstrated regional differences in the character of
reorientation with the anterior densely-packed mesenchyme showing a rapid,
all-or-nothing, rotational elevation while the posterior regions display a more
fluid remodelling.
Zimmerman and Wee (1984) have suggested that contractile abilities of shelf
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mesenchymal cells may participate in elevation. Contractile proteins, actin
and myosin, have been localised to cytoplasmic, nonmuscle contractile
systems on the oral and nasal sides of the murine vertical palatal shelves
(Lessard et al. 1974; Kuhn et al. 1980) In mouse embryos, incubation of
pre-elevation palatal shelves with adenosine triphosphate (ATP) causes
condensation of cytoplasmic actomycin complexes which results in almost
complete elevation of the anterior palate (Zimmerman & Wee 1984). The
ability of certain neurotransmitters to stimulate (serotonin and acetylcholine)
and inhibit (gamma-aminobutyric acid) shelf elevation in cultured murine
palates is thought to be mediated via mesenchymal cell contractility and
matrix degradation (Zimmerman & Wee 1984; Ferguson, 1988).
A role for the extracellular matrix (ECM) and, in particular,
glycosaminoglycans (GAGs) in shelf elevation was first suggested by
Walker and Fraser (1956). Pratt et al. (1973) studied the composition of the
GAGs present in murine palatal shelves and found the major component
(60-65%) to be hyaluronic acid (HA). The striking hydrophilic properties of
HA has led to the suggestion that the large changes in osmotic pressure that
result from a small increase in the concentration of HA (Comper & Laurent,
1978) may induce the rapid shelf movement in reorientation by expansion of
a gel matrix. Treating mouse embryos with compounds that cause
degradation of HA result in embryos with normal elevation of the anterior
portion of the palate and defective reorientation posteriorly (Brinkley, 1980).
Brinkley and Morris-Wiman (1984) also studied the role of the shelf
a
epithelia in directing the intrinsic force. Using [ HJthymidine derived
mitotic indices, they identified areas of morphogenetic activity on the
superior nasal and mid-oral epithelial surfaces of murine palatal shelves, it is
not clear whether the latter areas differ from the developing palatal rugae.
The function of the rugae that develop on the oral surface of the palate is not
known. Recent studies have shown a close temporal relationship between
development of the rugae and the secondary palate and suggest a possible
role in elevation (Sakamoto et al. 1989).
It has thus been proposed that at least two regionally distinct mechanisms are
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involved in mammalian shelf elevation. Anteriorly, an intrinsic system of
contractile proteins cause a rapid reorientation. Posteriorly expansion of a
mesenchymal gel matrix produces a force which is then directed by local
proliferative changes in the oral epithelial component and bundles of type I
collagen (Ferguson, 1987) which produces a more fluid reorientation.
Many other factors have been proposed as having a role in shelf elevation
these include; the mechanical effect of substantial vertical head growth with
little lateral growth (Diewert 1978), straightening of the flexed cartilaginous,
cranial base (Taylor & Harris, 1973) and pressure changes produced by
foetal mouth opening (Humphrey 1969), swallowing movements (Walker
1969) and hiccuping (Ferguson 1988). Although these have generally been
elegant and detailed studies, supporting evidence is lacking.
1.3.3 Fusion of the shelves
Almost immediately after elevation the medial edge epithelia (MEE) of both
shelves come into contact above the tongue. In the mouse embryo, fusion
begins at the border of the anterior and middle thirds of the secondary palate
in the region of the second rugae (Sakamoto et al. 1989) with formation of
the midline epithelial seam (MES) and proceeds in both anterior and
posterior directions until completion by stage 23. The final process of fusion
involves disruption of the MES to establish mesenchymal continuity.
Prior to elevation the MEE resembles other epithelia lining the oronasal
cavity. In hamster embryos the MEE is a bilayer consisting of a surface
squamous layer (periderm) overlying a glycogen-rich cuboidal cell layer
(Chaudhry & Shah, 1973) in contact with an intact basal lamina. The cells
are connected both within and between layers, by numerous small
desmosomes. After elevation, but prior to midline contact, the cells in the
peridermal layer of the MEE loose their intercellular connections, become
irregularly shaped and are shed from the outer surface (Waterman & Meller,
1974). In mouse embryos, the basal layer of the MEE shows continued
heavy staining for glycogen, abundant rough endoplasmic reticulum (RER)
and occasional mitotic figures (Fitchett & Hay, 1989).
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As the MEE fuse to form the MES the mechanism of initial adherence is
thought to be the formation of glycoconjugates on 'sticky' cell surfaces (Pratt,
1983; Shah, 1984). This 'stickiness' is, however, specific in mouse
embryos, as the MEE will only adhere to one another and not to other oral
epithelial surfaces (Ferguson et al. 1984). None of the known cell adhesion
molecules show specific staining in murine palatal epithelia (Obrink 1986),
although certain carbohydrate rich-molecules (Con A & Ulex europaeus)
have been localised to the MEE (Ferguson, 1988). In human embryos the
MES proper is established by the formation of desmosomes between
adhering cells (Morgan & Pratt, 1977; Shah, 1984). Ferguson (1988) has
shown desmoplakin accumulation (a desmosomal plaque protein) in murine
MEE, suggesting that there is specific and rapid construction of desmosomal
components immediately prior to fusion.
1.3.4 Disruption of the midline epithelial seam
Disruption of the MES has been cited as a prime example of programmed
cell death (Saunders 1966; Green & Pratt 1976). Evidence for this was the
apparent cessation of DNA synthesis in the MEE of rat embryos 24-36 hours
prior to fusion (Hudson & Shapiro, 1972; Pratt & Martin, 1975), reports of
macrophages and lysosomes in the rat MES in vitro (Hayward, 1969) and an
increase in cyclic adenosine monophosphate (cAMP), which is known to
induce MEE cell death in vitro (Pratt & Martin, 1975), in the prefusion
murine palatal mesenchyme. However Fitchett and Hay (1989) convincingly
showed that after sloughing of the periderm layer, cell death is uncommon in
the immediately prefusion MEE or the MES in the rat embryo. They also
presented evidence for epithelial-to-mesenchymal transformation within the
MES with characteristic changes in cell morphology (prominent nucleoli,
'robust' nuclei) and alteration in the cytoskeletal profile from predominantly
keratin (epithelial) to vimentin (mesenchymal). They propose epithelial-to-
mesenchymal transformation as the primary mechanism of MES disruption.
Dramatic changes in morphology of the remaining mammalian palatal
epithelia occur immediately after the disruption of the MES. The nasal
epithelium differentiates into pseudostratified ciliated columnar cells and the
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oral epithelium into stratified squamous cells (Sharpe & Ferguson 1988).
Using elegant epithelial-mesenchymal recombination techniques Ferguson &
Honig (1984) have shown that epithelial differentiation in the palatal shelves,
both within and across species, is controlled by the underlying mesenchyme.
In an attempt to identify the mesenchymal signals involved in epithelial
differentiation the distribution of extracellular matrix (ECM) molecules in
the murine palate around the time of fusion have been extensively studied
using immunohistochemical methods (Ferguson, 1988). The ECM may be
involved in the signalling process either directly or via interactions with
soluble factors such as growth factors. Most ECM molecules studied during
palate development were either undetectable (collagen types II, VIII and X)
or appeared to be ubiquitously distributed (collagen types I and III and
fibronectin). However several molecules did show specific staining patterns.
Collagen type IV and laminin were found throughout the epithelial basement
membrane while collagen types V and VII were localised to the MEE
basement membrane. Tenascin and collagen type IX have the most
interesting distribution patterns with both localised temporally and spatially
around the time of MES disruption. Collagen type IX has been localised to
the intersections of collagens in other systems (Muller-Glauser et al. 1986),
although its role during palate fusion remains unclear. More is known of the
in vitro and in vivo properties of tenacin and its close relationship with
transforming growth factor type beta expression which will be discussed in
section 1.5.
1.3.5 The post-fusion palate
There are very few studies of the ultrastructural or biochemical processes
involved in mesenchymal differentiation after disruption of the MES. It is
known that the subsequent differentiation of the ectomesenchyme must be
regionally-specified as the anterior portion (hard palate) undergoes
membranous ossification and the mesenchyme of the posterior palate
differentiate to myoblasts and form the musculature of the soft palate,
(tensor veli palatird, musculus uvulae etc.), the nature of the physiochemical
signals determining this polarity is, however, unknown (Slavkin, 1984).
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1.4 GROWTH FACTORS IN PALATE DEVELOPMENT
With increasing knowledge of their in vitro properties, peptide growth
factors have been cited as candidate genes for study of the complex
signalling systems that coordinate division, differentiation and cell death
during palate development (Ferguson 1988). Evidence for their involvment
in other morphogenetic processes is provided by studies of both RNA and
protein localisation that show spatial and temporal patterns of peptide growth
factors and their receptors in mammalian embryos (Heine et al. 1987,
Lehnert and Akhurst 1988, Pelton et al. 1989). Many of these growth factor
genes also display extraordinary degrees of evolutionary conservation, have
sequence and structural similarities to developmental genes and exhibit in
vitro properties suggestive of a role in development (Wozney et al. 1988,
Seyedin et al. 1986; Padgett et al. 1987, Weeks and Melton 1987, Greenwald
et al. 1985, Wharton et al. 1985; Slack et a/. 1987, Kimelman and Kirschner
1987). Five of the major classes of peptide growth factors will be dealt with
in more detail below, although many other peptide growth factor families
exist (eg. nerve growth factors, cytokines, colony stimulating factors and
interleukins) they have not been cited as candidate genes in the
study of palatal development (Ferguson, 1988).
1.4.1 Insulin-Like Growth Factors
There are two isoforms of insulin-like growth factor, IGF-I and IGF-II, both
are single chain polypeptides with extensive sequence and structural
homology to proinsulin. Although their physiological role is not yet clear,
both are potent promoters of growth and differentiation in many cell types in
vitro (Froesch et al. 1985). Studies of IGF expression patterns in
development using in situ hybridisation to sectioned rat embryos have
demonstrated expression of IGF-I in the somitic, hepatic bud and branchial
arch mesoderm and IGF-II in myoblast, maturing cartilage and centres of
membranous ossification (Beck et al. 1987). No specific hybridisation to
palatal tissues was detected.
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1.4.2 Heparin-binding Growth Factor Family
The prototypes of this family, acidic and basic fibroblast growth factors
(aFGF and bFGF) were first isolated from bovine neural tissue on the basis
of their mitogenic effect on a variety of cells of mesenchymal origin
(reviewed by Lobb et al., 1986). Recently new family members have been
identified: int-2 (Dickson & Peters, 1987), kFGF (Taira et al. 1987), FGF5
(Zhan et al. 1988) and FGF6 (Maries et al. 1989). All members of the
family display 40-50% amino acid identity with each other.
Although the physiological role of this family would appear to be
angiogenesis (Folkman & Klagsbrun, 1987), recently a role in mammalian
development has been proposed following studies that implicated both int-2
(Wilkinson et al. 1988) and FGFs (Slack et al. 1987) in the process of
mesoderm induction in the early embryo. Although no detailed embryonic in
situ localisation of these molecules has been published as yet, in vitro
studies on cultured cells from the medial edge palatal mesenchyme (MEPM)
have shown that both aFGF and bFGF induce profound changes in cell
morphology, stimulate GAG production and have a potent mitogenic effect
(Sharpe & Ferguson, 1988). The role that these substances have in the
developing palate is unclear, although the authors have suggested that they
may have a role in shelf cell migration.
1.4.3 Platelet-derived growth factor family
Platelet-derived growth factor (PDGF) is the principal mitogen present in
whole blood serum, stimulating the growth of connective tissue derived cells,
thus suggesting that PDGF may have an important physiological role in the
wound healing process (Ross et al. 1986). Two distinct chains are
synthesised.(A and B chains) and these are thought to form both homo- and
heterodimers. Transcripts of both these chains have been discovered in stage
6 mouse embryos (Mercola & Stiles, 1988) suggesting an important role in
morphogenetic events. The only clue that PDGF may have a role in
palatogenesis comes from their reported mitogenic effect on cultured MEPM
cells, although unlike FGF, EGF and TGF6 family members it does not seem
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to alter the ECM profile in vitro (Sharpe & Ferguson 1988)
1.4.4 Epidermal Growth Factor Family
This group of peptide growth factors have been studied more than any other
in palatogenesis, this is largely due to the pioneering work of Robert Pratt
and his co-workers in Bethesda. Although much of the in vitro work has
used epidermal growth factor (EGF), it would now appear that transforming
growth factor alpha (TGF alpha) is the predominant molecule of this group
interacting with the EGF receptors during mammalian development
(Adamson et al. 1981). TGF alpha has, therefore, been termed the embryonic
homologue of EGF (Derynck, 1985). The two molecules share 30% amino
acid sequence homology and are interchangeable in a number of biological
assays (Derynck, 1988).
EGF has been shown to have remarkable effects on palate epithelial and
mesenchymal cells in culture. Hassell (1975) and Tyler and Pratt (1980)
have shown that the MEE of palates cultured in the presence of EGF express
a nasal cell phenotype and terminal differentiation of the peridermal cells is
inhibited, thus preventing the fusion process, in a follow-up study, it was
found that cyclic adenosine monophosphate (cAMP) could partially block
this effect of EGF (Hassell & Pratt, 1976). Later Grove and Pratt (1983)
found that EGF was essential for the growth and differentiation of palatal
epithelia cultured on plastic or extracellular matrix (ECM). EGF also can
stimulate mesenchymal synthesis of type V collagen (Silver et al. 1984) and
hyaluronic acid (Turley et al. 1985). Nexo et al. (1980) found a dramatic
increase in the activity of an EGF-like substance (presumably TGF alpha) in
mouse embryos around the time of palatogenesis.
The EGF receptor has also proven to be of great interest in the study of the
developing palate as it has been localised to the epithelia of the vertical
palatal shelves (Nexo et al. 1980). Yoneda and Pratt (1981) have shown that
palatal mesenchymal cells also contain a high level of EGF receptor and that
these cells are responsive to the growth promoting properties of EGF.
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It would seem, therefore, that the EGF family of growth factors has an
important role in growth and differentiation during palatogenesis. Ardinger
et al. (1989) have provided further indirect evidence by showing an
association between a restriction fragment length polymorphism detected by
a TGF alpha gene probe in genomic DNA and in patients with isolated
CL(P).
1.4.5 The transforming growth factor type-beta family
The TGFBs are multifunctional molecules with predominantly growth
inhibitory or differentiative effects on a wide variety on cell types. TGFB
-related factors have recently emerged as polypeptides with central roles
in development. There are at least eight different types of TGFB (only
three have been found in mammals) with many other structurally-related
proteins are included in a 'superfamily'. The TGFB receptors would also
appear to exist in several forms although little is known about the molecular
nature of the receptor molecules and the intracellular signalling that results in
the diverse effects of this group.
1.4.5.1 TGFIU
Transforming growth factor type beta 1 (TGFBl) was discovered
independently by two groups (Moses et al. 1981; Roberts et al. 1981)
through its ability to induce anchorage-independent growth of rat fibroblasts
in soft-agar culture. The gene has been mapped to 19ql3.1 in the human and
produces a transcript of 2.5 Kb (Sandberg et al. 1988). The active (or
mature) complex of TGFBl is a dimer of identical 112a.a. polypeptides.
This is synthesised as a large precursor polypeptide (390a.a.) that is
proteolytically cleaved releasing a carboxyterminal mature monomer (112
a.a.) (Derynck et al. 1985). The amino acid sequence of the mature region
displays an extraordinary degree of interspecies conservation (Derynck et al.
1986; Jakowlew et al. 1988). The precursor region displays much less
homology between species (20-30%) and its role within the cell is not yet
clear, although it appears to be necessary for the efficient secretion of the
molecule (Sha et al. 1989).
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TGFB1 appears to leave the cell as a latent complex (Miyazono et al.
1988, Wakefield et al. 1988) consisting of the mature and precursor portions
of the protein bound with a TGFB-binding protein (Miyazono, 1989).
Activation occurs in the extracellular environment and can be achieved in
vitro by transient acidification or limited proteolysis. As TGFB1 is
synthesised by most cell types (Derynck et al. 1987) and its receptors are
ubiquitously distributed (Wakefield et al. 1987), it would appear that the
activation of the latent complex has a major role in the regulation of TGFB
biological activity.
1.4.5.2 TGFB2
TGFB2 was independently isolated by four groups (Seyedin et al. 1987;
Cheifetz et al. 1987; Hanks et al. 1988; Wrann et al. 1987), it is located on
lq41 in the human. The TGFB2 precursor protein is 442a.a. with similar
post-translational processing to TGFB I, producing a mature protein of
ll2a.a.(Madisen et al. 1988). There is 71% amino acid sequence identity
with TGFB1 including conservation of all nine cysteine residues. The
TGFB2 mature peptide portion also shows remarkable cross species
conservation (De Martin et al. 1987; Madisen et al. 1988; Hanks et al.
1988; Cheifetz et al. 1987; Seyedin et al. 1987).
1.4.5.3 TGFB3
TGFB3 has been cloned by several groups screening human, porcine, murine
and chick cDNA libraries with TGFB1 probes (ten Dijke et al. 1988,
Miller et al. 1988; Jakowlew et al. 1988a; Kondaiah et al. 1990). The gene
has been localised to 14q24 in the human. It is synthesised as a 412a.a.
peptide with the C terminal 112 amino acids sharing approximately 80%
amino acid identity with TGFB1 and TGFB2 and has a high level of cross
species sequence identity (ten Dijke et al. 1988a; Derynck et al. 1988;
Jakowlew et al. 1988a). TGFB3 is the most abundant TGFB family member
expressed in chick embryos and might, in this organism, fulfil the function of
TGFB1. There is little information on the biological activity or localisation
41
of TGFB3 in mammalian systems. Recently, however, ten Dijke et al. (1990)
have shown that recombinant TGFB3 is three to five times more potent than
TGF61 in certain biological systems.
1.4.5.4 Other TGFBs and the superfamily
TGFB4 was cloned from a chick library (Jakowlew et al. 1988b) it is
unusual in that the precursor only contains one N-glycosylation site
(Jakowlew et al. 1988b) which suggests that TGF84 protein may not be
secreted or is secreted by the cell using a different mechanism. The mature
portion of the TGF84 peptide is also unusual in that it is 114a.a. with a 2
amino acid insertion near the N-terminus. TGFB5 was cloned from a
Xenopus library (Kondaiah et al. 1990) and is expressed throughout
amphibian early development and in the Xenopus XTC cell line (Kondaiah
et al. 1990). These new forms of TGFB's do not represent the chicken or
Xenopus homologues of TGFBl, since the chicken TGFBl cDNA has been
cloned and the predicted mature protein found to be 100% identical to human
TGFBl (Jakowlew et al. 1988). Recently Thomsen and Melton (1990) have
cloned 8 new members of the family in the Xenopus, no further details of
these are available as yet.
The members the TGFB superfamily include well characterised
proteins such as the inhibins and activins. They show between 22% and 38%
amino acid sequence identity with TGFB and all share at least seven of
the nine C-terminal cysteine residues. They are synthesised as large
precursors with carboxyterminal mature sequences with many members of
the superfamily implicated in the regulation of developmental processes (see
Table IV).
1.5 THE BIOLOGICAL PROPERTIES OF TGFB
Most of the work described in this section relates to studies of the in vitro
properties of TGFBl peptide, however, much of the work has been

































































































































of TGF61 (Seyedin et al. 1987, Cheifetz et al. 1987). In some in vitro
systems TGF61 and TGF62 have been shown to form heterodimers (Cheifetz
et al. 1987; Danielpour et al. 1989) these have, however, not been detected
in vivo. One major difference between TGF61 and TGFB2 is the ability of
the latter to induce mesoderm formation in Xenopus embryos (Rosa et al.
1988).
1.5.1 The effect of TGFI1 on cell growth and differentiation
Although originally described as a mitogen, TGFB has proven to be
growth inhibitory to most cell types in culture. This inhibition appears to be
particularly evident in epithelial cell cultures, with TGFB showing
reversible inhibition of cultured keratinocytes (Shipley et al. 1986, Wilkie
et. al. 1988), but causing irreversible inhibition of proliferation in intestinal
(Urokowa et al. 1987), bronchial (Masui et al. 1986) and tracheal epithelial
cells (Jeyyen et al. 1986) with the appearance of terminal squamous
differentiation markers.
TGFB also has dramatic effects on cells of the lymphatic system being
one of the most potent immunosuppressives known, inhibiting lymphocyte
proliferation at femtomolar concentrations (Kehrl et al. 1986; Ristow et al.
1986, Ellingsworth and Nguyen 1988) and reducing IgG secretion by B-cells
(Kehrl et al. 1986b).
In contrast to the above examples endothelia display a paradoxical response
to TGFB, with inhibition of FGF-induced proliferation of cultured
endothelial cells (Frater-Schroder 1986) whereas the subcutaneous injection
of TGFB evokes a strong angiogenetic response (Roberts et al. 1986).
This in vivo response is almost certainly effected indirectly via TGFBs
chemotactic action on monocytes (Wahl et al. 1987) and the release of
angiogenetic factors from other cells.
The effect of TGFB on the cells of the liver has of considerable interest
because of the regenerative abilities of this organ. TGFB inhibits
EGF-induced growth of hepatocytes in vitro at very low concentrations
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(Nakamura et al. 1986; Carr et al. 1986; McMahon et al. 1986) and
localisation of TGF6 RNA have implied a negative regulatory role, by
paracrine mode of action, in the regenerating liver (Brann et al. 1988).
TGF6 has also proven to be a complex regulator of cell differentiation as
well as growth. It induces differentiation of certain cell types in vitro such as
bronchial epithelium (Masui et al. 1986), chondrocytes (Seyedin et al. 1986)
and keratinocytes (Reiss & Sartorelli, 1987) while inhibiting differentiation
of adipogenic and myogenic cells (Ingotz & Massangue 1986) with
prevention of myotube fusion and the expression of muscle specific proteins
(Massague et al. 1986, Florini et al. 1986, Olson et al. 1986; Allen and
Boxhorn 1987).
1.5.2 The effect of TGFB on the ECM
Induction of extracellular matrix synthesis is one of the most interesting
properties of TGFB. This is achieved by three mechanisms. Firstly TGFB
increases the rate of synthesis of the ECM molecules, collagen (type I,
II & III), fibronectin (Ignotz & Massague 1986; Seyedin et al. 1985; Varga
et. al. 1987), tenascin (Pearson et al. 1988), thrombospondin (Pentinnen et.
al. 1988) and cartilage-specific proteoglycans (Seyedin et al. 1985).
Although most work has been done on fibroblasts, tissue specific effects on
ECM are seen in bone (Noda and Rodan 1987), endothelial cells (Madri et.
al. 1988) and human arterial smooth muscle cells (Chen et al. 1987).
Secondly, TGFB effects a decrease in synthesis of the protease enzymes;
collagenase (Edwards et al. 1987), elastase (Redini et al. 1988),
transin/stromelysin (Machida et al. 1988) and increases the transcription and
synthesis of protease inhibitors such as plasminogen activator inhibitor (PAI,
Lund et al. 1987) and tissue inhibitor of metalloproteases (Edwards et al.
1987). Thirdly, TGFB also modulates the interaction between
mesenchymal cells and extracellular matrix by stimulating the expression of
surface receptors for extracellular matrix molecules on fibroblasts in vitro
(Ignotz and Massague 1987, Allen-Hoffmann et al. 1987). All three of these
actions could effect the rapid build-up of ECM that is important in
morphogenetic processes as well as wound healing (see 1.5.1.4).
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1.5.3 TGFB in specific systems
1.5.3.1 Wound healing
The commercial and clinical implications of TGFBs' role in wound
healing has made this the subject of much study since Roberts et al. (1986)
showed that TGFB injected into neonatal mice produces a localised
fibrotic response that is similar to a wounding response and Assoian and
Sporn (1986) found TGFB to be released from platelets at sites of injury.
It has recently been called a 'biological glue' after it was shown to induce
choroidoretinal adhesions following experimentally induced retinal tears
(Glaser at al. 1989). Monocyte chemotaxis, activation of growth factor
production (Wahl et al. 1987), deactivation of macrophage hydrogen
peroxide (Tsunawali et al. 1988) and blocking of the cytotoxic activity of
natural killer cells (Rook et al. 1986) are all properties of TGFB that may
be involved in the controlled tissue response to damage.
1.5.3.2 Bone formation and repair
Adult bone is the richest source of TGFB in the body (Seyedin et al.
1987). TGFB also seem to be important in morphogenesis of the skeletal
system as it is synthesised in fetal bone cells (Heine et al. 1987; Sandberg et.
al. 1988). The in vitro effects of TGFB on the cells of the developing
skeletal system are complex with site and stage specific effects on ECM
synthesis (Rosier et al. 1988) and chondroblasts and chondrocytes growth in
vitro (O'Keefe et al. 1988). The role that TGFB plays in the homeostasis
and repair of adult bone is less clear, although it may be involved in bone
resorption as part of the constant remodelling (Tashijian et al. 1985) and has
been localised in the callous of healing fractures (Borlander et al. 1989).
1.5.4 TGFBs in embryogenesis
Most of the work that suggests a role for the TGFBs as embryonic
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modulators comes from localisation of either protein or RNA in sectioned
mouse embryos. Both TGFBl and TGFB2 are known to be
synthesised in the preimplantation mouse embryo (Rizzino 1985; Mummery
et al. 1990) although their role is not yet clear. Akhurst et al. (1990) found
high concentrations of TGFBl RNA in the extraembryonic blood islands
suggesting a role for this gene in both haematopoiesis and angiogenesis.
One major role for TGFB isoforms in the embryo would appear to be in
epithelial mesenchymal interactions. Lenhert and Akhurst (1988) showed
TGFBl RNA to be localised to epithelia overlying mesenchyme where
the protein had been localised (Heine et al. 1987) such as the tooth bud and
whisker follicle thus suggesting a paracrine mode of action in these systems.
TGFB isoforms has also shown site- and stage- specific RNA localisation
patterns during cardiac development (Akhurst et al. 1990), lung and gut
development (Pelton et al. 1989; Gatherer et al. 1990; Millan et al. 1990)(see
section 4.2).
1.5.4.1 TGFB in palate development
The ability of TGFB to alter the ECM profile and to control mesenchymal
growth and induce terminal differentiation in certain epithelia make it of
great interest in the study of palatogenesis. Heine et al. (1987) used
immunohistochemical techniques to detect TGFB in the mesenchyme of the
developing palate. Subsequently Ferguson et al. (1988) have shown TGFB
can inhibit the growth of cultured palatal mesechyme, stimulate synthesis of
fibronectin and collagen types III, IV and V and inhibit collagen I synthesis
(see section 4.2).
1.6 AIMS OF THE STUDY
The aims of this study fall into two broad groups:
1. a) Calculation of the birth prevalence of cleft lip, cleft palate or
both by attempting complete ascertainment of all cases born to
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mothers resident in the West of Scotland during a five year
period beginning 01/01/80.
b) Use of the collected data to investigate laterality, sex ratio,
seasonal and geographical distribution within the cleft lip
group (with or without cleft palate) and the cleft palate group.
c) Identification of those patients in the group that have
recognised diagnoses and tabulation of associated
abnormalities in the 'unknown' group.
d) Establishment of a database of these patients that can be used
in future studies of empiric recurrence rates and association
studies.
2. a) To make staged mouse embryo sections of the critical stages
of murine palatogenesis and, using in situ hybridisation of
riboprobes to these sections, identify the expression patterns
of genes encoding for transforming growth factor to type beta
type 1 (TGFB1), TGFB2 and TGFB3 during murine
palatogenesis.
b) To make staged mouse embryo sections from mice treated
with retinoic acid at dosage and developmental stage that is
known to cause clefting of the palate and investigate the effect
of retinoic acid treatment on the expression patterns of genes
for TGFG1, TGF62 and TGF83 in these embryos.
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CHAPTER 2 MATERIALS AND METHODS
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2.1 BIRTH PREVALENCE STUDY
The birth prevalence study was conducted over a five year period from
the 1st January 1980 to 31st December 1984. The births studied were
those to mothers whose first residence was within Greater Glasgow,
Lanarkshire, Forth Valley, Dumfries & Galloway, Argyll & Clyde or
Ayrshire & Arran Health Boards. The figures for both the number of
total births and live births over this period for residents of these Health
Boards, were kindly supplied by Dr. Susan Cole, Common Services
Agency, Trinity House, Edinburgh. These figures were then subdivided
by month of birth and sex of child to facilitate comparison with the
ascertained group. A calculation of birth prevalence was used in
preference to an estimation of the incidence of facial clefting as the
common occurrence Gf facial clefts in early spontaneous abortions
(Iizuka, 1973), would make the latter figure impossible to calculate.
2.1.1 Ascertainment
The index cases were identified through four main sources a) SMR11
neonatal discharge forms b) the Glasgow EUROCAT register c) hospital
diagnostic indices of the Royal Hospital for Sick Children, Glasgow,
Cannisburn Hospital, Glasgow and Seafield Hospital, Ayr d) SMR1
hospital admission records, kindly supplied by Dr. John Clarke, Common
Services Agency, Trinity House, Edinburgh. Follow-up information on
the index cases with associated abnormalities was obtained from hospital
records, West of Scotland regional genetic records and detailed
post-mortem reports. Both ascertainment and follow-up were aided
considerably by the fact that all facial cleft patients that come to
operation in the West of Scotland were treated by two regional specialist
surgeons who have kept independent records of the patients they have
seen and treated. Patients with microforms of facial clefts (bifid uvula
and submucous cleft palate) were excluded as these defects may not
come to medical attention and would, therefore, require a population
survey for complete ascertainment.
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2.1.2 Data Storage
The data recorded on each case were identifying number, name, date of
birth, sex, residence post-code at time of birth, present address, details of
facial cleft (type, side and severity), the number and nature of any
associated abnormalities and whether a syndrome could be identified.
The severity of the cleft was quantified using the method described by
Jensen et al. (1988)(Fig.3). These data were stored on a microcomputer
using the dBASE III plus program (Ashton-Tate).
2.1.3 Statistical Analyses
The birth prevalence figures were calculated per 1000 total births or live
births and quoted with 95% confidence intervals. The standard deviations
were calculated using the formula;
SD = 1000 x (N)~2/n Czeizel & Tusnady (1984).
N = number of affected births
n = number of births in study period
To estimate the birth prevalence of facial clefts as isolated congenital
anomalies, the number of cases in the study with no associated congenital
anomalies was calculated (p.). This figure however may be lower than the
true figure for isolated CL(P) and CP as it ignores the possibility of
random associations with other common congenital anomalies. To
estimate a corrected birth prevalence for isolated facial clefts (p^) the
following calculation was used;
p^ = 1000 x p./l - p Czeizel & Tusnady (1984)
PT = total birth prevalence of congenital anomalies
The total birth prevalence for congenital anomalies of 36.6 per 1000 total
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FIGURE 3
JENSEN SEVERITY SCORING SYSTEM





FIGURE 3. Jenson severity score. Diagrammatic representation of the
scoring system used by Jensen et al. (1988). Cleft lip 1: notching of
the upper lip to one-third of lip height 2: cleft of one- to two- thirds
of lip height 3: two-thirds to subtotal cleft 't: total. Cleft palate 1:





birth was used in the study was calculated from the Glasgow EUROCAT
registery over the study period (De Wals & Lechat 1986).
Groups were compared using the chi-squared test, the Yates correction
factor was used in the two by two contingency tables. Evidence of
cyclical trends within the facial clefts groups were assessed using both
the non-parametric rank-sum method described by Hewitt et al. (1971)
and the parametric method described by Edwards (1961).
2.1.4 Syndrome identification
Many of the patients had been assessed prior to the study by one or
other of the regional specialists involved in the care of facial clefts (Mr.
P.A. Raine, consultant paediatric surgeon, RHSC, Glasgow and Mr. J.O.
Boorman, consultant plastic surgeon, Canniesburn Hospital, Glasgow).
The cases notes, post-mortem reports or obstetric records of all the index
cases were reviewed. Syndrome diagnoses made prior to the study were
critically evaluated, whenever possible clinical examination was carried
out by the investigator; when this was not possible hospital or
post-mortem records and clinical photographs were reviewed. All cases
with associated abnormalities were assigned to 'known' (syndrome
identified) or 'unknown' (no syndrome diagnosis) catagories. The
unknown catagory was further reviewed with the help of DrJ.L.Tolmie,
consultant clinical geneticist, the London Dysmorphology Database and
the Dysmorphology Group, Institute of Child Health, London.
2.2 RNA LOCALISATION STUDIES
The source of the chemicals and enzymes used in the study are shown in
Table V.
2.2.1 Mouse Strains and Embryo Collections
In the fust part of the RNA localisation study, outbred strains of NIH and
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TABLE V
Sources of chemicals and enzymes
Chemical Source
^11-trans retinoic acid Sigma
S uridine triphosphate Amersham
BSA, DNAse and RNAse free Pharmacia
Corn oil (pfs) Sigma









K5 nuclear track emulsion Hford
Molecular size markers (lkb ladder) Gibco BRL

















UTP-S New England Nuclear
Enzyme Source
DNAse I (RNAse-free) Pharmacia




SP6 RNA polymerase (cloned, FPLC pure) Pharmacia
T7 RNA polymerase (cloned, FPLC pure) Pharmacia
T3 RNA polymerase (cloned FPLC pure) Pharmacia
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Parkes mice were used. Parkes females or NIH/Parkes females were
mated with NIH males to generate litters and embryos. These animals
were obtained from the National Institute of Medical Research, London.
The C57BL/6 mice (Harlan Olac) used to generate the control and RA-treated embryos used in the
second part of the study chosen for two reasons. (1) TGF|3 expression in normal embryos of a different
mouse strain could be studied thus showing whether expression patterns in NIH/Parkes embryos are
strain-specific. (2) The effects of RA-administration (at different gestational ages and dosages) on palate
development had been extensively studied in this strain (Abbott et al. 1989) thus facilitating experimental
design.
The animals were kept on a 15 hr light/9 hr dark cycle. The day on which the copulation plug was found
was called day 0.5 of development.
2.2.2 Dosing
All-trans retinoic acid (RA) was stored in the dark at -20°C. The dosing
solutions were prepared immediately prior to administration. RA was
dissolved in 2 parts dimethyl sulphoxide and then 3 parts corn oil to a
final concentration of lOmg/ml. Pregnant mice were weighed and
received a single gavage of lOOmg/kg on gestation day (GD) 12. Dosage
and vehicle selection were based on the studies of Abbott et al. (1989).
Embryos were collected on GD 13.5 and 14.5.
(Personal licence No: PIL 60/02854 issued under Animal (Scientific Proceedures) Act 1986, expires June 1991)
Other sections of RA-treated C57BL/6 murine embryos (lOOmg/Kg in
com oil on GD 10 & GD 12) were kindly supplied by Dr. Barbara Abbott
(NIH, Bethesda). These sections, fixed and embedded using an identical
protocol, were supplied as part of a collaborative study of the effect of
RA administration on TGF6 expression patterns
2.2.3 Preparation of solutions and glassware techniques
All solutions for RNA techniques, including solutions for the
prehybridisation treatments of sections for in situ hybridisation and
solutions used in riboprobe synthesis reactions, were millipore filtered,
treated with diethylpyrocarbonate (DEPC) and autoclaved unless
otherwise specified.
All glassware used in the above mentioned procedures was baked
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overnight at 250°C to destroy contaminating nucleases. Disposable
plasticware was soaked in a DEPC solution and autoclaved for the same
reason.
Chloroform/Isoamvlalcohol
Chloroform was mixed with isoamylalcohol at 24:1 (v/v).
Denhardt's Solution (50x1
1% (w/v) bovine serum albumin, 1% (w/v) Ficoll and 1% (w/v)
Polyvinylpyrolidone were dissolved in milliQ H20, cleared by millipore
filtration and stored in aliquots at -20°C.
Gel Loading Buffer (6x1
0.25% bromophenol blue and 0.25 % xylene cyanol were dissolved in 30
% glycerol in milliQ H20 and stored at 4°C.
Paraformaldehyde (PFA) solution
4% (w/v) paraformaldehyde was dissolved in phosphate buffered saline
(PBS) at 70°C and used the same day.
Phosphate Buffered Saline (PBS) pH 7.2
1 litre PBS was made up by dissolving 8g NaCl, 0.2 g KC1, 2.89 g
Na^HPC) (xl 2 H20) and 0.2 g KH PC) in milliRO HO,2 4 ' ® 2 4 2
Phenol (pH5.0)
A 0.1% hydroxyquindone solution in phenol was equilibrated with 0.3M
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sodium acetate, PH 5 .0 until the pH stabilised. Phenol pH 5.0 was stored
at4°C protected from light under 0.3M sodium acetate, pH 5.0.
Phenol/Chloroform
Equilibrated phenol, chloroform and isoamyl alcohol were mixed at
25:24:1 and stored under buffer at 4°C.
Polvacrvlamide Stock
19% acrylamide (w/v) and 1% bisacrylamide (w/v) were dissolved in
milliRO H?0 and stored at 4°C in the dark.
Standard Sodium Citrate (SSO pH 7.0
A 1 x solution of SSC is 0.15 M NaCl, 0.015M Na3citrate. A 20 x
concentrated stock solution was made by dissolving 175.3g NaCl and
88.2g sodium citrate in 1 litre of H^O and adjusting the pH to 7.0 with
NaOH.
THE Electrophoresis Buffer (pH 8.31
The working solution of this electrophoresis buffer is 0.089 M
Tris-borate and 0.089 M boric acid. A 10 x concentrated stock solution
was made by dissolving 121.0 g Tris base and 5.8 g of EDTA in 2 litres
of H20 and adjusting the pH to 8.3 by adding about lOOg of solid boric
acid.
57
2.2.4 Fixation and Embedding of Tissue
Tissue was fixed at 4°C by mixing for 16-24 hrs in freshly prepared,
ice-cold 4% PFA. The fixative was removed by rinsing with ice-cold
PBS, then ice-cold 0.85% saline for 30 min each. The solution was then
replaced with 10ml saline and an equal volume of 100% ethanol was
layered on, followed by thorough mixing for 15 min. The specimens
were then dehydrated by putting through ethanol:saline (1:1), two
changes of 70% ethanol for 30 min each, 85% ethanol, 95% ethanol and
100 % ethanol for 30 min each. The ethanol was replaced by Histoclear
for about 15 min or just before the specimen starts to darken. The
specimens were then transferred to a prewarmed (60°C) container of
histoclear:paraffin solution (1:1) and incubated for about 15 min (at
60°C). The solution was replaced at 60°C with filtered paraffin, three
times for 20 min each. The specimens were transferred to a plastic
mould, topped up with fresh paraffin wax, oriented as necessary with
prewarmed forceps and the blocks cooled down quickly in an ice/water
bath. Blocks were stored at 4°C.
2.2.5 Sectioning
3-Aminopropyltriethoxysilane (Tespa) coated slides were prepared
according to the method of Rentrop et al. (1986). Microscope slides
were washed overnight at 65 °C in 10% Decon and rinsed the next day in
hot (approx. 60°C) running tap water for four hours. This was followed
by 3 rinses in distilled water and a final rinse in milliQ water. The slides
were baked overnight at 250°C and dipped for 5 sec in 2% TESPA in
acetone. The slides were then rinsed in four changes of acetone and four
changes of milliQ water. This was followed by rapid, dust-free drying
either in a 40-50°C oven or in a laminar flow hood. Slides were stored
under dust-free conditions for up to two weeks before use.
Sections of 5-7 micron thickness were cut using a microtome with
disposable blades. The sections were floated on a sectioning waterbath
containing fresh milliQ water at 42°C and dried on a slide-drier at 42°C
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for 4 hours or o/n. If possible, the sections were used immediately or
stored at 4°C in the presence of dessicant.
2.2.6 Radiolabeled cRNA Probe Synthesis
To generate radiolabeled cRNA probes an in vitro transcription system
g
was used (Fig.4). These riboprobes were produced with high (10
dpm/pg) specific activity, by using 35S UTP (1000 Ci/mole) diluted 1:1
with unlabelled UTP-S. A typical incubation contained 75 pmoles each
of radiolabeled and unlabeled S-modified UTP in a 10 pi reaction
volume which also contained ATP, GTP and OTP at ImM each and 1 pg
of template DNA (see below) in the following buffer: 40 mM Tris pH
7.5, 6mM MgCl2, 4mM spermidine, 10 mM DTT, lpl RNAguard was
added together with 10 units of SP6 polymerase and the incubation
allowed to proceed for 60-90 minutes at 37°C.
The transcription reaction was followed by DNase I digestion to remove
the DNA template which might impair hybridisation reactions.
RNase-free DNase I was diluted in 25 mM Tris pH 7.6, 50% glycerol to
500 units/ml and 6pl of this dilution used in a total reaction volume of
50pl containing lOOmM NaOAc and 5mM MgS04. One more microlitre
of RNAguard was added and the reaction incubated at 37°C for 15
minutes. 30 pg carrier RNA (tRNA) was added before phenol extraction
and ethanol precipitation.
To digest the probe down to a length of around 100 bases, which is
considered the optimal probe length for in situ hybridization (Cox et. al.
1984), alkaline hydrolysis was performed. The precipitated RNA was
taken up in 50pl of 10 mM DTT and a 1 x 10 dpm sample reserved for
an analytical gel. 450pl of alkaline digestion buffer (100 mM
NaHC03/Na2CC>3 pH 10.2, DEPC treated and millipore filtered, DTT
added to lOmM just before use) was added and the digestion was
















FIGURE 4. In vitro transcription system. Diagram»*»»<- representation of
the production of radiolabelled riboprobes by in vitro transcription
method. A cDNA fragment of the gene to be studied is subcloned into a
plasmid vector in specific orientation with respect to the RNA
polymerase promotor. A mixture of labelled and unlabelled
ribonucleotides can then be incubated with the RNA polymerase to produce
a cRNA strand. This RNA is then fragmented by alkaline hydrolysis to





t - time in minutes
Lq= origi nal probe length in kb
desired probe length = 0.1
k = 0.11
For the full-length TGF81 probe, incubation time was 90 minutes. The
reaction was stopped by adding 50 ul 1M NaOAc pH 6.0, 50 ul 5% acetic
acid and 10 pg carrier RNA.
The sample was then run over a Sephadex G50 spin column (1100
r.p.m/1 min.) to free it from the sodium carbonate salts and to eliminate
any unincorporated radioactivity. The column buffer was 0.3 M NaOAc
pH 5.0, 10 mM Tris, 1 mM EDTA, 0.1% SDS, with DTT added to
lOmM just before use. The radiolabeled probe was precipitated with
ethanol, vacuum dried and taken up in lOul lOmM DTT. A 1 x 106 dpm
aliquot of digest and undigested probe was run on a 6% polyacrylantide
gel in 8M urea/TBE to check final probe length and quality of the
original transcription product (Fig.5A-F).
2.2.6.1 TGF1H Probe
The TGF81-specific probe was a 600 nucleotide Apal-Kpnl fragment
from the 51 divergent precursor region of the gene
(Fig.6A). This fragment was subcloned into Bluescribe (Stratagene) in
antisense orientation with respect to the T3 promotor. The full-length
murine TGF81 cDNA (Derynck et al. 1986) was kindly provided by Dr
R. Derynck (Genenteck). The subclone corresponds to the precursor
region of the TGF81 polypeptide (amino acids 68-268).
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Figure 5
P.A.G.E. GEL OF RADIOLABELLED RIBOPROBES
FIGURE 5. P.A.G.E. gel of radiolabelled riboprobes. Denaturing
polyacrylamide gel of the radiolabeled cRNA produced by in vitro
transcription, Full-length transcripts (A,C,E) and post-alkaline
digestion products (B,D,F) are represented. (A,B) TGF betal (C,D) TGF
beta2 (E,F) TGF beta3
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2.2.6.2 The TGFB2 Probe
The TGFB2 DNA probe was obtained by amplification of the reverse
transcriptase product of total mouse embryo RNA using the polymerase
chain reaction (Saiki et al. 1988). The oligonucleotide primers spanned
the initiation and termination codons. This probe was identical in
nucleotide sequence to that reported by Miller et al. (1989) (F. Denhez
unpublished). The initial experiments in this study used the full-length
TGFB2 probe cloned into Bluescribe (Stratagene) in antisense orientation
with respect to the T3 promotor. However in the latter part of the study a
TGFB2 specific probe became available. This was a 501 nucleotide
Pstl-Sacl fragment, spanning amino acid residues 81-249 (Fig.6B),
inserted antisense with respect to the T7 promotor. Both of these probes
have shown identical hybridisation patterns during murine palatogenesis
and in all other developmental systems in the mouse embryo (Millan et
al. 1991)
2.2.6.3 The TGFII3 Probe
The TGFB3-specific probe was a 732 nucleotide Xbal fragment
subcloned into pBluescript KSII (Stratagene) orientated such that
antisense probe was generated using the T3 promotor (Fig.6C). This
region spans amino acid residues 8 to 251 of the precursor polypeptide
(Denhez et al. 1990).
2.2.6.4 Control Probe
The control probe used was a full-length TGFB1 human cDNA, kindly
supplied by Dr G. Bell (unpublished). It was also subcloned into the
Bluescribe vector in sense orientation with respect to the T7 promoter.
Nucleotide sequence homologies between the three gene-specific probes
were 42% (betal to beta2), 47% (beta2 to beta3) and 36% (betal to
beta3)(Pelton et al. 1989; Denhez et al. 1990).
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FIGURE 6
TGFB Gene Specific Probes







FIGURE 6. TGF beta subclones. Diagramatic representation of the cDNA
fragments used to generate the riboprobes used in the study. (A) TGF
betal Apal-Kpnl fragment (B) TGF beta2 specific Pstl-Saci fragment (C)
TGF beta3 Xbal fragment.
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2.2.7 In situ Hybridization
The in situ hybridisation procedure used in the study is based on that of
Wilkinson et al. (1987). Sections were de-waxed in fresh histoclear for
10 minutes (twice), washed in 100% ethanol for 2 minutes and
rehydrated quickly by putting through an ethanol series (100%, 100%,
95%, 85%, 70%, 50%, and 30%) and rinsed in 0.85% saline, then PBS,
for 5 minutes each. A 20 minute post-fixation in 4% PFA was followed
by two 5 minute washes in PBS and treatment with 20pg/ml proteinase K
in 50mM Tris, 5mM EDTA (freshly diluted from stock) at room
temperature for 7.5 minutes. Slides were washed twice in PBS for 5
minutes and refixed in 4% PFA for 5 minutes, quickly rinsed in distilled
water and placed in a glass trough containing 200 ml 0.1 M
triethanolamine pH 8.0 and a stir bar. While stirring, 500pl of acetic
anhydride was added to the dish and left stirring for 10 minutes. The
sections were then washed for 5 mins each in PBS and saline, followed
by dehydration through ethanol series and air drying. The slides were
used the same day for hybridisation.
Hybridisation was carried out in the following buffer: 60% formamide,
0.3 M NaCl, 20 mM Tris pH 8.0, 5 mM EDTA, 10 mM NaPC>4 pH 8.0,
10% Dextran sulphate, 1 x Denhardt's, 0.3 mg/ml tRNA, 0.3 mg/ml
rRNA, 0.3 mg/ml polyA.
Probes were taken up in this buffer at 3 ng/ul/Kb probe complexity.
3-10pl of hybridisation mixture was used to overlay each specimen
which was then covered with a siliconised coverslip. Slides were placed
horizontally in a plastic slide box containing a tissue paper soaked in
50% formamide, 5 x SSC and sealed with tape. The box was then placed
in a dry incubator at 52°C for 16-18 hours.
The next day, slides were washed for 15 minutes in 5 x SSC, 20 mM
2-mercaptoethanol at 50°C to remove the coverslips and then put through
the following washes:
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1) 50% formamide, 2 x SSC, 0.2M 2-mercaptoethanol, 65°C,
20 minutes.
2) RNase buffer (0.5 M NaCl, 10 mM Tris, 5 mM EDTA)
37°C, 10 minutes, three times.
3) 20|jg/ml RNase A in RNase buffer 37°C, for 30 minutes
4) RNase buffer 37°C, 15 minutes.
5) 50% formamide, 2 x SSC, 0.2M B-mercaptoethanol, 65°C.
20 minutes.
6) 2 x SSC, 50°C, 15 minutes.
7) 0.1 x SSC, 50°C, 15 minutes.
The slides were then dehydrated through an ethanol series, air dried and
dipped in 0.1% gelatine, 0.01% CrK(SC>4), followed by air drying under
dust free conditions.
2.2,8 Autoradiography
ilford K5 nuclear track emulsion was diluted on the day of use by
melting 6ml of emulsion shreds at 50°C with an equal volume of 2%
glycerol in H20. Each experimental slide was dipped into emulsion, left
to drain vertically for two seconds and dried horizontally in a large light
tight box after the back of the slide has been wiped clean.
When the slides were dry (usually after about three hours), they were
transferred to a light tight plastic slide box containing dessicant.
Exposure at 4°C was usually for 3 days, one week or three weeks.
Before development, the slides were allowed to warm up to room
temperature for two hours. Slides were developed for 2.5 minutes in
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Ilford phenisol, development was stopped in 2% acetic acid (30 seconds),
followed by a 30 second rinse in distilled H^O and fixation in freshly
made 30% sodium thiosulphate for five minutes. The slides were then
washed under running tap water in the dark room for one hour, rinsed in
distilled H20 and stained with haematoxylin, destained as required and
mounted in neutral mounting fluid.
2.2.9 Microphotography
Results were photographed on an Olympus BH2 microscope equipped
with dark-field optics and a manual C35DA-2 35mm camera. Kodak
Panatomic X film (ISO 32) was used and developed in Kodak D76
developer for 5 minutes at 20°C. Dark-field images were photographed
by using a 6-8 fold underexposure and bright-field images were exposed
at the normal setting, using a LBD-2N blue filter.
In later experiments double-exposure colour photography was used to
demonstrate the distribution of silver grains. The Olympus IF550 filter
was used on light field exposure with a 4-6 fold underexposure on






286 patients affected with cleft lip, cleft palate or both were identified
amongst the 187,321 total births to women residing in the West of
Scotland between 1st January 1980 and 31st December 1984. The birth
prevalence for this time period was thus estimated as 1.53 +/-0.09 per
1000 total births (°/ TB). 51/286 (17.8%) of the cases had cleft lip
OO
(CL), 147/286 (51.4%) had cleft palate (CP) and 88/286 (30.8%) had
cleft lip and palate (CLP). Table VI shows the total birth prevalence of
each of these sub-groups. 268/286 (93.7%) of the patient were liveborn
out of the 186,139 live births during the study period, thus the live birth
prevalence can be calculated as 1.44 +/-0.09 per 1000 live births ('V^JLB)
for all facial clefts. Of the live born patients 51/268 (19.0%) had CL,
142/268 (53.0%) had CP and 75/268 (28.0%) had CLP (Table VI).
TABLE VI Birth Prevalence of Facial Cleft Subgroups





CL 51 0.27 +/-0.038 51 0.27 +/-0.038
CLP 88 0.47 +/-0.050 75 0.40 +/-0.046
CP 147 0.79 +/-0.065 142 0.78 +/-0.064
In 168/286 (58.7%) of the patients the facial cleft represented an isolated
congenital anomaly. If patients with isolated Pierre Robin sequence
(PRS) are included the proportion rises to 187/286 (65.4%). However
the birth prevalence of isolated facial clefts calculated by excluding all
cases with associated major congenital malformtions (p.) may be an
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underestimate as it will ignore the possibility of randomly associated
congenital anomalies. Table VII shows the corrected birth pevalence (p^)
of the sub-groups calculated using the method of Czeizel & Tusnady
(1984) (see section 2.1.3).
TABLE VII Birth Prevalences of Isolated Facial Clefts
Cleft Type No.isolated p.










3,2 CLEFT LIP WITH OR WITHOUT CLEFT PALATE
3.2.1 Side of cleft
139 cases of cleft lip with or without cleft palate (CL(P)) were identified,
51/139 (36.7%) had cleft lip only (CL) and 88/139 (63.3%) had cleft lip
and palate. Of these 139 patients with CL(P), 86 (61.9%) had unilateral
defects, two cases had midline defects (1.4%) and in 41 cases (29.5%)
the defect was bilateral. In 10 cases (7.2%) the nature of the lip defect
was not recorded in the hospital or pathology records and no
photographic or clinical follow up was available.
In the unilateral CL(P) cases (where laterality was recorded) left sided
defects were more common accounting for 55/86 (63.9%) of this group.
This excess was statistically significant (x = 6.7 p<0.01). Table VIII
shows that left sided lesions are commoner in the sub-groups with no
associated abnormalities although only the isolated CL(P) male excess
achieves statistical significance (x~=7.8 p<0.05). In CL(P) cases with
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associated abnormalities there was no difference in unilateral CL
laterality and bilateral defects constituted a higher proportion of the
defects with 20/43 (46.5%) with bilateral defects, 10/43 (23.3) with right
sided and 13/43 (30.2%) left sided defects. This difference however was
not statistically significant (YM x2=3.54 p<0.1 p>0.05).
TABLE VIII Laterality of Hp defect in the CL(P) group
Side Isolated Associated Abn
CL CLP CL CLP
Right 14 10 1 6
Left 21 27 2 5
Bilateral 5 19 0 17
3.2.2 Severity of cleft
The distribution of defect severity, quantified using the method of Jensen
et al. (1988), is presented graphically in Figure 7. 43/51 of the cleft lip
only group could be scored, 32/43 (74.4%) had scores of 2 or 3. 84/88
of the cleft lip and palate group could be scored, 69/84 (82.1%) had a
score of 4 compared to 7/43 (16.2%) of the cleft lip only group. This
difference was highly statistically significant (YM x =48.64 p<0.001).
3.2.3 Sex differences
In the 139 CL(P) group there was a statistically significant excess of
males accounting for 90/139 (64.7%) of the cases (YM x2=8.36 p<0.01)
thus giving a male:female ratio (m:f) of 1.84:1 (cf. 1.052:1 for total births
in this period). If cases with associated major anomalies are excluded the
sex difference in the 103 remaining cases becomes more marked with
males representing 74/103 (71.8%) with a m:f=2.55:l (YM x2=15.45
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FIGURE 7. Severity score in the facial cleft groups. Jensen severity
scores of the ascertained patients displayed graphically. (A) Cleft lip
group (B) Cleft lip and palate group (C) Cleft palate group.
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p<0.002). There is no statistically significant sex difference in the group
with associated major abnormalities (Table IX).
TABLE IX Sex differences within the facial cleft group
Defect Isolated Associated
Male Female Male Female
CL 35 11 3 2
CL+P 39 18 13 18
CL(P)Total 74 29 16 20
CP excl. PRS 30 40 27 27
PRS 5 14 4 0
3.2.4 Geographical distribution in CL(P) group
The geographical distribution assessed by the mother's Health Board of
residence at time of birth is shown in Table X. None of the differences
in birth prevalence between Health Boards achieve statistical
significance.
3.2.5 Seasonal distribution of births in the CL(P) group
The temporal distribution by month of birth is shown in Figure 8. Using
either the Edwards parametric test (Edwards, 1961) or non-parametric
rank-sum (Hewitt et al. 1971) tests no significant cyclic trend was
demonstrated within the group (or subgroups) when compared with
figures for total births in the West of Scotland over the same time period.
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Figure 8
Seasonality in the Facial Cleft Groups
Seasonal distribution in die
CL(P) group by month of birth
Month of birth
Seasonal Distribution in CP
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
Month
FIGURE 8. Seasonal variation in the facial cleft groups. Graphical
representation of the births to women resident in the West of Scotland
during the study period by month. (A) Cleft lip with or without cleft




13/139 cases in the CL(P) group were stillborn, all of the stillborn infants
with CL(P) had major associated abnormalities (Appendix C). Of the
126 live born cases in the CL(P) group 10 had died by 1/1/90, 8 of the 10
fatalities had major associated anomalies (Appendix D). The proportions
of stillbirths (YM x2=2.89 p<0.1 p>0.05) and early deaths (YM x~=0.08
p»0.1) are not statistically significantly different from those found in
the CP group (see (section 3.3.5).
TABLE X Health Board of residence at time of birth
Health Board Total Births CL(P) cases CP cases
(1980-84) (1980-84) (1980-84)
Argyll & Clyde 30518 24 [0.79] 26 [0.85]
Ayrshire & Arran 24899 22 [0.88] 19 [0.76]
Diwifries&Galloway 8787 9 [1.02] 6 [0.68]
Forth Valley 17340 13 [0.75] 8 [0.46]
Greater Glasgow 65257 45 [0.69] 59 [0.91]
Lartarksire 40520 26 [0.64] 29 [0.72]
Total 187321 139 [0.74] 147 [0.79]
[n] = Birth prevalence (°/ TB)
3.2.7 Associated abnormalities
48/139 (34.5%) of the CL(P) group had associated abnormalities. 36/48
(75%) were major malformations. Single gene defects account for 8/139
(5.7%) chromosomal aberrations 5/139 (3.6%) and identifiable
malformations 8/139 (5.7%). A further 17/139 (12.2%) had multiple
malformations that could not be identified as part of a particular
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syndrome. The known diagnoses in this group are summarised in Table
XII. The abnormalities associated with the CL(P) in the unknown group
are summarised in Table XI. Details of these patients can be found in
Appendix E.
147 cases of cleft palate (CP) were identified in the study, in two of the
cases the degree of cleft was not recorded. 130/145 (89.6%) had severity
scores of 2 or 3, represented graphically in Figure 7.
TABLE XI Abnormalities associated with facial cleft cases
with no identified syndrome
Defect CL(P) Cases CP Cases
3.3 THE CLEFT PALATE GROUP

































3.3.2 Sex distribution in the CP group
81/147 (55.1%) of cases in the CP group are female giving a male:female
ratio of 0.81:1. This female excess is not statistically significant (YM
x =3.11 p>0.05). There was however a statistically significant excess of
females in the subgroup of CP without associated abnormalities
(m:f=35:54=0.65:l)(YM x2=6.19 p<0.05). In the subgroup of CP with
associated abnormalities there was no female excess (m:f=31:27=1.15:1).
The m:f ratios in the isolated CP group are highly statistically
significantly different from those found in the isolated CL(P) group (YM
xs=19.27 p<0.001) (Table VII). No statistically significant difference is
found between the CP and CL(P) groups with associated abnormalities
(YM x2=0.41 p>0.1).
3.3.3 Geographical distribution in CP group
The geographical distribution of the cleft palate group by mother's Health
Board of residence at time of birth is shown in Table VIII. No significant
differences are seen in the total birth prevalence figures although Forth
Valley would appear to have fewer cases of CP than would be predicted
(YM x2=l .78 p>0.l).
3.3.4 Se .sonal distribution of births in the CP group
The temporal distribution in the CP group shown by month of birth is
graphically summarised in Figure 8. There are no statistically significant
differences in the whole group or the sub-groups when compared with
the total births for the same period.
3.3.5 Outcome in the CP group
5/147 (3.4%) ca;es in this group were stillborn, all had associated
abnormalities; details of this group are given in Appendix C. Of the 142
live born children with cleft palate, 14 (9.7%) had died by 1/1/90
(Appendix D), a!! had major associated abnormalities. Neither of these
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TABLE XH Known diagnoses in the CL(P) group
Single Gene Defects Chromosomal Defects Malformation Syndromes
Myotonic dystrophy

















TABLE XIII Known diagnoses in the CP group























Pierre Robin anomalad (23)
Schisis association (4)
VATER association
lst/2nd arch syndrome (2)
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figures are significantly different from those found in the CL(P) group
(see section 3.2.6).
3.3.6 Associated abnormalities
86/147 (58.5%) of the CP group had associated abnormalities, 58/86
(67.4%) had major malformations associated with cleft palate. Single
gene defects accounted for 12/147 (8.2%), chromosomal abberations
8/147 (5.4%), malformation syndromes 30/147 (20.4%) and teratogenic
agents 1/147 (0.7%, fetal alcohol syndrome). The known diagnoses are
summarised in Table XIII. A further 22/149 (14.8%) had associated
malformations that could not be placed in a particular syndrome
diagnosis, the anomalies occurring in these 'unknown' malformation
syndromes are shown in Table XI, no significant differences are seen in
the associated abnormalities occuring in the CL(P) group and those
seen in the CP group. Details of the patients with unknown
syndromes can be found in Appendix E.
3.4 RNA LOCALISATION STUDIES
The spatial and temporal distributions of RNAs encoding the three
related growth factors, TGFBl, B2 and B3 were investigated during
murine palatogenesis from 11.5 to 15.5 days gestational age. In situ
hybridisation was performed on 5-7 pm coronal sections of the murine
embryonic head using radioactive gene-specific probes complementary to
each transcript (see 2.2.6). As a negative control, a human TGFBl sense
probe was employed which gave no specific hybridisation signal (Fig.
9B). In total 50 embryos from 12 litters were studied (Table XIV).
No specific hybridisation of any probe was seen in the very early palatal
shelves at 12.5 days gestational age (Fig.9C-H). The first appearance of
TGFB transcripts occurred at the late vertical shelf stage. In this study two
patterns of RNA distribution were seen at this time and later in shelf
development. TGFBl and B3 are expressed in the medial edge epithelia,
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whereas TGFB2 RNA is localised in the underlying mesenchyme.
3.4.1 Late vertical palatal shelves.
At 13.5 days gestation the TGFB 1-specific probe showed strong
hybridisation to the submandibular gland (Fig.IOC). At this stage, the
palatal shelves, which are growing vertically, show no specific
hybridisation to this probe.
The first TGFB gene to show high level expression in the palatal
processes is that for TGFB3 (Fig.lOG,H). This gene is expressed in the
epithelial component of the palatal shelves in the region that will give
rise to the future medial edge epithelium. In several embryos examined,
the spatial extent of the hybridisation signal is identical. TGFB3
expression is more extensive in the vertical epithelium facing the tongue
and stops abruptly on the oral side. In the most anterior region of the
oro-nasal cavity, the epithelium of the nasal septum, which is also
destined to fuse with the palatal shelves, shows high level TGFB3
expression (Fig.lOG).
There is a low level of hybridisation of the TGFB3 probe to the
mesenchyme of the tongue, mandible and the upper regions of the
maxillary processes. The mesenchyme immediately adjacent to the
medial edge epithelium is, however, markedly devoid of
autoradiographic signal. This observation was also made at later stages
(see Fig.11,12).
At this early stage, TGFB2 does not appear to be specifically expressed in
the palatal processes, although a characteristic signal is seen in the
differentiating olfactory epithelium of the nasal process (Fig.lOE,F). On
some sections, small regions of the medial edge epithelia show
hyperplasia which represent the developing palatal rugae. The epithelial
cells within these small blebs of stratified epithelium (Fig.lOE) express
very high levels of TGFB2 RNA (Fig.lOF), whereas there is no
hybridisation with either TGFB I or B3.
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Figure 9
TGF beta ISOFORMS IN EARLY PALATOGENESIS
Localisation of TGF betal, _2 and _3 in early palatal shelves. Coronal
sections are presented from 12.5-day embryos through the anterior third
of the palatal shelves. A,C,E and G are bright-field images, B,D,F and H
are dark-field. (A) Bright-field image showing tongue (to),palatal
shelves (ps) and nasal septum (ns). (B) Dark-field images showing
non-specific hybridisation with sense probe. (C) Bright-field image of D
(D) TGF betal probe showing no specific hybridisation (E) Bright-field
image showing TGF beta2 hybridisation to the nasal epithelia (ne) (F)
TGF beta2 showing no specific hybridisation in the palatal shelves (G)






IGF beta ISOFORMS IN VERTICLE PALATAL SHELVES
Coronal sections are presented from 13.5-day embryos through the
anterior third of the vertical palatal shelves. A and E,F,G,H are
bright-field images, B,C,D are dark-field. (A) Bright-field image
showing tongue (to),palatal shelves (ps) and nasal septum (ns). (B)
Dark-field images showing non-specific hybridisation with sense probe.
(C) TGF betal probe showing hybridisation to the submandibular gland
(sm). (D) Non-specific mesenchymal hybridisation of TGF beta2 probe with
localised area of expression in the epithelium of the left palatal
shelf. (E) High-power image of adjacent section to D showing localised
hyperplasia (hy) in the epithelia of one palatal shelf (ps). (F)
High-power view of epithelial expression in D. (G) Hybridisation of the
TGF beta3 probe to the medial epitheiia of the palatal shelves and the
oral epithelium of the nasal septum. (B) High-power view of the palatal
shelf (ps) epithelial expression (boxed area) in Cj. Scale bar




3.4.2 The horizontal palatal shelf.
After elevation of the palatal shelves at around 14.0 days gestation, the
medial edge epithelia come into almost immediate contact (Fig. 11 A). At
this stage, TGFBl is now detectable in the medial edge epithelia in the
same cells that express TGFB3 (Fig. 1 IB). TGFBl expression is also seen
in regions of membramous ossification is also seen within the developing
maxilla (Fig.l IB).
By this time the quantity of TGF83 RNA in the medial edge epithelium
has increased considerably. There is striking hybridisation with this
probe in both in the medial edge epithelia and the epithelium of the oral
aspect of the prefusion anterior nasal septum (Fig.llF,G,H).
TGFB2 RNA is excluded from the palatal epithelium, but a gradient of
expression is seen within the mesenchyme beneath the medial
epithelium, with highest expression levels immediately adjacent to the
epithelium (Fig.l IE).
3.4.3 The fusing palate.
With fusion of the medial edge epithelia to form the epithelial seam, the
expression patterns established in the horizontal shelves continue.
TGFBl (Fig.l2B) and TGF83 (Fig.l2D,G,H) RNAs are localised to the
epithelial cells of the seam. This expression is lost as the seam disrupts
and the cells lose their epithelial phenotype by transformation into
mesenchymal cells.
TGFB2 transcript levels increase and are are now easily seen in the
mesenchyme on either side of the seam (Fig.l2C,E,F). The RNA
distribution is asymmetric with a higher concentration towards the nasal
side of the palate.
85
Figure 11
TGF beta ISOFORMS IN HORIZONTAL PALATAL SHELVES
All sections are from 14.0-day embryos. (A) Coronal bright-field image
of horizontal, middle third palatal shelve (ps) medial edge epithelia
(me) with the nasal septum (ns) above and oral cavity (oc) below. (B)
Adjacent section to A with TGF betal probe hybridising to the maxilla
(ma) and medial edge epithelia (me). (C) Bright-field paramedial
sagittal section through posterior medial edge epithelia (me). (D)
Dark-field image of C with TGF betal probe specifically hybridising to
the medial edge epithelium. (E) Dark-field image of coronal section TGF
beta2 hybridising to the medial and nasal palatal mesenchyme. (F) TGF
beta3 hybridising to the medial edge epithelia on adjacent section to A.
(G) Dark-field image of coronal section through middle third of palate,
posterior to F, TGF beta3 probe hybridises to the medial edge epithelia.
(H) High-power view of the palatal shelves (ps) and medial edge
epithelia (me) expression in G (boxed area). Scale bar (A,B,C,D,E,F,G)
represents 50um and in (H) 200um.
 
Figure 12
TGF beta ISOFORMS IN THE FUSING PALATE.
All sections are coronal through the middle third of the fusing palate
of lit.5-day embryos. (A) Bright-field image of fusing palate with the
midline epithelial seam (es). (B) Dark-field image showing TGF betal
faint hybridisation to the epithelial seam. (C) Dark-field image of TGF
beta2 hybridisation to the medial and nasal palatal mesenchyme. (D)
Dark-field image of specific hybridisaton of TGF beta3 to the epithelial
seam. (E) High-power bright field image of the epithelial seam (es) in C
showing absence of TGF beta beta2 expression in the seam. (F) Dark-field
image of E. (G) High-power image of the epithelial seam (es), showing
hybridisation only where the seam is intact. (H) Dark-field image of G.
Scale bar (A,B,C,D) represents 50um and in (E,F,G,H) 200um.
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3.4.4 The maturing palate.
After fusion, TGFB2 continues to be expressed in a diffuse region of the
mesenchyme around the midline of the palate (Fig.l3C). Postfusion,
TGFB3 expression also switches to become primarily mesenchymal (Fig.
13D). Hybridisation is seen in the perichondrium of the nasal septum as
well as in the mesenchyme of the anterior secondary palate (Fig. 13D).
TGFB1 expression in the maturing palate is limited to areas of
ossification within the palate and around the nasal processes (Fig.l3B).
3.5 Retinoic acid-treated embryos
In this part of the study sections of mouse embryos treated with RA were
hybridised with anti-sense radiolabeled riboprobes to detect TGFB1, B2,
B3 RNA. Two groups of treated embryos were used in this study. The
first group, named the Glasgow embryos (Fig.l4A-H), were generated
from C57BL/6mice and treated by the author at GD 12 with lOOmg/kg of
RA and collected on GD 14. A total of 30 embryos from 6 litters
were studied (Table XIV). The second group, named the Bethesda
sections (Fig.15, 16 & 17) were supplied by Dr. Barbara Abbott (N1H,
Maryland) as part of a collaborative study. These were generated from
C57BL/6 crosses with the embryos treated with lOOmg/Kg of retinoic
acid on GD 10 (see section 2.2) and collected on either GD 12.5 or GD
14.5. A total of 20 embryos from 6 litters were studied (Table XIV).
3.5.2 The Glasgow Sections
The control (untreated) embryos collected on GD 14 from this group
showed no difference in developmental stage or hybridisation pattern to
those reported in section 3.4, with TGFB1 (Fig.l4C) and TGFB3 (Fig.
14E) being expressed in the MES and TGFB2 in the medial edge palatal
mesenchyme. The RA-treated embryos the palatal shelves do not appear
hypoplastic, however, they are phenotypically abnormal as the palatal
shelves have not undergone reorientation and are therefore still vertical in
position. In spite of this developmental delay the hybridisation of TGFB3
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Figure 13
TGF betas IN THE MATURING PALATE
Sections have been cut coronally through the middle third of the palates
of 15.5-day embryos. A is a bright field image and B,C,D are dark-field.
(A) The maturing palate (p). (B) TGF betal probe hybridising to the
areas of ossification within the palate and around the nasal processes
(np). (C) Diffuse hybridisation of the TGF beta2 probe to the mesenchyme
around the midline of the palate. (D) Specific perichondria! (pc)
hybridisation of the TGF beta3 probe around the nasal septum and the




to the MEE is clearly seen (Fig.l4H), with no specific TGFB2 RNA
localisation (Fig.l4F). TGF61 probe hybridises to the submandibular
gland but not to the MEE (Fig.l4D).
3.5.3 The Bethesda Sections
The control (untreated) embryos from this group of slides showed no
difference in expression pattern from the NIH/Parkes crosses (see section
3.4) either on GD 12.5 (Fig.l5A,C,E) or GD 14.5 (Fig. 16A,C,E). In the
treated embryos collected on GD 12.5, the palatal shelves were
considerably less distinct than those in the control embryos (Fig. 15B,D,F).
There was no specific pattern with any probe at this gestation with either
control or RA treated sections (Fig.l5A-F).
In the sections from the RA treated embryos collected on GD 14.5, the
palatal shelves are noticably hypoplastic with grossly abnormal orofacial
structure (Fig.l6B,D,F). These changes are similar to those previously
reported by Abbott et al. (1989). Although the treated sections are
phenotypically abnormal the hybridisation signal for all three TGFBs
follows the 'normal' patterns established in the NIH/Parkes (section 3.4)
and untreated C57BL embryos (see above). TGFC3 RNA is abundant in
the MEE (Fig. 16F), with TGF62 hybridising to the medial edge palatal
mesenchyme (Fig.l6D) and a TGFI51 low-level signal is seen in the same
palatal areas as TGFB3 (Fig.l6B). The control embryos at this gestation
have normal, elevated shelves and have formed midline epithelial seams
(Fig.l6A,C,E).
One difference in hybridisation pattern between the control and
RA-treated embryos is the localisation of TGF62 RNA to the MEE as
well as the medial edge palatal mesenchyme (Fig. 17A). TGF82 is also




Coronal sections through the anterior third of the palate of embryos
harvested on 14.5 GD. Double exposure images are shown with red
representing the silver grains. Untreated C57BL embryo (A) and
RA-treated embryo (B) showing no specific hybridisation of the sense
probe. (C) Untreated embryo showing hybridisation to the developing
maxilla (ma) with slight signal in the MES of the palatal shelves (ps)
with the TGF betal probe (D) RA-treated showing hybridisation of the TGF
betal probe to the submandibular gland only (E) Untreated embryo probed
with TGF beta2 showing slight hybridisation to the medial edge palatal
mesenchyme (F) RA-treated showing non-specific mesenchymal hybridisation
of the TGF beta2 probe to the mesenchyme surrounding the submandibular
gland (G) Untreated embryo probed with TGF beta3 with strong
hybridisation to the medial epithelial seam (mes) (H) RA-treated embryo
with hybridisation of TGF beta3 probe to the MEE.
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Table XIV Numbers of embryos studied
Study No. ofLitters No. ofembryos
NIH/Parkes study 12 50
Glasgow C57B controls 3 15
C57B RA-treated 3 15
Bethesda C57B controls 3 10
C57B RA-treated 3 10
In summary a distinctive pattern of the three mammalian TGFB isoform
expression has been demonstrated. This expression pattern is not




BETHESDA RA-TREATED EMBRYOS 12.5 GD
Coronal sections through the anterior third of the palate of embryos
harvested on 12.5 GD. Double exposure images are shown with red
representing the silver grains. Untreated C57BL embryo (A) and
RA-treated embryo (B) showing no specific hybridisation signal in the
palatal shelves (ps) with the TGF betal probe. (C) Untreated embryo
probed with TGF beta2 showing hybridisation to the mesenchyme and
epithelia of the nasal septum (D) RA-treated showing hybridisation of
TGF beta2 probe to chondrogenic blastema (ch) of the snout (E) Untreated
embryo probed with TGF beta3 with no specific RNA localisation (F)
RA-treated embryo with hybridisation of TGF beta! probe to the maturing
chondrogenic blastema.
Sections B,D,F in this figure appear to be anterior to sections A,C,E this effect is due to the remarkable











BETHESDA EA-TREATED EMBRYOS 14.5 GD
Coronal sections through the anterior third of the palate of embryos
harvested on 14.5 GD. Double exposure images are shown with red
representing the silver grains. Untreated C57BL embryo (A) and
RA-treated embryo (B) showing hybridisation to the developing maxilla
(ma) with slight signal in the MEE of the palatal shelves (ps) with the
TGF betal probe. (C) Untreated embryo probed with TGF beta2 showing
hybridisation to the medial edge palatal mesenchyme and epithelia of
the nasal septum (D) RA-treated showing hybridisation of the TGF beta2
probe to the MEPM, the MEE and the rugae (r) of the palatal shelves (E)
Untreated embryo probed with TGF beta3 with strong hybridisation to the
medial epithelial seam (mes) (F) RA-treated embryo with hybridisation of





TGF beta2 IN RA-TREATED EMBRYOS
High-power, light-field image of the palatal shelve in Fig.l6D. (A) TGF
beta2 hybridisation to the mesenchyme of the palatal shelf and the
medial edge epithelium (mee). (B) TGF beta2 hybridising to the






4.1 THE CLINICAL STUDIES
As one of the most common easily recognisable birth defects in humans,
it is perhaps surprising that it took until 1942 for a large scale, well
ascertained study of the clinical and family aspects of facial clefts to
appear (Fogh-Anderson 1942). Although earlier studies of facial cleft
incidence had been published (Davis, 1924), the Danish study was the
first to recognise cleft lip with or without cleft palate (CL(P)) and
isolated cleft palate (CP) as distinct entities and to provide unbiased data
on recurrence risks. Since that time the developmental aspects and
etiology of these defects have been the subject of many hundreds of
scientific and clinical studies. In spite of this explosion of interest it
would appear that these studies have posed many more questions than
they have answered.
4.1.1 Birth prevalence
Since Fogh-Anderson published his landmark study there have been
more than one hundred studies reporting the birth prevalence of facial
clefts in many different populations. Fourteen of the most widely quoted
of these are summarised along with the results from the present study in
Table XV. Some of these studies use either hospital based records
(Fogh-Anderson, 1942; Bear 1976; Bonaiti et al. 1982) or birth
certificates (Woolfe et al. 1963; Tenconi et al. 1988) as ascertainment
data. The limitations of single-source data have already been discussed
and are essentially those of under-reporting and ascertainment bias
(section 1.4.2). As these problems will hamper any population based
study, the use of multiple sources of information has become accepted as
the optimal method of data collection and many recent studies attempting
to calculate true birth prevalence, including the present one, have used
diverse sources of ascertainment (Beckman & Myrberg 1972; Welch &
Hunter 1980; Wormsley & Stone 1987; Jensen et al. 1988).
Before comparing these data an attempt to estimate the efficiency of
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TABLE XV Reported birth prevalences of facial clefts
Author Year Total CL CL+P CP Population
Incidence
(No. Cases)
Present study 1990 1.53 (286) 0.27 0.47 0.79 West of Scotland
Fogh-Anderson 1942 1.5 (625) 0.375 0.75 0.375 Danish
Neel 1958 2.68 (171) - - Japanese
Longnecker et al. 1965 0.59 (163) -- -- Black Americans
Stevenson et al. 1966 1.21 (528) 0.98 0.23 WHO Multicentre Study
Chung & Myrianthopoulus 1968 1.82 (24) 1.34 0.48 European Americans
0.82 (64) 0.41 0.41 Black Americans
Lowry & Renwick 1969 3.17 (64) 0.25 2.45 0.44 Candian Indians
1.63 (737) 0.38 0.71 0.54 European Canadians
Beckman & Myberg 1972 1.72 (298) 1.17 0.55 Sweden
Saxen & Lahti 1974 1.72 (599) 0.83 0.86 Finland
Czeizel 1980 1.43 (1437) 0.37 0.71 0.35 Hungary
Welsh & Hunter 1980 2.00 (507) - -- Canada
Bonaiti et al. 1982 1.52 (646) 0.96 0.56 French
Womersley & Stone 1987 1.56 (247) 0.21 0.54 0.81 West of Scotland
Jensen et al. 1988 1.89 (678) 0.64 0.74 0.51 Danish
Tenconi et al. 1988 - (203) 0.92 -- Italy
Naguib et al. 1989 1.56 (166) 0.63 0.78 0.15 Kuwait
Total Incidence: This is given as the number of cases per 1000 total births.
(No. Cases): This figure refers to the total number of cases used in the study.
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ascertainment and identify any ascertainment bias in the present study
was made. Figures for facial cleft birth prevalence estimated from the
Glasgow EGROCAT registry were compared with those from the
non-Glasgow areas. The Glasgow EGROCAT registry is one of
seventeen EEC-funded registries established throughout Western Europe.
It catalogues all congenital malformations born to mothers resident in the
Greater Glasgow Health Board (GGHB) using multiple sources of
ascertainment and it is subjected to systematic evaluation of the accuracy
and completeness of its data (Stone, 1979). The register has access to
many privileged sources of information and considerable manpower and
is thought to have approaching 100% ascertainment for facial clefts
(Wormesly & Stone 1987). Thus, in what can be considered the well
ascertained group of GGHB residents, the birth prevalence of facial clefts
during the study period was 1.61 per 1000 total births (°/ TB) and 1.51uu
per 1000 live births (0/oqLB), whereas in non-Glasgow residents they
were 1.48 °/00TB and 1.40 °/ LB. Although these proportions are not
statistically significantly different (YM x2=0.37 p>0.1), they suggest an
under-ascertainment in the order of 8% in non-GGHB areas.
No one source for this possible under-ascertainment in the non-GGHB
areas could be identified as no pattern difference between the various
subgroups was found (e.g. CL(P):CP ratio, stillbirth rate, %age with
associated abnormalities). It is interesting that Czeizel & Tusnady (1984)
have noted very similar differences in estimates of the facial cleft birth
prevalence in the Hungarian population between the figures collected in
the city of Budapest where the study was based and a greater number of
investigators were working to complete ascertainment, and figures
collected in the'areas outside Budapest. They too failed to detect any
particular subgroup that was under-ascertained. In summary, although
there is some suggestion of under-ascertainment in the present study,
there would appear to be no ascertainment bias.
From the published reports of facial cleft birth prevalence summarised in
Table XV it can be seen that the total birth prevalence varies widely from
0.59 to 3.17 per 1000 total births. There would appear to be consistent
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racial differences in birth prevalence of CL(P), being lower than
Caucasians in African races (0.49 - 0.82 per 1000 total births) and
considerably higher than Caucasians in Oriental races (eg. Japanese,
North American Indians) at around 3 per 1000 total births (see section
1.4.1). Within populations of European origin, however, there is
considerably less variation in the reported total birth prevalence of facial
clefting, which range from 1.42 +/- 0.04 to 1.89 +/- 0.07 per 1000 total
births. These differences are relatively small and could be caused by low
sample size in individual studies, a difference in the efficiency of
ascertainment or a genuine genetic or environmental difference between
the populations. The first of these would seem an unlikely explanation
as there is no overlap at the 95% confidence intervals between the two
examples quoted above. A difference in efficiency of ascertainment
between studies, although possible, would also seem unlikely as both the
higher (Jensen et al. 1988) and the lower of these birth prevalence figures
(Czeizel, 1980) were conducted by highly respected investigators using
diverse sources of information to maximise ascertainment in well ordered
highly cooperative communities.
The third possible explanation for the differences within European
populations in overall birth prevalence is that there is genuine
environmental and/or genetic heterogeneity that alters population
thresholds for facial clefting. This view may be supported by the
significant differences in the CL(P):CP ratio between European
populations. These differences can be exemplified by comparing the
CL(P):CP ratios Scottish and Finnish studies with those in other groups.
In the present study, the CL(P):CP ratio was 0.94:1, this is similar to the
ratios obtained in two previous Scottish studies of 0.92:1 (Womersley &
Stone 1987) and 1.2:1 (Drillien et al. 1966) and the ratio of 0.96:1
reported from Finland (Saxen & Lahti 1974). The Scottish and Finnish
figures do, however, differ significantly from all other reported European
figures with an average ratio of 2.3:1 (range 1.71:1 - 3.09:l)(x2=23.45
p<0.01). It would seem unlikely that these figures represent an
ascertainment bias, as this would be likely to cause an
under-ascertainment of less obvious cleft palate as compared to cleft lip
107
with or without cleft palate. It is probable that this is a genuine but, as
yet, inexplicable difference between these groups. Beckman & Myrberg
(1972) reported a total incidence of 1.82 per 1000 total births in the
Swedish population, this total birth prevalence is similar in Northern,
Central and Southern counties of Sweden . The CL(P):CP ratio,
however, varied being 1.46:1 in Northern counties, 1.82:1 in Central
counties and 3.72:1 in Southern counties. They cited possible ethnic
heterogeneity due to an admixture of Lapps and Finns as a possible
explanation, however, it is equally possible that environmental factors
may be responsible. It would appear, therefore, that there is a relative
excess of isolated cleft palate in the more Northern regions of Europe.
4,1.2 Severity scoring
Once a patient with facial clefting has been ascertained an accurate
classification of the primary defect is desirable. If complex segregation
analyses (Lalouel et al. 1983) are to be performed and/or empiric family
recurrence data (Carter et al. 1982) calculated from this group, a method
of scoring severity of the cleft is of particlular importance. Furthermore,
some authors have suggested that knowledge of the distribution of cleft
severity within the various subgroups may contribute to our
understanding of the malformation aetiology (Jensen et al. 1988).
Several different systems have been proposed to enable quantification of
defect severity (Fogh-Andersen, 1942; Kernahan & Stark 1958; Harkins
et al. 1962; Jensen et al. 1988). In the CL(P) group, however, the
simplest method to estimate the distribution of severity is to calculate the
ratio of cleft lip only (CL) to cleft lip and palate (CL+P), in the present
study this ratio was 1:1.73 which is similar to ratios previously reported
in European populations which range from 1:1.4 - 1:2.0 (for review see
Czeizel & Tusnady 1984). However, a quantitative severity score allows
more detailed analyses to be performed. In the present study, therefore,
the method described by Jensen et al. (1988) as it was simple and
reproducible (Jensen et al. 1988) and has the advantage that patients can
be easily scored from clinical photographs.
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The Jensen defect severity scores within both the CL and CP groups
appeared to be normally distributed with the majority of patients in both
these groups scoring either 2 or 3. However, the CL+P group showed a
marked skew towards the more severe defects (score of 4). These are
remarkably similar finding to those in the Jensen et al. study (1988).
This distribution of severity of defect in the CLP group is in keeping with
the proposal, based on embryological and recurrence risk data, that CL+P
is a more severe manifestaion of CL. Czeizel & Tusnady (1984) have
used the higher incidence of CL+P compared with CL in stillborn cases
with facial clefts as further evidence that CL+P is the result of a more
severe developmental insult than CL. Results from the present study
agree with this assessment. Of the 13/139 (9.3%) of the CL(P) cases that
were stillborn, all had CLP.
4.1.3 Sex differences
One of the many puzzling features of facial cleft epidemiology is the
different sex ratios that have been reported between the two main groups
of facial clefts. In the CL(P) group, the present study has shown a
significant excess of affected males with a maleifemale ratio of 1.84 (YM
x = p<0.0l). All European studies shown in Table XV have a similar
excess of males with an average m:f ratio of 1.95:1 (range 1.82:1 -
2.11:1). However Japanese studies with a high birth prevalence of CL(P)
have shown that either the male excess is markedly reduced (Tanaka et
al. 1967) or that there is a slight excess of females in this group (Fujino et
al. 1967). Analysis of the data on both CL(P) has ruled out a significant
role for an X-linked gene (Csik & Mather, 1938; Chung et al. 1986).
Thus, the explanation that is currently most widely accepted is a
modification of the multifactorial or quasicontinuous model of
inheritance (see section 1.6.2). In this model the cumulative effect of
numerous, weak, independent factors, both genetic and environmental,
have to exceed a threshold, which is different in male and female
embryos, to cause a facial cleft (Carter 1965). Although this model has
been supported by reports showing higher risks of recurrence in the
relatives of affected females (Woolf 1971; Carter et al. 1982) there has
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been no embryological basis suggested for the sex-modified threshold in
CL(P).
Another possible explanation for the sex ratio heterogeneity within the
CL(P) group has been raised with the introduction of segregation
analysis under a unified model (Lalouel et al. 1983). Chung et al. (1986)
reanalysed extensively researched family data from Denmark and Japan
and found evidence for the action of a major autosomal recessive gene in
the Danish populations that could not be determined in the Japanese data.
Since a male excess is found in the Danish but is less apparent in the
Japanese data, it is tempting to speculate that this, as yet, unidentified
major gene acting in European populations is sex-limited, with a single
threshold multifactorial model operating in the Japanese population,
however no evidence supporting this theory is available at present.
The sex ratio within the CP group is markedly different. In the present
study the m:f = 0.81:1 which is significantly different from that in the
CL(P) group (YM x~"=10.7 p<0.002) but not from the total birth sex ratio
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(YM x~=3.11 p<0.1 p>0.05). This slight excess of females has been a
constant feature of reported studies in Table XV, with an average m:f
ratio of 0.8:1 and a range of 0.5:1 - 1:1 (for review see Gorlin et al.
1976). Unlike the sex ratio in the CL(P) group this female excess would
appear to be present in both Caucasian and Japanese populations but may
be absent from African races (Shapiro et al. 1976). Like CL(P), a
sex-modified multifactorial threshold for the sex differences in the CP
group has been invoked (Carter, 1965). In support of this Burdi & Silvey (1969)
has suggested a possible embryological basis for the threshold difference
by reporting that the palate closes approximately one week later in
female than male human embryos and suggesting that this may have an
as yet undefined role in the aetiology of cleft palate. Watanabe & Endo
(1989), however, found that although female mouse embryos had
retarded development of palate and digital structures at 12 days gestation
(period of early palatal shelf growth), there was remarkable catch-up of
these developmental processes by 14.4 days gestation (time of shelf
fusion) when female embryos were developmentally in advance of their
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larger male equivalents. If this catch-up period exists in human embryos
it may alter the cleft palate threshold for female embryos.
4.1.4 Laterality
Another intriguing aspect of this group of patients is the developmental
lateralisation that is implied by the excess of left-sided defects in the
unilateral cleft lip group. In the present study, 55/86 (64%) of the
unilateral CP(P) cases had left sided defects. This is a highly statistically
significant excess (x =6.7 p<0.01). All the reported studies that have
analysed the defects by sidedness have given similar results (for review
see Fraser, 1970). However no convincing explanations for this
phenomenon have been advanced. The remarkable laterality of defect
within CL(P) patients has led to interest in other systems that display
laterality, thus leading to several studies of the concordance of
handedness with side of defect in this group. Unfortunately, the four
major studies of handedness in cleft lip patients (Tisserand, 1944;
Rintala, 1985; Fraser & Rex 1985; Yorita & Melnick 1988) give
conflicting results. Tisserand (1944) was the first study of this type and
showed an excess of non-right-handedness (NRH) in patients with
right-sided lip defects. Both Rintala (1985) and Yorita & Melnick (1988),
however, found an excess of NRH in patients with left sided defects.
Fraser & Rex (1985) failed to find any association between handedness
and side of cleft. It is now obvious that large multicentre studies are
required to clarify this situation. The supporters of the relationship
between cleft lip side and contralateral handedness (Rintala 1985; Yorita
& Melnick 1988) have suggested that any embryological insult affecting
the cranial neural crest cells (that will go on to form the facial
prominences) could also involve adjacent cells in the neural folds (that
v/ill go on to form the forebrain) and thus influence handedness.
Although this is an interesting possibility it must remain speculative until
the association between handedness and cleft side is proven or suggestive
defects in forebrain development can be demonstrated. It is obvious that
the above theory could not explain all laterality in facial clefts. Even if
the association of cleft side and handedness is statistically proven it was
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not present in the majority of patients in any of the three 'positive'
studies.
4.1.5 Pre- and Postnatal selection
Evidence of early lethality in facial cleft groups is available from several
studies (Iizuka, 1972; Bonaiti et al. 1982; Czeizel & Tusnady, 1984) and
has been the source of some debate. A prenatal selective mechanism has
been postulated as acting in this group (Czeizel & Tusnady 1984) and the
high rate of stillbirths in the CL(P) (13/139 (9.3%)) and CP (5/147
(3.4%)) group in the present study would support this postulate. Further
evidence for the existence of prenatal selection in facial clefts comes
from the v/ork of Iizuka (1973) who has shown an incidence of 1.56% of
facial clefting (1.32% CL(P), 0.32% CP) in early human embryos
collected from social terminations of pregnancy. Furthermore Bethmann
& Eifert (1969) have shown a higher incidence of premature births
among a group of patients with facial clefting which may be further
evidence for prenatal selection. Niswander et al. (1972) have, therefore,
proposed that an increased liability to embryonic death may be associated
with a liability to facial cleft and have called this phenomenon
'developmental noise' (see below).
However Bear (1978) has pointed out that, if the above hypothesis was
correct, then an increased embryonic loss would be seen in families with
two or more affected individuals. On the contrary Bear (1978) has
shown that the number of self-reported spontaneous abortions is greater
in mothers of a single affected child than in mothers of two or more
affected sibs. It has also been observed that in Caucasian populations,
the normal male excess in individuals affected with CL(P) (see below)
becomes less apparent in sibships with two or more affected members
(Niwander et al.1972). Bear (1978) has, therefore, suggested that the
equal sex ratio of affected members within multiply-affected sibships is
due entirely to female embryos being spared, which is obviously at
variance with what is predicted by the theory of developmental noise.
The sex ratio, however, suggested that factors influencing embryonic
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survival are sex-specific
It would appear from the relatively high mortality rate in both CL(P)
(10/126 (7.9%)) and CP (14/142(9.7%)) groups in the present study, that
post-natal selection may also may also be operating in the facial cleft
groups, mainly in the first year of life. The deaths in the present study
were all related to associated severe congenital anomalies and the
mortality rates within the CL(P) and CP groups are similar to those
previously reported by Mackeprang & Hay (1972).
4.1.6 Aetiology
The complete ascertainment of facial cleft patients within a community
provides the investigator with an opportunity to study the various
contributions of genetic and environmental factors in this highly
heterogeneous group. Genetic factors can be assessed initially by looking
for conditions with single gene or chromosomal aetiology (see below).
The study of environmental factors is often more difficult as, in the
absence of a specific teratogenic syndrome, few clues are available to the
nature of the teratogenic factors. Seasonal variation with respect to
congenital malformations has been useful as an indicator of an
environmental component in the etiology and has the advantage that
accurate dates of birth are almost always available in a patient data set
(Edwards 1961). In the present study no cyclic trend could be detected in
total group or the various subgroups using either the parametric test
described by Edwards (1961) or the non-parametric method of Hewitt et
al. (1971). Previous reports of seasonal variations in facial clefts have
shown no significant cyclic trend in the CP group (Lutz & Moor 1955;
Edwards 1961; Fraser & Calnan 1961), but have given conflicting
answers in the CL(P) group. Lutz and Moor (1955) were the first to
study seasonality in the CL(P) group reporting an excess of births
between June and August. Edwards (1961) in a study from Birmingham
and Fujino et al. (1963) in Japanese patients have however shown a
significant excess of CL(P) patients born in early spring with a peak in
March. Other studies have shown no significant seasonal differences
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(Fraser & Calnan 1961; Drillien et al. 1966). The interpretation of these
conflicting data is difficult, although the fact that two of the studies
(Edwards 1961; Fraser & Calnan 1961) took place in the same country,
during the same time period, but gave conflicing reports, must cast doubt
on this phenomenon as a significant factor in facial cleft aetiology.
Many authors who have endeavoured to establish the causes of facial
clefts have stresse 1 the importance of cataloguing abnormalities and
identifying syndromes associated with these defects (Fraser & Calnan
1961; Fraser 1970: Gorlin, 1976; Pashayan, 1983; Shprintzen et al.
1985). The identification of cases with unifactoxial aetiology (single
gene defects, chromosomal anomalies and teratogenic agents) is
necessary, not only for accurate counselling of the family, but also to
provide unbiased data for research use such as segregation analysis.
Even if the aetiology of a malformation syndrome is not known, the
diagnosis may provide valuable prognostic information. The published
reports of the incidence of abnormalities associated with facial clefts are
summarised in Table XVI.
As can be seen from Table XVI the percentages of facial cleft patients
with associated abnormalities would appear to vary from 3% (Fraser,
1970) to over 50% (Shprintzen et al. 1985). It is not, however,
appropriate to compare these figures directly. Fraser (1970) used the 3%
figure as an estimate of the proportion of facial cleft patients that have
identifiable syndromes rather than the total number with multiple
congenital anomalies. In 1970 Fraser estimated there to be around 50
recognised syndromes associated with facial clefting, in 1990 there
would appear to be around 230 syndromes (excluding chromosomal
anomalies) with facial clefting as a recognised feature (Appendix A&B).
Thus, it may be assumed that many more of the patients seen in 1970
may be recognised today as syndromic. Both Rollnick & Pruzansky
(1981) and Shprintzen et al. (1985) took a different approach by studying
all abnormalities associated with facial cleft, whether as part of
recognised syndromes or not. This method has the advantage of giving
an overall picture of associated abnormalities, but may lead to confusion
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TABLE XVI Abnormalities associated with facial clefts
Study Year Cleft Associated Single Chromo¬ Teratogenic Recognised
type anomalies Gene some agents malformation
(%age) Defects anomalies (%age) syndromes
(%age) (%age) (%age)
Present study 1990 CL(P) 34.5 5.7 3.6 5.7
CP 57.7 8.1 5.4 0.7 20.1
Shprintzen et al. 1985 CL(P) 46 13 3 3 5
CP 59 20 1 5 9
Rollnick & 1981 CL(P) 35 _ _ 22.7
Pruzansky CP 54 - 33.4
Tenconi et al. 1988 CL(P) 22 3.0 8.9 - 3.4
Czeizel 1980 CL(P) 22.8 - - - -
Fraser & Calnan 1961 CL 1.1 _ _ _ _
CL+P 1.9 - - - -
CP 13.3 - * -
Knox & 1963 CL 2.8 _ _ _ _
Braithwaite CL+P 7.3 - - - -
CP 12.2
115
unless the definitions of what constitutes a major and minor
malformation are clearly defined. In the present study the definitions of
major and minor anomalies used by Czeizel & Tusnady (1984) were
adopted.
The present study has shown that a higher proportion of the CP group
had associated abnormalities than the CL(P) group (YM x =15.54
p<0.001). This is in agreement with previous reports (Fraser 1970;
Gorlin et al. 1976; Shprintzen et al. 1985). At least part of this difference
is due to the relative frequency of Pierre Robin syndrome (PRS) which
accounts for 23/86 (26.7%) of the CP group with associated
abnormalities. If the isolated PRS group are removed from the
calculation the excess of associated abnormalities in the CP group is not
statistically significant (YM x2=3.18 p<0.1 p>0.05).
In comparing data from the present study with those from the report of
Shprintzen et al. (1985), there would appear to broadly similar rates of
abnormalities in the CP groups (Table XVI) with some discrepancy
between the associated abnormality rates in the CL(P) groups. There is
also discrepancy in the aetiological sub-groups with a higher percentage
of the Shprintzen group having single gene defects and a higher
percentage of the West of Scotland patients having a chromosomal
aberration (Table XVI). It would seem likely that these differences are
due to the different methods of ascertainment used in the two studies, as
the study of Shprintzen et al. (1985) is based on patients referred to the
Center for Craniofacial Disorders in New York and is, therefore, likely to
under-ascertain lethal multiple congenital abnormality syndromes (eg.
trisomy 13) and, perhaps, over-estimate certain single gene defect as part
of specialist referral policies (eg. Treacher-Collins syndrome).
In the present study, a significant proportion of facial cleft patients have
associated abnormalities that cannot be identified as part of a specific
syndrome or sequence. This has also been observed in previous reports
(Rollnick & Pruzansky 1981; Shprintzen et al. 1985). This may suggest
that there are many more rare malformation syndromes not yet delineated
116
that include facial clefting. However, large studies of well documented
cases will be required to identify specific and new patterns of
malformations. Other authors have suggested that the common occurrence
of other malformations in this group is part of a generalised
developmental instability (Adams & Niswander 1967; Fraser 1970;
Czeizel & Tusnady 1984). Adam & Niswander (1967) advanced the
theory that facial clefting may be one manifestation of what they termed
'developmental noise' to denote the asymmetry of paired organs caused
by non-genetic factors. They suggested that developmental noise may
result from a familial susceptability to a specific teratogen and that this
should be reflected by an increased incidence of congenital anomalies in
close relatives and evidence of instability in other paired organs in the
index cases. Again, the published data give conflicting results, with two
studies showing no increased incidence of malformation in first degree
relatives of patients with facial clefts (Rank & Thomson 1960; Curtis et
al. 1961) and two giving statistically significant increases (Drillien et al.
1966; Niswander & Adams 1968). There has been considerably more
consensus on the presence of asymmetry in the index cases. This being
demonstrated in familial CL(P) cases by the use of dermatoglyphic
patterns (Adams & Niswander 1967) or dental impressions (Crawford &
Sofaer 1987). It is of interest that this increase in asymmetry was not
present in non-familial CL(P) or in any subgroup of CP, and thus may
represent a minor role in the aetiology of this very heterogeneous group
of patients.
In conclusion, it would seem that the data presented in this study are in
broad agreement with previous reports of facial clefts in European
populations. It is of interest, however, that there would appear to be a
relative excess of isolated cleft palate in reports from this study and from
previous reports from other more Northern regions of Europe which, in
the absence of a demonstrable seasonal variation, may suggest a
non-cyclic environmental agent contributing to aetiology. The present
study would also appear to be one of the first reports to detail the number
and nature of major congenital abnormalities associated with a
completely ascertained population of facial clefts. Finally, this study has
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established a database of patient data that can be used in future
investigations to calculate empiric recurrence rates for family
counselling and for association studies with restriction fragment length
polymorphisms.
4.2 The RNA localisation studies
As the questions raised by clinical investigations of facial clefts become
more defined, it is of increasing importance to understand the
mechanisms controlling mammalian palatogenesis at the cellular and
molecular level. The difficulty in obtaining non-traumatised human
embryos of the appropriate developmental stages has led to the
widespread use of animal models in the study of palatogenesis. The
mouse represents a good model for such a study since the mechanisms of
palate development are almost identical to those in the human, and the
process can be disturbed in a controlled manner by the administration of
teratogens (Morriss, 1973; Abbott et al. 1988). Furthermore, several
genetic lines of mice are available which show increased susceptiblity to
this malformation (Fitch, 1957; Gasser et al. 1981).
The genes involved in any disease process can be identified either
directly by studying the expression patterns of candidate genes in normal
and diseased tissue, or indirectly by linkage analysis or haplotype
association. In this study the former approach was taken, using in situ
hybridisation of anti-sense ribonucleotide probes to sectioned staged
mouse embryos. The genes that were chosen for study were the
transforming growth factor type 6, isoforms 1, 2 and 3 (TGF61, TGF62
and TGF63). These genes are part of an extensive family of polypeptide
multifunctional cell regulators (see section 1.) and have been suggested
by Ferguson (1988) to be candidate genes in normal palate development
on the basis of in vitro properties and immunohistochemical localisation
(Heine et al. 1987).
The use of in situ hybridisation to cellular RNA has several advantages
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over other RNA detection methods in the study of developmental
processes. The first is the ability to analyse the tissue distribution of
RNA species very precisely (Pardue, 1985). Detailed localisation studies
are not possible using Northern blot or reverse transcription/polymerase
chain reaction (RT/PCR) methods as these both require RNA to be
extracted from the tissue. Another advantage that the in situ technique
offers is its high degree of sensitivity (Bandtlow et al. 1987) with an
ability to detect 10-20 copies of mRNA per cell. Although in situ
hybridisation is not the most sensitive method of RNA detection
(RT/PCR is capable of detecting a single RNA molecule:) it would appear
to be more sensitive than Northern blot analysis which has a limit of
detection thought to be in the order of 10,000 mRNA molecules.
(Kawasaki 1990).
The technical limitations of in situ hybridisation are related to the
inability to quantify the results in detail and the possibility of
cross-hybridisation with similar RNA species. These problem have been
minimised in the present study by careful control over the size and
specific activity of the radioactive probe, the use species specific
riboprobes from relatively non-homologous areas of the gene and highly
stringent hybridisation conditions (see section 2.2).
In die RNA localisation studies presented below two assumptions are
made. First that the gene-specific probes used in the in situ hybridisation
recognise bona fide mRNA for the genes they represent. In a study using
the same TGFB1 probe that was used in this study good correlation was
found between the in situ data and RNA gel blot analysis (Akhurst et
al.1988). Furthermore the gene-specific probes used in the present study
do recognise transcripts of the predicted size for each of the isoforms
(Denhez et al. 1990). The second assumption is that the RNA detected is
translated into biologically active protein. This is complicated by the
presence of post-transcriptional mechanisms that are known to control
the production of biologically active TGF6, by limiting both protein
secretion and activation of the latent form in the extracellular
environment (Roberts & Sporn, 1990).
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4.2.1 RNA localisation in normal mouse embryos
The stages of normal mouse palatogenesis can be summarised as
appearance and vertical growth of the palatal shelves down the side of
the tongue from 11.5 to 13.5 gestational days (GD), elevation of the
shelves to the horizontal position (14.0 GD) with apposition and fusion of
the shelves above the tongue (14.5 GD)(see section 1.). In the present
study, in situ hybridisation was used to study the expression of TGF8
genes during these critical stages of palatogenesis. The first evidence of
the expression of these genes during murine palatogenesis is at 13.5 GD
with epithelial expression of TGF63 in the vertical palatal shelves and in
the epithelium of the nasal septum that will go on to fuse with the palatal
shelves. The palatal shelf epithelial expression of TGF83 would appear
to be restricted to the areas that will form the medial edge epithelium
(MEE) of the palatal shelf after reorientation. This remarkable restriction
of TGF83 expression to the MEE is also seen after shelf elevation and
continues in the epithelial seam that is formed from the MEE
immediately after fusion, with loss of this epithelial expression as the
epithelial seam disrupts by epithelial to mesenchymal transformation.
TGF81 RNA shows a similar epithelial pattern of expression to that of
TGF83, but is not detectable in the MEE until after palatal shelf elevation
and at this stage apparently has a lower transcript prevalence than
TGF83. As mentioned above the comparison of relative transcript levels
of different genes by in situ hybridisation is difficult to make, despite
control over the size and specific activity of the radioactive probe. Thus,
although there would appear to be temporal differences between the
expression patterns of TGF81 and TGF 83 these may simply reflect the
quantitative limitations of the technique used. One conclusion that can
be drawn regarding transcript prevalence is that the medial edge
epithelial cells are the most abundant source of TGF83 RNA within the
murine embryo at this period of development (Millan et al. 1991).
The distribution of TGF82 gene expression is distinct from those of
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TGF131 and TGF83. TGF62 RNA can first be detected in the
hyperplastic nodules on the putative oral epithelia of the palatal shelves
that will go on the form the palatal rugae (Sakamoto et al. 1989). After
shelf elevation, however, TGF62 expression is limited to the
mesenchyme that underlies the MEE and epithelial seam. The temporal
and spatial distribution of transcripts from these three genes is
summarised in Figure 18.
After the results from the present study were published (FitzPatrick et al.
1990) a study from an independent laboratory, using in situ hybridisation
of gene- and species-specific cRNA probes to sectioned mouse embryos
reported identical RNA localisation results for TGF81, TGF62 and
TGF63 during palatogenesis (Pelton et al. 1990). As Pelton et al. (1990)
used riboprobes complementary to different regions of the TGF8
isoforms transcripts, their results confirm the different expression
patterns of all three isoforms during palatogenesis.
Obviously knowledge of the distribution of the active protein product of
the TGF8 isoforms is necessary for an understanding of their mode of
action in the palate. Several problems have, however been encountered
in the localisation of these gene-products. The most widely used method
of detecting tissue distributions of proteins is by using directly or
indirectly labelled antibodies (for review see Harlow & Lane 1988). The
generation of isoform-specific antibodies in the TGF6 family has,
however, proved very difficult with cross-reactivity between the isoforms
often occurring in one assay but not in another (Flanders et al. 1988) and
further complicated by the fact that antibodies raised to identical peptides
can recognise different epitopes (Flanders et al. 1989). The problems
encountered in raising specific antibodies to the TGFB family members
are presumably related to the high degree of homology between the
isoforms at an amino acid level and similar tertiary protein structure.
Although there is almost the same degree of homology at a nucleotide
level the ability of the investigator to design riboprobes that take
advantage of the regions of relatively low homology between isoforms is
not available to those working with antibodies.
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Figure 18 Expression of TGFB Isoforms During Palatogenesis
12.5 days 13.5 days
TGF beta - 3 expression
TGF beta - 2 expression
TGF beta -1 & beta - 3 expression
14.0 doys 14.5 days
Figure IS. Diagrarrw-tt representation of the role of the TGF beta family
in the developing palate. The line drawings represent coronal sections
through the midpalate at the gestations (in days) indicated above the
drawings. The diagrams show the palatal shelves (ps) growing down beside
the tongue (to) and then elevating to fuse between the tongue and nasal
septum (ns). The filled black areas illustrates TGF beta3 expression,
diagonal striping for TGF beta2 and stippled areas for the combined
expression of TGF betal and beta3.
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Heine et al. (1987) used a polyclonal antibody to study
immunohistochenvical localisation of TGF61 polypeptide in the mouse
embryo. This study showed TGF61 to be present in the mesenchyme of
the fusing palate. Although no detail was given of the spatial distribution
within the palatal mesenchyme, these results are consistent with a
paracrine mode of action of epithelially-derived TGF 61, as previously
suggested by Lehnert & Akhurst, (1988). This model for TGF61 action
was proposed after TGF61 RNA had been localised to certain
differentiating epithelia at sites undergoing morphogenesis (eg. whisker
follicle, tooth bud) where TGF61 polypeptide had previously been
localised to the underlying mesenchyme (Heine et al. 1987). Lenhert &
Akhurst (1988) suggested that a latent form of the peptide, which is not
recognised by the polyclonal antibody used by Heine et al. (1987), is
produced in the epithelial cells, transported to the underlying
mesenchyme where it is proteolytically cleaved to its active form. It is
also possible, however, that the antibody used in the localisation could be
recognising a different gene (eg TGF62). It will be difficult to resolve
this dilemma until a more specific method of localising these proteins is
available.
From the similar pattern of epithelial TGF6 3 gene expression one might
speculate that this growth factor also has paracrine activities on the
mesenchyme. However there have been no embryonic localisation
studies of TGF63 polypeptide reported as yet.
Assuming the paracrine mode of action, TGF61 ( and 63?) may act on
the underlying mesenchyme in a variety of ways. TGF61 is known to
stimulate differentiation, proliferation and chemotaxis of cells of
mesenchymal origin (Moses et al. 1985; Robey et al. 1987; Postlethwaite
et al. 1987). Sharpe and Ferguson (1988) however have shown that
although transforming growth factor type alpha (TGF alpha), fibroblast
growth factor (aFGF,bFGF) and platelet derived growth factor (PDGR)
were potently mitogenic in cultured medial edge palatal mesenchyme
(MEPM), TGF61 consistantly inhibited MEPM cell proliferation at a
concentration of 1 ng/ml. Since both cell migration and proliferation are
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essential features of palatal shelf development these data suggest that
TGFB1 may have a role in regulating cell growth in the palatal shelves.
In this context it is interesting that the timing of TGF 63 expression as a
putative growth inhibitor in the vertical shelves corresponds to the period
when their linear growth ceases (Ferguson 1987), it is also known
however that this is the period of maximal mesenchymal proliferation
judged by counting mitotic figures in colchicine-treated embryos (Jelirnk
& Dostal 1973) and [3H]-thymidine incorporation (Hassel et al. 1974). It
is therefore tempting to speculate that delineated areas of proliferation
adjacent to areas of inhibition may have a role in the dramatic processes
involved in shelf reorientation .
)
TGFB1 is also known to have a major effect in the elaboration of the
extracellular matrix (ECM) components and on the synthesis of
cell-surface receptors for ECM components (Heine et al. 1990). It is
now widely accepted that the composition of the ECM can influence
cell-to-cell and cell-to-substratum connections, which will result in cell
migration or stabilisation of organ structure. This suggests that ECM
molecules play an important role in embryogenesis, Nakanishi et al.
(1986), for example, have shown that collagen type III is essential to cleft
formation in the development of the salivary gland.
TGFBl is known to induce the synthesis of collagens and fibronectin
(Roberts et al. 1986; Ignotz et al. 1987), tenascin (Pearson et al. 1988)
and chondroitin/dermatan proteoglycans (Hiraki et al. 1988; Sharpe &
Ferguson, 1988). Accumulation of the latter class of molecules is
thought to be important in palatal shelf elevation by virtue of the rise in
osmotic pressure resulting from hydration of the proteoglycan network
(Pratt et al. 1973; Brinkley & Morris Wiman, 1987; Derynck et al.
1988a). In this respect it is interesting that high levels of TGF63 RNA are
observed 24 hours prior to palatal shelf elevation.
The distributions of many extracellular matrix proteins are fairly
ubiquitous within the palatal mesenchyme. Two significant exceptions
are collagen IX and tenascin. Collagen IX appears on the cell surface of
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medial edge epithelial cells prior to shelf elevation (Ferguson, 1988).
Tenascin is localised beneath the medial edge epithelium prior to and
during palatal shelf fusion (Sharpe & Ferguson, 1988). Since TGF61 is
known to induce synthesis of both of these proteins (Sharpe & Ferguson,
1988; Pearson et al. 1988), it is a reasonable supposition that these ECM
molecules may mediate some of the effects of TGFBs. The distribution of
tenascin is particularly significant since the embryonic distribution of this
molecule is almost completely correlated with the prescence of epithelial
TGFB1 RNA (Chiquet-Ehrismann et al. 1986; Lehnert & Akhurst, 1988;
Akhurst et al. 1990; Sharpe & Ferguson, 1988).
Tenascin has two properties that strongly suggest a functional role in
palatal shelf mesenchyme. The first is the ability of tenascin to disrupt
epithelial sheet continuity by breaking cell-cell and cell-substratum
contacts (Chiquet-Ehrismann et al. 1989). The second is its ability to
promote specifically the mobility of neural crest cells in vitro (Halfter et
al. 1989). Both of these events would be necessary for fusion along the
mid-line seam, a time when the epithelial sheet disrupts, epithelial cells
transdifferentiate to a mesenchymal cell phenotype and there is much cell
mixing.
The processes involved in the disruption of the midline epithelial seam
(MES) have been the subject of much interest over the last two decades.
For most of this time the major mechanism in the disappearance of the
epithelial cells was thought to be terminal differentiation, or
"programmed cell death" with the removal of the cell remains by
macrophages (Pratt & Martin, 1975; Greene & Pratt, 1976). Programmed
cell death is a fascinating event in palatogenesis, with cessation of
epithelial DNA synthesis estimated by the incorporation of
[ H]-thymidine occuring 24-36 hours prior to fusion (Pratt & Martin,
1975). It is accompanied by a down-regulation in epidermal growth
factor (EGF) receptors (Abbott et al. 1988), and is not dependent on shelf
contact in vitro. This lethal differentiation is specific to the medial edge
epithelium; it is not seen in the oral or nasal components (Pratt & Martin,
1975; Tyler & Koch, 1975). However, little is known of the cellular
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events that cause this autolysis. It is interesting that the activation of
TGFB3 gene expression occurs 24 to 36 hours prior to fusion and could
be important in this growth inhibitory process.
However, recently the work of Fitchett & Hay (1989) has convincingly
shown that a second mechanism is involved in MES disruption. Using
electron microscopy they have demonstrated transdifferentiation of the
medial edge epithelial cells to mesenchymal phenotype and suggest that
this may be the predominant process in the disruption of the MES, with
programmed cell death resulting in peridermal sloughing before
apposition of the shelves and formaton of the MES. Transdifferentiation
has been shown to be important in the morphogenesis of several systems
such as the thyroid gland (Greenburg & Hay 1988) and the regression of
the Mullerian ducts (Cunha et al. 1981); both of these processes would
appear to be under careful developmental control. Little is known of the
cell signals that induce transdifferentiation, however it is interesting to
note that lens epithelia transform to mesenchymal phenotype when
cultured within a collagen matrix (Greenburg & Hay 1982), which could
point to a role for the TGFB family in this process.
TGFB1, TGFB2 and TGFB3 are each known to be growth inhibitory to
epithelial cells, antagonising the mitogenic activities of TGF alpha and
epidermal growth factor (EGF) (Massague, 1985; Like & Massague,
1986; Coffey et al. 1988; Grayar et al. 1989). It is however unlikely that
EGF receptor down-regulation (Abbott et al. 1988) is directly initiated by
TGFBs. Although this is a mechanism of negative growth regulation
utilised by endothelial cells (Takehara et al. 1987), TGFB acts distally to
the EGF receptor in growth inhibition of all epithelial cells that have
been examined (Massague, 1985; Like & Massague, 1986; Coffey et al.
1988).
TGFB2 RNA distribution during palatogenesis is in marked contrast to
that of TGFs B1 and B3. Its predominant localisation in the mesenchyme
would agree with the observations of Pelton et al. (1989). It was
suggested by Pelton et al. that mesenchymal expression of TGF B2 might
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be important, not only in modulating the mesenchyme per se, but in
supporting growth of the overlying epithelium via secondary events such
as induction of TGF alpha. In this context, it is interesting that the TGF62
RNA distribution is asymmetric with respect to the nasal and oral
regions. Differential concentrations of growth factors within the
mesenchyme could contribute to the generation of regional heterogeneity
of the overlying epithelium.
Recently Abbott & Birnbaum (1991) have reported
immunohistochemical localisation of TGFB2 during murine
palatogenesis using a commercial polyclonal antibody to porcine TGFB2.
This antibody gave a uniform staining pattern over the epithelia and
mesenchyme of the palatal shelves from 12 GD to fusion of the palate.
This pattern is difficult to explain given the site- and stage-specific RNA
localisation pattern shown by in situ hybridisation (FitzPatrick et al 1990;
Pelton et al. 1990). The authors, however, suggest that the results are
consistent with a paracrine mechanism of action for TGFB2 in the palatal
shelf epithelia. Given the problems of producing isoform-specific
antibodies mentioned above further studies will be required to confirm
this protein localisation.
The localised high level expression of TGFB2 in the hyperplastic nodules
of the early medial edge epithelium that represent the palatal rugae is
consistent with this growth factor acting as an inducible homeostatic
regulator of epithelial growth and differentiation. The role that the rugae
play in the development of the palate is unclear, however, in their
comprehensive investigation, Sakamoto et al. (1989) suggest that the
'stiffness' of the rugae may facilitate shelf elevation. Pelton et al. (1989)
previously observed the expression of TGFB2 in the suprabasal
keratinocytes of the embryonic skin at a time when the rate of
keratinocyte cell division would be slowing.
One question raised by these RNA localisation studies is why genes
encoding proteins with such similar in vitro biological activities should
be expressed in the same developing organ, in some cases with
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overlapping but distinct patterns of expression. One explanation of the
apparent temporal sequence of expression (TGF63 followed by TGF61
and TGFB2) would be the induction of one member of the TGF6 family
by another, to amplify specific prefusion biological effects. It is known
that TGFB1 positively regulates its own expression in normal and
transformed cells (Van Obberghen-Schilling et al. 1988), but little is
known about "cross-talk" between these individual genes. Clearly these
different genes must serve some disparate in vivo biological functions.
This is supported by the fact that some in vitro biological activities
reported for the TGFBs do show some specificity in isoform requirement
(Rosa et al. 1988; Jennings et al. 1988).
Further insight into the role of these isoforms may be gained by studying
their localisation in the other developmental processes. During the
period of this study several reports of TGFB isoform expression in
embrogenesis were published (Akhurst et al. 1990; Gatherer et al. 1990;
Millan et al. 1991; Pelton et al. 1990). Gatherer at al. (1990) have
published the first extensive study of TGFB isoforms expression in
mammalian embryogenesis using in situ hybridisation to early human
embryos. This study suggested that the three isoforms are not generally
expressed in the same developing systems. The only exception to this
rule in the human embryo appears to be the developing lung where TGF
B2 RNA was seen in the primitive lung epithelia from around 43 GD;
this is the period of proliferation and branching of the lung buds. TGF
B3, however, showed a different expression pattern, being found
submucosally in the larger airways (bronchi and trachea) at around 57
GD. These results were supported by a similar pattern reported in the
murine developing lung (Millan et al. 1991). Using mouse embryos
Millan et al. (1991) were, however, also able to report concommitant
expression of two or more of the TGFB isoforms in the epithelia of
several developmental systems that could not be studied in the human
embryos, such as the whisker follicles (B1, B2 and B3 RNA detected) and
the salivary gland and the tooth bud (B1 and B2). While no direct
analogies can be drawn, these systems all represent structures that are
actively involved in the process of morphogenesis and therefore display
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some similarity to the developing palate.
It is also interesting that these localisation studies show that each of the
TGFB isoforms are expressed epithelially at some point during murine
and human embryogenesis. Specifically, the association of these
isoforms with epithelia overlying active mesenchyme in developmental
structures beyond the palate strengthen the conclusion from the present
study that they have a major role in the development of the palate.
4.2.2 RNA localisation in retinoic acid treated embryos
A natural extension of the initial studies presented above was to repeat
the in situ hybridisation studies on embryos that would go on to develop
cleft palate. This could be done either by breeding from mice
homozygous for a non-lethal recessive gene that causes clefting (eg Tw
or Pcp mutants) or by treating pregnant mice from susceptible strains with
the appropriate teratogenic agent. The latter approach was taken in the
present study, employing all-trans retinoic acid-treated C57BL/6 mouse
embryos. There were two reasons for this choice. First, the teratogenic
effects of retinoic acid (RA) have been the subject of a great many
studies (see section 1.1.3.2 ) and the doses required to induce cleft palate
in this strain of mice have been published (Abbott et al. 1989).
Secondly, RA has long been considered an important modulator of
normal development (Sporn & Roberts, 1984) and recent in vitro studies
have suggested that at least some of its morphogenic actions may be
mediated via TGFB gene activation (Glick et al. 1989) .
Two sets of embryos were used in the experiments, those supplied as
tissue sections by Dr. Barbara Abbott (NIH, Bethesda) and those treated
and collected in Glasgow as part of the present study. Both sets of
embryos were from C57BL/6 crosses, timed and collected in the same
manner with identical fixation and embedding protocols. The major
difference between the sets of embryos was the timing of the RA
treatment (lOOmg/Kg), which in the Bethesda embryos was on 10.0 GD
(with embryos collected on 12.5 GD and 14.5 GD) and in the Glasgow
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was on 12.0 GD (embryos collected on 14.5 GD).
The C57B control embryos used in this part of the study gave TGF6
isoform expression patterns which were identical to those seen in the
NIH/Parkes embryos (see section 4.2.1). This suggests that the
expression patterns are independent of the strain of mouse used, although
further studies on different species will be required before this can be
accepted as a general pattern in mammalian development. The
phenotypic abnormalities in the RA-treated specimens were obvious on
the embryos collected on both 12.5 GD and 14.5 GD with severe
hypoplasia of the palatal shelves. However, the RNA expression patterns
shown by the treated embryos on 14.5 GD were similar to those in the
control embryos regardless of timing of treatment. TGF61 and 63
riboprobes hybridising to the MEE and TGF62 RNA localised to the
medial edge palatal mesenchyme.
Glick et al. (1989) have shown that RA treatment of cultured
keratinocytes causes the induction of TGF62 RNA expression, with
subsequent secretion of biologically active peptide by the treated cells.
This is the first direct evidence for involvement of the TGF6 family in
retinoid-induced mechanisms. It is tempting to speculate that the
induction of TGF62 may have a role in the hypoplasia of the palatal
shelves in RA-treated embryos. Although no studies of the effect of TGF
62 peptide on palatal mesenchyme has been published it is reasonable to
assume that it would have the same potently growth-inhibitory effect as
TGF61 (Sharpe & Ferguson, 1988). The difficulty in quantification of
results makes in situ hybridisation a poor technique for the study of
up-regulation of gene transcription. It is possible, iherefore, that
although a normal expression pattern is seen in the RA-treated embryos
in the present study more RNA is present than in the control embryos.
Another possiblity is that normal amounts of RNA are present in the
palatal shelves with post-translational regulation of TGF62 activity.
Abbott & Birnbaum (1991) have recently published a study of
immunohistochemical localisation of TGF61 and TGF62 in retinoic
acid-treated mice which has shown a significant increase in TGF62
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antibody staining in the nasal epithelial cells but not the subepithelial
mesenchyme. The authors, therefore, suggest that TGF82 gene is
up-regulated with the secreted peptide acting on the nasal epithelium via
a paracrine mode of action. Doubts over the specificity of antibodies to
the TGF6 isoforms have, however, been raised (see section 4.2.1) and
evidence of up-regulation of the gene on RNA gel electrophoresis
analysis is required to confirm this.
The cloning of the three retinoic acid receptors (R AR's) (Petkovich el al.
1987; Giguere et al. 1987; Brand et al. 1988; Zelent et al. 1989) has
provided evidence that TGFB molecules may modulate RA action in
ways other than via TGFB2 gene activation. The RAR's are members of
the steroid hormone receptor superfamily (Zelent et al. 1989) and several
recent studies have suggested that TGFB polypeptide acts as a local
mediator of cellular responses to steroids and related hormones such as
parathyroid hormone (Pfeilschifter & Mundy 1987) and oestrogen
(Knabbe et al. 1987; Komrn et al. 1988). Obviously, if the interaction of
TGFGs and RAR's are important in the teratogenic effects of RA, then
one would expect these genes to be co-expressed in or around the
affected tissues during organogenesis. Unfortunately no studies of RAR
expression during palatogenesis are available as yet. Dolle et al. (1990)
have, however, studied the expression of RAR-alpha, -6 and gamma
genes during murine organogenesis. Although RAR-alpha was found to
be expressed almost ubiquitously, both RAR.-B (gut, bronchi, kidney,
eye) and RAR-gamma (lung, oesophagus, endocardial cushions, skin)
were found to have site- and stage- specific expression patterns. These
localisations, however, do not correspond exactly to the
embryonic expression patterns of TGF 81 (Lenhert & Akhurst 1988),
TGFB2 (Pelton et al. 1989; Gatherer et al. 1990; Millan et al. 1991) or
TGFB3 (Gatherer et al. 1990; Pelton et al. 1990; Millan et al. 1991).
Further detailed studies of individual systems in both normal and retinoic
acid treated embryos are therefore required to clarify this fascinating
area.
In conclusion the expression patterns of the TGFB isoforms are not
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altered in retinoic acid-treated embryos that would go on to develop cleft
palate. They must, however, remain candidate genes both as modulators
of RA morphogenetic/teratogenic activity and important regulators of the
normal processes involved in palatogenesis.
4.3 FUTURE PROSPECTS
4.3.1 Future directions for clinical investigation
The present study, like so many before it, would appear to have raised
more questions than it has answered. However it must be hoped that
establishing a well ascertained database of patients with facial clefts will
provide a useful resource for clinical research. By collecting
three-generation family trees from the families of the ascertained cases
accurate empiric recurrence risk data can be calculated for use in genetic
counselling. Furthermore, these family data can be used in complex
segregation analysis to determine if there is evidence for the action of a
major gene causing facial clefting in the West of Scotland. Chung et al.
(1986) have reported that an autosomal recessive gene with low
penetrance may be a significant cause of CL(P) in the Danish population.
This last point has taken on particular significance with the reported
association of a variation in the TGF alpha gene with non-syndromic
cleft lip with or without cleft palate in a group of unrelated American
patients (Ardinger et al. 1989). If confirmed in local populations, the
association of a specific restriction fragment length polymorphism
detected by a TGF alpha gene probe could be used to adjust the
recurrence risk to the parents of a child with the 'low risk' haplotype.
Another intriguing avenue for clinical research has been suggestion that
recurrences of facial clefts can be prevented by periconception
multivitamin supplementation (Conway, 1958; Tolorova, 1982).
Tolarova (1982) reported 1 recurrence out of 85 pregnancies (1.2%) in
mothers with a previous child with CL(P) who were given periconceptual
vitamin supplementation compared with 15/212 (7.4%) recurrences in the
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control group. From the experience of vitamin supplementation trials in
the prevention of neural tube defects a large multicentre trial would be
required to confirm these findings.
A large number of patients with associated major anomalies which
cannot be categorised have been shown in this and other studies of facial
cleft populations. This fact must raise the possibility that a significant
number of unrecognised syndromic entities are present within these
groups. By pooling of data from several studies recognition of 'new'
syndromes can be facilitated. To this end clinical details and
photographs have been stored in all patients in the 'unknown' group in the
present study.
4.3.2 Future directions for developmental biology
The present study has provided evidence for an important role for TGF6
isoforms during normal murine palate development. Obviously,
establishing the presence of biologically active peptide products for each
of these genes is important, although this will not be possible until the
sensitivity and specificity of immunohistochemical localisation of TGFB
isoforms improves. At present the most exciting option in studying the
role of these isoforms during palatogenesis is through transgenic
technology. These techniques offer unparalleled opportunities to
investigate the role of cloned genes in developmental processes.
Although the most basic of these techniques (general overexpression and
gene elimination studies) are unlikely to yield useful information in the
study of palate development, the prospect of stage- and site-specific
gene inactivation by using inducible promotor sequences which produce
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APPENDIX A
Single gene defects causing facial clefts







BRACHIAL PLEXUS NEURITIS + CP
CEREBRO-COSTO-MANDIBULAR
CLEFTTNG-ECTROPION-CONE TEETH























MEIGE - LYMPHEDEMA PRAECOX
MYHRE [1981]
NAGER





































































Isolated cleft of soft palate
Oral frenulae-CP-MR






















































CHRISTIAN [1971] ADDUCTED 201550
THUMBS SYNDROME
CLEFT LIP+/-CLEFT PALATE 215900
CLEFT PALATE AND OMPHALOCELE 258320





































CP-Congenital heart disease-Characteristic facies
Heterochromia of iris-Deafness
Neonatal form of Stickler syndrome
Oligodactyly-CP
Triphalangeal thumb-Congenital anemia-CL+/-P




Popliteal pterygium-Severe AR form












Acral defects-Cloudy comeae-Diaphragmatic defects
Hypotonia-MR-Unusual face
CP -Oligodontia-Stapes Fixation-Carpal anoms




Treaclier-Collins like syndrome (AR)
Hydrocephalus-Hydramnios-Polydactyly
Deficient ossification lumbar vertebrae-Short limbs
















MULTIPLE PTERYGIUM SYNDROME 253920
(Type Chen)
NANCE-SWEENEY DWARFISM 215150
NUCHAL BLEBS-LETHAL DYSPLASIA 257350
OCULO-PALATO-CEREBRAL 257910
ODONTOTRJCHOMELIC 273400





























OFD-1 ORO FACIO DIGITAL [TYPE 1 ] 311200
OPD IIOTO-PALATO-DIGITAL II FITCH 304120
OPD OTO-PALATO-D1GITAL [TAYBI] 311300
OPITZ-BBB 313600
PALLISTER-W 311450
ROBIN SEQUENCE WITH PERSISTENCE 311900
OF LEFT SUPERIOR VENA CAVA
TOLMIE [1987] 312150








Microcephaly-CP-Pcrsistant hypertrophic primary vitrious
Tetramelia-Ectodermal dysplasia
Oral frenulac-Lobed tongue-Polysyndactyly









Abnormal face-Diaphragm, limb and gut anomalies












































































SR Cleft palatc-Coloboraa-Radial synostosis
SR Aciocephaly-Buphthalmos-CP-CHD-Syndactyly
SPORADIC Constriction rings-Brain abnormalities-CL+/-P
SR ?AR Clefting-Comeal opacity-MR
V. Cerebral/cranial abn-Genital abn-CP
SR Oculo-Ccrebro-AcraUlobcns like + Ectrodactyly
SPORADIC Hypoplastic right heart-CP-Microcephaly
SR MR-Cleft palate-Aqueductal stenosis-Contractures
SR ?AR Clefting-MR-Eaodermal dysplasia
SR Campomelia-Fractures-Ankyloglossia superior
SPORADIC Coloboma-CHD-Choanal atr-Ear abn-Shoit
SR CL+/-P-Hypopituitarism
SR ?AR Craniostenosis-Coloboma-Clefting-MR
SR ?AD Microcephaly-Agenesis prcmax-MR-CP
SR 7AR Clefting with skeletal anomalies
SR ?AR Campomelia-Polycystic dysplasia-Polysplenia
?? Unusual face-Gut abn-MR
SR ?AR MR-Unusual facies-CP-Genital abn
SPORADIC rUGR-Microcephaly-Synophiys-Limb defects
SR MR-Short stature-Cleft palate-Abnormal ears
SR Short stature, lUGR-Malar/Mandibular hypoplasia
?? Femoral hypoplasia-Unnsual facies
SR Severe plagiocephaly, Megacoraea- Cleft palate
SR ?AR Contractures-Torticollis-Hypenhennia
SR Short stature-Cleft palate
SPORADIC Hemifacial microsomia-Epibulb. dermoid-Vert. abn
SR Craniofacial abnormalities-Osseous defects-MR
?? Syngnaihia
SR ?AD Microcephaly-Cleft palate-Retinal pigmentation





SR Renal agenesis-Cleft palate-Skeletal anoms
SR Microcephaly-Clefting-Preaxial Polydactyly
SR Prenatal neuroaxonal dystrophy-Peripheral gangrene
SR ?AR Peculiar face-Deafness-Pseudoliennaplirt)dite-MR
SR Glossopalatine ankylosis-Cataracts-Abnormal digits




SR Short stature-Multiple vertebral anomalies
SR Short stature-MR-Unusual face
SR CHD-Diaphragmatic defect-MR-Clefting
SR Cutis laxa-Cleft palate-Unusual facies
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Facial cleft syndromes of unknown aetiology cont.
MADOKORO [1987] SR Microcephaly-Short palpebral fissures-Micrognathia
MARTSOLF [1977] SR Skeletal dysplasia-Polydactyly-Pierre Robin
MELNICK NEEDLES-LIKE SYNDROME SR Short stature-Prominent eyes
MICHELS [1979] SR Clefting with ocular anomalies
MIRROR IMAGE EAR PLUS SR Corneal dermoid-Duplication of ear
OTHER ANOMALIES
MOERMAN [1985] SR Lethal-Short limb-Brain anomalies
NAGER (with very severe limb defects) SR Severe limb defccts-Craniofacial anomalies
OCULO-PITUITARY SR Similar to septo-optic dysplasia
PEARL [1984] SR Anotia-Facial weakness CHD
PIEPKORN [1977] SR Short rib-Polydactyly
PJLOTTO [1975] SR MR-Clefting-Vertebral defects
RANTA [1984] ? Pierre Robin-Cleft lower lip
RJCHIERI-COSTA [1983] SR Acrofacial dysostos-CL+-/-P-Triphalangeal thumb
SALINAS [1976] SR Microcephaly-Atypical clefting
SANDERSON [1983] SR Proplosis-Abnl fisting-Robin assoc-Hypospadias
SAY [1975] SR Cleft palate-Small head-Large ears
SCH1SIS ASSOCIATION SPORADIC CP-NTD-Diaphragmatic hernia
SPERBER [1986] SR Acalvaria-Holoprosenccphaly-Facial dysmorphism
STE1NFELD [1982] SR Holoprosencephaly and limb defects
TERUEL [1987] SR Absent abdominal musculature-Microphihal-Joint lax
TOLLNER [1981] SR Polydactyly and visceral anomalies
TRABOULSI [1984] SR Clefting-Ptosis
VICI [1988] SR Agen corpus callosum-Immunodef-Cataract-Hypopig
VOLAR NAILS ? Volar nails-CP
VSR ? Joint contractures-Craniofacial malformation
WALKER [1974] SR Treachcr-Collins-Liinb defects
WEAVER [1987] SR Craniosynostosis-Facial and limb defects
WEAVER-WILLIAMS SR Microcephaly-CP-MR-Thin
WOLTER [1971] SR Papilla nigra-Cleft palate- Extra thumb
WOON [1980] SR Craniosynostosis-Absent thumbs
YIM [1982] SR Amelia-Hydrocephalus-Iris coloboma-CL+/-P
YOLKEN [1976] SR Sh limbed dwarf-Bowed femurs-Metaphyseal irrcg
YOUNG [1982] SR Keratoconus-Corneal opacity-CL+/-P-MR
ZADIK [1983] SR Hypothyroid-Dermoid cysts-Cleft palate-Dry skin
ZIMMER [1985] SR Tetra-amelia with multiple malformations
ZLOTOGORA [1987] CLEFT LIP SR CL-Syndactyly-Hair alterations
SR = Single case report only
?? = Several reported cases but inheritance pattern uncertain
?AR/?AD = Possibly autosomal recessive/autosomal dominant






































































































































































































































































































































































































































































































Facial cleft patients (excluding stillbirths and fatalities) ascertained in
present study




55940 R2 00 11/01/80 M AA 0 0 NONE
378078 L2 00 18/01/80 M GG 0 0 NONE
56405 04 04 22/02/80 M AA 0 0 NONE
336115 B4 04 24/03/80 M GG 0 0 NONE
249590 L4 CC 04/04/80 M GG 0 0 NONE
CSA01 U? 77 07/04/80 r AC 0 0 NONE
56949 L4 04 13/04/80 F AA 0 0 NONE
251065 L4 04 21/04/80 M LA 0 0 NONE
266566 R4 04 23/04/80 M AA 1 2 MR/SYNDACTYLY/ANAL PIT
251153 R4 00 24/04/80 M CC 1 0 PREAURICULAR PITS
58023 R2 00 03/05/80 M DG 0 0 NONE
250642 R3 00 05/05/80 F GC 1 1 LIP PITS/CDH
251781 R2 00 27/06/80 F CC 0 0 NONE
57774 L4 04 29/06/80 M DG 0 0 NONE
UNK10 U? 00 21/07/80 M FV 0 0 NONE
254101 B4 04 02/08/80 M LA 0 0 NONE
253434 B4 04 04/08/80 M GG 0 0 NONE
254597 L4 04 22/08/80 M LA 0 0 NONE
254623 L2 03 28/08/80 F AC 0 0 NONE
58558 L4 04 23/09/80 M AA 2 0 PTOSIS/LOW SET EARS
252835 B4 00 20/10/60 M LA 0 0 NONE
256095 L3 04 09/11/80 M AC 0 0 NONE
59274 L4 04 04/12/80 M LA 0 0 NONE
CSA02 U? 00 07/12/80 F CG 0 0 NONE
257358 L4 03 31/12/80 M LA 0 0 NONE
257999 L2 00 03/01/81 M AC 0 1 IUGR
257792 L2 00 08/01/81 M LA 1 0 CYST LEFT EAR
59648 B3 00 17/01/81 M AA 0 0 NONE
269884 B4 04 12/02/81 M FV 0 0 NONE
260650 B4 04 11/03/81 M CG 0 0 NONE
260136 L2 02 25/03/81 M GG 0 0 NONE
327541 B3 03 04/06/81 F LA 0 0 NONE
263565 L2 00 08/07/81 M GG 0 0 NONE
263573 L2 00 14/07/81 M GG 0 0 NONE
CSA03 U? 00 23/07/81 M GG 0 0 NONE
266859 R3 00 30/07/81 F LA 0 0 NONE
265812 R1 00 07/08/81 F GC 0 0 NONE
265283 R4 04 15/08/81 M AC 0 0 NONE
265820 B3 04 17/09/81 F GG 2 0 STRABISMUS/HYPERMETROPIA
267638 L3 CO 21/09/81 M FV 0 0 NONE
266165 R4 04 27/09/81 F AC 0 0 NONE
266017 R2 00 11/10/81 M LA 0 0 NONE
62519 L4 04 12/10/81 M AA 0 0 NONE
266878 L3 00 14/10/81 M AC 0 0 NONE
266064 1.4 04 15/10/81 M LA 0 0 NONE
266794 R4 00 20/10/81 F GG 2 0 DUPLICATED HALLUX
268632 B4 04 01/12/81 M LA 0 0 NONE
268572 U? 00 10/12/81 M LA 0 0 NONE
270687 R3 03 27/12/81 M GG 0 0 NONE
268904 R4 04 07/01/82 F LA 0 1 DYSPLASIC EAR
278784 R4 04 15/01/82 M AC 0 0 NONE
268951 R4 04 22/01/82 F AC 0 0 NONE
280963 L2 0(1 03/02/82 M LA 0 0 NONE
270578 L4 04 23/02/82 F AA 0 5 MR/ASYMMETRY/VERTEBRAL ANOMS
272128 L4 04 01/03/82 M GG 0 0 NONE
65010 B2 00 06/03/82 M AA 0 0 NONE
276582 L3 00 20/03/82 H GG 0 0 NONE
66530 B2 01 12/04/82 M AA 0 0 NONE
273425 L4 04 17/05/82 M CG 0 0 NONE
273372 L4 00 01/06/82 M GG 0 0 NONE
65990 L4 04 01/06/82 M AA 0 0 NONE
275162 L4 04 17/06/82 F GG 1 0 LIP PITS
274635 L4 04 22/06/82 M CG 0 0 NONE
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274579 B3 00 30/06/82 F AC 0 0 NONE
277011 B4 SM 25/07/82 M FV 1 0 NEUTROPAENIA
CSA04 U? CO 22/08/82 M CG 0 0 NONE
277801 R2 00 10/11/82 M AC 0 0 NONE
279570 B4 04 07/12/82 M GG 0 2 FALLOT/POSTERIOR FOSSA CYST
278755 L3 00 15/12/82 M LA 0 0 NONE
281659 L4 03 12/01/83 M GG 1 1 CONST IPATION/NTD
282569 R4 04 10/03/83 M DG 0 0 NONE
281697 L4 04 22/03/83 M GG 1 2 MR/SHORT STATURE
282311 B3 04 03/04/83 F AC 0 0 NONE
282547 B4 04 08/04/83 M LA 0 0 NONE
297937 L4 04 10/04/83 M LA 0 0 NONE
282665 L4 00 11/04/83 M GG 0 0 NONE
284331 L4 04 17/04/83 F FV 0 0 NONE
287175 L4 04 05/05/83 F AA 0 1 HYDROCEPHALUS
CSA05 U? 00 13/05/83 M AA 0 1 CHD
296097 B4 03 17/05/83 M I.A 0 0 NONE
412419 R3 00 08/06/83 M GG 0 0 NONE
287850 B4 04 29/06/83 F DG 0 0 NONE
235510 R4 04 19/07/83 M LA 0 0 NONE
139954 U? 00 02/09/83 M AC 0 0 NONE
2898 IS L2 00 23/09/83 M AC 3 0 DYSPLASTIC EAR/SYNDACTYLY
288225 L3 00 27/09/83 F AC 0 0 NONE
289817 B4 04 02/10/83 M DG 2 0 ANKBLEPHARON/LIP PITS
291327 L3 00 06/10/83 M FV 0 0 NONE
282556 L4 04 21/10/83 F LA 0 0 NONE
71338 B4 04 21/10/83 F AA 0 0 NONE
293025 R4 04 02/11/83 F FV 0 0 NONE
CSA06 U? 04 02/11/83 M GG 0 1 CHD
291418 B3 00 08/12/83 F AC 0 0 NONE
290346 L2 02 14/12/83 F LA 0 0 CHD
291167 B4 04 10/01/34 M LA 0 0 NONE
291350 R4 04 04/02/84 F DG 0 3 CHOLEDOCHAL CYST/RENAL ANOM
293042 L4 04 26/02/84 F GG 0 0 NONE
295181 LI 00 22/03/84 M DC 0 0 NONE
72454 L2 00 29/03/84 F AA 0 0 NONE
72464 B4 04 02/04/84 F AA 0 2 ANKBLEPHARON/ECTODERMAL DYSPL
294616 Ml 00 04/04/84 M GG 1 1 HYPERTELGRISM/MR
305365 L2 03 14/07/84 M FV 0 0 NONE
298520 R2 00 23/07/84 M AC 0 0 NONE
299131 LI 00 12/08/84 M AC 0 0 NONE
300467 L3 00 31/08/84 F GG 0 0 NONE
301385 L3 00 06/09/84 M GG 0 0 NONE
300133 R3 03 09/09/84 M CG 0 0 NONE
73682 L4 04 12/09/84 F AA 0 0 NONE
299954 LI 00 16/09/84 M CG 0 0 NONE
302309 B4 04 23/10/84 M CG 0 0 NONE
305177 R3 03 26/10/84 M FV 0 0 NONE
CSA07 U? 00 30/10/84 M DG 0 0 NONE
64815 R2 00 25/11/84 F AA 0 0 NONE
302355 R2 00 26/11/84 M GG 1 0 RECTAL POLYP
303255 L3 03 05/12/84 M AC 0 0 NONE
303482 R2 00 28/12/84 M GG 0 0 NONE
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248031 00 02 02/01/80 M DG 0 0 NONE
CSA08 00 03 05/01/80 F GG 0 3 CHD/HYDROCEPHALUS/MICTOT1A
246856 00 02 07/01/80 F LA 0 0 NONE
248032 00 03 23/01/80 F CG 1 0 STRABISMUS
UNK14 00 01 03/02/80 M GC 0 0 NONE
244055 00 03 02/03/80 F CG 0 1 MR
UNK15 00 03 02/03/80 M GG 1 1 ANKCLOSSIA/CHD
249483 00 02 20/03/80 M AC 0 2 SYNDACTYLY/ECTODERMAL DYSPL
250643 00 02 07/05/80 F GG 1 0 MICROGNATHIA
253688 00 01 07/05/80 F GC 0 2 MR/ATAXIA
251126 00 02 16/05/80 F LA 0 0 NONE
252449 00 03 05/06/80 F AC 0 0 NONE
251740 00 03 11/06/80 M CG 1 0 MICROGNATHIA
57700 00 02 20/06/80 F AA 1 0 MICROGNATHIA
254478 00 02 06/07/80 M GG 0 0 NONE
256030 00 02 12/07/80 F AA 0 0 NONE
289067 00 02 20/07/60 M LA 0 3 MICROTIA/VERTEBRAL ANOMALIES
252781 00 03 21/07/80 M GG 2 0 INGUINAL HERNIA/SACRAL DIMPLE
255336 00 02 18/08/80 F LA 0 3 SCOLTOSIS/JAW CYST/SHORT STATURE
299133 00 02 25/08/80 F AC 0 1 CHD
255628 00 02 04/09/80 F DG 0 0 MICROGNATHIA
255394 00 03 22/09/80 F LA 1 0 MICROGNATHIA
328968 00 03 29/09/80 F GG 0 0 NONE
256466 00 02 28/11/80 F GG 0 0 NONE
257817 00 03 23/12/80 F LA 0 0 NONE
327540 00 02 14/01/81 F LA 0 0 NONE
258510 00 02 31/01/81 M GG 0 0 NONE
269195 00 03 04/02/81 F GG 0 0 NONE
259264 00 03 21/02/81 F GG 1 1 STRABISMUS/SHORT STATURE
279724 00 01 07/03/81 F AC 1 0 MICROGNATHIA
260537 00 02 11/03/81 M DC 1 1 TEV/MR
260541 00 01 18/03/81 M AC 0 0 NONE
261453 00 02 06/04/81 F LA 2 0 SYNDACTYLY/ANKYLOGLOSSIA
262151 00 01 30/04/81 F LA 0 0 NONE
269880 00 02 30/04/81 M FV 0 0 NONE
262139 00 02 06/05/81 M LA 0 0 NONE
261833 00 02 06/05/81 M AC 0 2 CHD/NTD
263186 00 02 27/05/81 F GC. 0 0 NONE
263183 00 02 01/06/81 M AC 0 0 NONE
263553 00 03 02/06/81 M LA 0 1 SEVERE MR
283380 00 02 11/06/81 M LA 2 0 INGUINAL HERNIA/UNDECENDED TESTES
264126 00 02 13/07/81 F GG 1 0 MICROGNATHIA
61751 00 03 13/07/81 M AA 0 0 NONE
62198 00 02 06/08/81 M AA 0 0 NONE
62304 00 03 23/08/81 F AA 1 0 MICROGNATHIA
265420 00 03 10/09/81 F GG 0 0 NONE
265699 00 03 19/09/81 F LA 0 0 TWIN
266233 00 03 18/10/81 M LA 1 0 INGUINAL HERNIA
62964 00 03 09/11/81 F AA 1 0 MICROGNATHIA
266949 00 01 15/11/81 F GG 0 0 NONE
UNK17 00 03 26/11/81 F - GG 0 0 NONE
270685 00 02 22/02/82 M CC 0 0 NONE
270978 00 01 28/02/82 F AC 0 2 ACHALASIA/MR
272808 00 03 06/04/82 F LA 0 0 NONE
281837 00 01 15/04/62 M FV 0 0 NONE
274580 00 03 16/04/82 M AA 1 2 CHD/HYDONEPHOSIS/INCUINAL HERNIA
273957 00 03 23/04/82 F CG 1 0 INGUINAL HERNIA
273420 00 02 05/06/82 M AC 0 0 NONE
237322 00 03 21/07/82 F GG 1 1 CMP/DYSPLASTIC EAR
276151 00 02 07/08/82 F GC 0 1 MILD MR
276502 00 01 25/08/82 M AC 0 0 NONE
288309 00 02 13/09/82 F GG 0 0 NONE
277078 00 02 23/09/82 M GG 1 0 MICROGNATHIA
275375 00 02 . 24/09/82 M AC 1 0 ECTOPIC TESTIS
276902 00 02 01/10/82 F GG 1 0 MICROGNATHIA
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277540 00 01 09/10/82 F AC 0 0 NONE
278609 00 01 04/12/82 F GG 0 0 NONE
280171 00 02 05/12/82 M GG 0 2 SKELETAL DYSPLASIA/ASTIGMATISM
278890 00 02 11/12/82 M AC 0 0 NONE
279665 00 03 12/12/82 M GG 0 1 SHORT STATURE
280200 00 02 19/12/82 F GG 1 0 STRABISMUS
68656 00 03 23/12/82 F AA 0 1 MR
UNK19 00 02 10/01/83 F GG 0 0 NONE
279724 00 02 22/01/83 M AC 1 0 MICROGNATKIA/MYOPIA
279893 00 03 23/01/83 F AA 0 0 NONE
295216 00 03 10/02/83 F GG 0 0 NONE
69256 00 02 14/03/83 M AA 1 1 HYPERTELORISM/COLOBOMA
CSA11 00 03 14/03/83 M FV 0 0 NONE
282228 00 03 07/04/83 F LA 0 0 NONE
UNK20 00 02 16/04/83 F GG 1 1 MICROGNATHIA/SKIN ABNORMAL
296027 00 02 23/04/83 M FV 0 0 NONE
69812 00 03 25/04/83 M AA 1 0 MICROGNATHIA
UNK21 00 02 28/05/83 M GG 0 3 CHD/PULMONARY HYPOPLASIA/GENITAL
70928 00 02 05/08/83 F DG 0 0 NONE
293112 00 03 12/08/83 F GG 1 1 CHD/MYOPIA
287121 00 02 22/08/83 F GG 0 0 NONE
C3A12 00 03 28/08/83 M GG 0 0 NONE
287305 00 01 05/09/83 F LA 0 0 NONE
71358 00 02 07/10/83 M AA 0 1 CHD
71356 00 03 09/10/83 F AA 0 1 SCOLIOSIS
292011 00 03 11/10/83 M LA 1 1 PREMATURITY/INGUINAL HERNIA
290677 00 02 09/11/83 F GG 0 0 NONE
324384 00 02 16/11/83 F AC 1 0 MIDFACE HYPOPLASIA
290423 00 03 19/12/83 M LA 0 1 CHD
291271 00 02 20/12/83 F AA 0 0 NONE
305174 00 02 31/12/83 M FV 0 0 NONE
294515 00 03 07/01/84 M GG 0 1 CHD
72367 00 03 04/02/84 F AA 0 0 CHD/MR/TEV
294167 00 02 02/03/84 M DG 0 0 NONE
294521 00 02 15/03/84 M GG 0 4 FITS/MR
294177 00 02 06/04/84 F AC 0 1 MICROTIA
294338 00 02 09/04/84 F GG 0 0 NONE
295174 00 02 13/04/84 M LA 0 0 NONE
296065 00 02 16/04/84 M GG 0 3 MICROTIA/SHORT STATURE
73822 00 04 25/05/84 F AA 0 0 NONE
298258 00 02 06/06/84 F AC 1 0 FH LEBERS
UNK22 00 02 07/06/84 F GG 0 2 NTD/TEV
297497 00 03 05/07/84 M GG 0 0 NONE
MG3994 00 03 08/07/84 F GG 0 4 MICROCEPHALY/POLYDACTYLY
323128 00 03 20/07/84 F AC 0 0 NONE
CSA14 00 03 25/07/84 F FV 0 2 CHD/CNS MALFORMATION
298974 00 03 27/07/84 F LA 1 0 PTOSIS
299133 00 02 31/07/84 M GG 0 1 SHORT STATURE
298434 00 03 08/08/84 M GG 0 0 NONE
2991 18 00 02 09/08/84 M GG 1 1 ASTHMA SHORT STATURE
73591 00 03 10/08/84 F AA 1 0 MICRONGATHIA
298718 00 03 15/08/84 M LA 1 3 NTD/CDH/UNDECENDED TESTIS
301141 00 01 05/09/84 F DG 0 0 NONE
299884 00 03 06/09/84 F LA 0 0 NONE
73821 00 02 11/09/84 F AA 0 0 NONE
301284 00 02 12/10/84 F AC 1 0 UMBILICAL HERNIA
302706 00 02 18/10/84 M GG 0 0 NONE
302511 00 01 29/10/84 M LA 0 0 NONE
64919 00 03 15/11/84 F AA 1 0 MICROGNATHIA
302697 00 03 20/11/84 F AC 0 0 NONE
303663 00 02 18/12/84 M GG 0 0 ADOPTED
303571 00 03 26/12/84 M LA 0 0 NONE
303367 00 03 31/12/84 M GG 1 1 CHD
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Summary
We have studied the expression of genes encoding
transforming growth factors (TGFs) betal, beta2 and
beta3 during development of the secondary palate in the
mouse from 11.5 to 15.5 days postcoitum using in situ
hybridisation. The RNA detected at the earliest develop¬
mental stage is TGF beta3, which is localised in the
epithelial component of the vertical palatal shelf. This
expression continues in the horizontal palatal shelf,
predominantly in the medial edge epithelium, and is lost
as the epithelial seam disrupts, soon after palatal shelf
fusion. TGF betal RNA is expressed with the same
epithelial pattern as TGF beta3, but is not detectable
until the horizontal palatal shelf stage. TGF beta2 RNA
is localised to the palatal mesenchyme underlying the
medial edge epithelia in the horizontal shelves and in the
early postfusion palate. The temporal and spatial distri¬
bution of TGF betal, beta2 and beta3 RNAs in the
developing palate, together with a knowledge of in vitro
TGF beta biological activities, suggests an important
role for TGF beta isoforms in this developmental pro¬
cess.
Key words: TGF beta, in situ hybridisation, mouse embryo,
palatogenesis.
Introduction
The murine secondary palate arises from the bilateral
maxillary processes of the head. These structures are
composed of migratory neural crest cells associated
with craniopharyngeal ectoderm (for reviews see
Greene and Pratt (1976) and Ferguson (1988)). Mes¬
enchymal cell proliferation within the maxillary pro¬
cesses results in the appearance of primordia of the
palatal shelves (Burdett et al. 1988), which grow verti¬
cally down beside the tongue. A rapid elevation of the
palatal shelves brings the two processes into horizontal
apposition above the tongue. This is followed by the
fusion of the medial edges of the palatal shelves
resulting in a continuous palate which later undergoes
chondrification and ossification in its anterior portion
(Greene and Pratt, 1976; Ferguson, 1988).
The epithelia that cover the palatal shelves are
regionally heterogeneous. The oral, nasal and medial
edge epithelia can be identified by position, mor¬
phology and cell surface markers (Ferguson, 1988).
They also have different cell fates. Whereas the nasal
and oral epithelia differentiate into pseudostratified and
squamous epithelia, respectively, the medial edge epi¬
thelium is destined to disrupt by a combination of
epithelial cell death and epithelial-mesenchymal trans¬
formation (Fitchett and Hay, 1989). Palatogenesis oc¬
curs comparatively late in embryogenesis (fusion at
gestation day 14.5 in the mouse), making it an easily
amenable model for studying several developmental
processes, most notably epithelial-mesenchymal inter¬
actions.
The importance of epithelial-mesenchymal interac¬
tions in the developing palate was established by the
tissue recombination studies of (Ferguson and Honig,
1984), who showed that the regional specification of the
palatal epithelium is controlled by the underlying mes¬
enchyme. Little is known of any reciprocal signalling
from the palatal epithelium. Recently, a paracrine
mechanism of transforming growth factor betal (TGF
betal) action was proposed in certain epithelial-
mesenchymal interactions, as suggested by localisation
of TGF betal RNA in epithelia which overlie mes¬
enchymal tissue containing the TGF betal protein
(Heine et al. 1987; Lehnert and Akhurst, 1988; Akhurst
et al. 1990b). To extend this study further, particularly
with respect to mammalian palatogenesis, we examined
the distribution of RNAs encoding TGF betal, beta2
and beta3, from the time of appearance of the palatal
processes, at 11.5 days gestation, to completion of
palatogenesis at 15.5 days post-coitum.
The TGF betas are a family of related polypeptides
which show a high degree (65-80%) amino acid hom¬
ology within the mature C-terminal portion of the
molecule and are highly conserved throughout evol¬
ution (Sporn et al. 1986; Roberts and Sporn, 1990).
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There are currently five vertebrate members of this
family termed TGF betal (Derynck et al. 1985), TGF
beta2 (Madisen et al. 1988; Miller et al. 19896), TGF
beta3 (ten-Dijke et al. 1988; Derynck et al. 1988;
Jakowlew et al. 19886; Denhez et al. 1990; Miller et al.
1989a), TGF beta4 (Jakowlew et al. 1988a) and TGF
beta5 (Kondaiah et al. 1990), though only three have
been molecularly cloned from mammalian sources.
TGF betal was originally identified as a mitogen
(Roberts et al.' 1981; Moses et al. 1981), but has since
proven to have growth inhibitory effects on many cell
types in culture (Moses et al. 1985). It also has tissue-
specific effects on cellular differentiation in vitro, in¬
ducing differentiation of some cell types (Masui et al.
1986; Seyedin et al. 1986), whilst inhibiting differen¬
tiation of others (Massague et al. 1986; Ignotz and
Massague, 1985). One major biological activity of TGF
betal is its ability to induce deposition of extracellular
matrix (ECM) by mesenchymal cells. This is mediated
by increased biosynthesis of ECM components
(Roberts et al. 1986; Ignotz and Massague, 1986) and of
protease inhibitors and by decreased synthesis of extra¬
cellular proteases (Lund et al. 1987; Edwards et al.
1987).
TGF beta2 protein was isolated from demineralised
bovine bone on the basis of its cartilage-inducing
activity in culture (Seyedin et al. 1987). It was later
found to be structurally and functionally related to TGF
betal (Seyedin et al. 1987)). The spectrum of in vitro
biological activities of TGF betal and TGF beta2 are
very similar, though there are some marked specificities
as well. TGF beta2 has potent mesoderm-inducing
activity in a Xenopus bioassay (Rosa et al. 1988),
whereas TGF betal can only act in a synergistic capacity
along with fibroblast growth factor (FGF) in this assay
(Kimelman and Kirschner, 1987). Conversely, of the
two, TGF betal is the most potent growth inhibitor of
endothelial cells in culture (Jennings et al. 1988). In the
mouse embryo, TGF beta2 RNA has been shown to
have a very different spatial and temporal expression
pattern from that of TGF betal RNA, being localised to
the mesenchymal components of tissues such as bone,
cartilage, blood vessels and gut (Pelton etal. 1989). This
gives further support to the proposition that these two
very similar molecules serve different in vivo biological
functions.
TGF beta3 was isolated by molecular cloning of
cDNAs (ten-Dijke et al. 1988; Jakowlew et al. 19886;
Derynck et al. 1988), and there is comparatively little




Mouse embryos were obtained from Parkes females mated
with NIH males. The day on which the copulation plug was
found was called day 0.5. All tissues were fixed overnight in
ice-cold 4% paraformaldehyde in phosphate-buffered saline,
then dehydrated and embedded in paraffin wax. The palates
of embryos 14.0 days gestational age or older were dissected
in ethanol to ascertain the developmental stage of palatogen-
esis prior to paraffin-embedding.
Probe synthesis
35S-labelled riboprobes were generated to a specific activity of
109disints per min /<g_1 using either the T3 or T7 polymerase
transcription systems. Probes were digested to an average of
100 nucleotides by controlled alkaline hydrolysis (Cox et al.
1984) and used at a final concentration of 30pg^l_I in
hybridisations.
The TGF betal-specific antisense probe was a 600 nucleo¬
tide Apal-Kpnl fragment subcloned into Bluescribe (Strata-
gene) from the full-length murine TGF betal cDNA (Der¬
ynck et al. 1986) which was kindly provided by Dr R. Derynck
(Genenteck). The subclone corresponds to the precursor
region of the TGF betal polypeptide (amino acids 68-268).
The control probe used was a full-length TGF betal human
cDNA, kindly supplied by Dr G. Bell (unpublished). It was
also subcloned into the Bluescribe vector in sense orientation
with respect to the T7 promoter.
The TGF beta2 DNA probe was obtained by amplification
of the reverse transcriptase product of total mouse embryo
RNA using the polymerase chain reaction (Saiki et al. 1988).
The oligonucleotide primers spanned the initiation and ter¬
mination codons. This probe was identical in nucleotide
sequence to that reported by Miller et al. (19896) (F. Denhez
unpublished). This study used the full-length probe; however,
a TGF beta2 specific, 501 nucleotide Prd-SucI fragment has
shown identical hybridisation pattern (data not shown).
The TGF beta3-specific probe was a 732 nucleotide frag¬
ment spanning amino acid residues 8 to 251 of the precursor
polypeptide (Denhez et al. 1990).
Nucleotide sequence homologies between the three gene-
specific probes were 42% (betal to beta2), 47% (beta2 to
beta3) and 36% (betal to beta3) (Pelton etal. 1989; Denhez et
al. 1990).
In situ hybridisations
In situ hybridisation to 7 pm tissue sections was performed
according to the protocol of Wilkinson et al. (1987) using 60 %
formamide in the hybridisation mixture and a hybridisation
temperature of 52 °C. The slides were dipped in Ilford K5
emulsion and exposed for 3, 7 and 21 days. After develop¬
ment the slides were stained in haematoxylin and mounted.
Photomicrography was performed on an Olympus BK2
microscope using Panatomic X film (Kodak).
Results
The differential distributions of RNAs encoding the
three related growth factors, TGF betal, beta2 and
beta3 were investigated during murine palatogenesis
from 11.5 to 15.5 days gestational age. In situ hybridisa¬
tion was performed on 7,urn coronal sections of the
embryonic head using radioactive gene-specific probes
complementary to each transcript. As a negative con¬
trol, a human TGF betal sense probe was employed
which gave no specific hybridisation signal (data not
shown).
No specific hybridisation of any probe was seen in the
very early palatal shelves at 11.5 to 12.5 days gestational
age (data not shown). The failure to localise transcripts
at this stage may relate to the limits of detection of the
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in situ hybridisation technique. The first appearance of
TGF beta transcripts occurred at the late vertical shelf
stage. Two patterns of RNA distribution were seen at
this time and later in shelf development. TGF betal and
beta3 are expressed in the medial edge epithelia,
whereas TGF beta2 RNA is localised in the underlying
mesenchyme.
Late vertical palatal shelves
At 13.5 days gestation the TGF betal-specific probe
showed strong hybridisation to the submandibular
gland (Fig. 1C), as previously shown by Lehnert and
Akhurst (1988). At this stage, the palatal shelves, which
are growing vertically, show no specific hybridisation to
this probe.
The first TGF beta gene to show high level expression
in the palatal processes is that for TGF beta3
(Fig. 1G,H). This gene is expressed in the epithelial
component of the palatal shelves in the region that will
give rise to the future medial edge epithelium. In
several embryos, examined the spatial extent of the
hybridisation signal is identical. TGF beta3 expression
is more extensive in the vertical epithelium facing the
tongue and stops abruptly on the oral side. In the most
anterior region of the oro-nasal cavity, the epithelium
of the nasal septum, which is also destined to fuse with
the palatal shelves, shows high level TGF beta3 ex¬
pression (Fig. 1G).
There is a low level of hybridisation of the TGF beta3
probe to the mesenchyme of the tongue, mandible and
the upper regions of the maxillary processes. The
mesenchyme immediately adjacent to the medial edge
epithelium is, however, markedly devoid of autoradio¬
graphic signal. This observation was also made at later
stages (see Figs 2F,G and 3D).
At this early stage, TGF beta2 does not appear to be
specifically expressed in the palatal processes, although
a characteristic signal is seen in the differentiating
olfactory epithelium of the nasal process (data not
shown). On some sections, small regions of the medial
edge epithelia appear to show hyperplasia, resulting in
small blebs of stratified epithelium (Fig. IE). The
epithelial cells within these hyperplastic nodules ex¬
press very high levels of TGF beta2 RNA (Fig. 1D,F),
whereas there is no hybridisation with either TGF betal
or beta3 (data not shown).
The horizontal palatal shelf
After elevation of the palatal shelves at around 14.0
days gestation, the medial edge epithelia come into
almost immediate contact (Fig. 2A). At this stage, TGF
betal is now detectable in the medial edge epithelia in
the same cells that express TGF beta3 (Fig. 2B,C,D).
The expression of epithelial TGF betal RNA is corre¬
lated with the presence of the polypeptide in the
underlying mesenchyme (Heine et al. 1987). TGF betal
expression is also seen in regions of membranous
ossification within the developing maxilla (Fig. 2B), as
previously reported by Lehnert and Akhurst (1988).
By this time the quantity of TGF beta3 RNA in the
medial edge epithelium has increased considerably.
There is striking hybridisation with this probe in both in
the medial edge epithelia and the epithelium of the oral
aspect of the prefusion anterior nasal septum
(Fig. 2F,G,H). In fact, the palatal epithelium at this
stage is by far the richest source of TGF beta3 RNA
within the entire embryo (F. Millan and R. Akhurst
unpublished).
TGF beta2 RNA is excluded from the palatal epi¬
thelium, but a gradient of expression is seen within the
mesenchyme beneath the medial epithelium, with
highest expression levels immediately adjacent to the
epithelium (Fig. 2E).
The fusing palate
With fusion of the medial edge epithelia to form the
epithelial seam, the expression patterns established in
the horizontal shelves continue. TGF betal (Fig. 3B)
and TGF beta3 (Fig. 3D,G,H) RNAs are localised to
the epithelial cells of the seam. This expression is lost as
the seam disrupts and the cells lose their epithelial
phenotype by transformation into mesenchymal cells.
TGF beta2 transcript levels increase and are now
easily seen in the mesenchyme on either side of the
seam (Fig. 3C,E,F). The RNA distribution is asymmet-
Fig. 1. Localisation of TGF betal, beta2 and beta3 in
vertical palatal shelves. Coronal sections are presented from
13.5-day embryos through the anterior third of the vertical
palatal shelves. A and E,F,G,H are bright-field images,
B,C,D are dark-field. (A) Bright-field image showing
tongue (to), palatal shelves (ps) and nasal septum (ns).
(B) Dark-field images showing non-specific hybridisation
with sense probe. (C) TGF betal probe showing
hybridisation to the submandibular gland (sm). (D) Non¬
specific mesenchymal hybridisation of TGF beta2 probe
with localised area of expression in the epithelium of the
left palatal shelf. (E) High-power image of adjacent section
to D showing localised hyperplasia (hy) in the epithelia of
one palatal shelf (ps). (F) High-power view of epithelial
expression in D. (G) Hybridisation of the TGF beta3 probe
to the medial epithelia of the palatal shelves and the oral
epithelium of the nasal septum. (I) High-power view of the
palatal shelf (ps) epithelial expression (boxed area) in H.
Scale bar (A.B,C,D,G) represents 200 micrometers, scale
bar (E,F,H) 50 micrometers.
Fig. 2. TGF betal, beta2 and beta3 expression in the
horizontal palatal shelves. All sections are from 14.0-day
embryos. (A) Coronal bright-field image of horizontal,
middle third palatal shelve (ps) medial edge epithelia (me)
with the nasal septum (ns) above and oral cavity (oc)
below. (B) Adjacent section to A with TGF betal probe
hybridising to the maxilla (ma) and medial edge epithelia
(me). (C) Bright-field paramedial sagittal section through
posterior medial edge epithelia (me). (D) Dark-field image
of C with TGF betal probe specifically hybridising to the
medial edge epithelium. (E) Dark-field image of coronal
section TGF beta2 hybridising to the medial and nasal
palatal mesenchyme. (F) TGF beta3 hybridising to the
medial edge epithelia on adjacent section to A. (G) Dark-
field image of coronal section through middle third of
palate, posterior to F, TGF beta3 probe hybridises to the
medial edge epithelia. (H) High-power view of the palatal
shelves (ps) and medial edge epithelia (me) expression in G
(boxed area). Scale bar (A,B,C,D,E,F,G) represents
200 ,um and in (H) 50 ^m.
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Fig. 1. For legend see p. 587
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Fig. 2. For legend see p. 587
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Fig. 3. Localisation of TGF betal, beta2 and beta3 in the fusing palate. All sections are coronal through the middle third of
the fusing palate of 14.5-day embryos. (A) Bright-field image of fusing palate with the midline epithelial seam (es).
(B) Dark-field image showing TGF betal faint hybridisation to the epithelial seam. (C) Dark-field image of TGF beta2
hybridisation to the medial and nasal palatal mesenchyme. (D) Dark-field image of specific hybridisation of TGF beta3 to
the epithelial seam. (E) High-power bright field image of the epithelial seam (es) in C showing absence of TGF beta2
expression in the seam. (F) Dark-field image of E. (G) High-power bright field image of TGF beta3 expression in the
disrupting epithelial seam (es), showing hybridisation only where the seam is intact. (H) Dark-field image of G. Scale bar
(A,B,C,D) represents 200/<m and (E,F,G,H) 50/rm.
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ric with a higher concentration towards the nasal side of
the palate.
The maturing palate
After fusion, the midline epithelial seam rapidly dis¬
rupts by a process of epithelial-mesenchymal trans¬
formation and cell death, thus establishing mesenchy¬
mal continuity (Fitchett and Hay, 1989). The fate of the
palatal mesenchyme is regionally determined, an¬
teriorly becoming ossified to form the bone of the hard
palate and posteriorly giving rise to muscle (Ferguson,
1988).
TGF beta2 continues to be expressed in a diffuse
region of the mesenchyme around the midline of the
palate (Fig. 4C). Other studies from this laboratory
suggest that this TGF beta2 expression may be associ¬
ated with condensation of mesenchymal tissue prior to
chondrification (D. Gatherer, F. Millan, D. Baird and
R. Akhurst unpublished).
Postfusion, TGF beta3 expression also switches to
become primarily mesenchymal. Hybridisation is seen
in the perichondrium of the nasal septum as well as in
the mesenchyme of the anterior secondary palate
(Fig. 4D). In general, we have found that TGF beta3
expression is associated with chondrification in early
mouse and human embryos (D. Gatherer, F. Millan, D.
Baird and R. Akhurst unpublished).
Finally TGF betal expression in the maturing palate
is limited to areas of ossification within the palate and
around the nasal processes (Fig. 4B), as previously
reported (Lehnert and Akhurst, 1988).
Discussion
Cleft palate is amongst the most common of congenital
Fig. 4. TGF betas in the maturing
palate. Sections have been cut coronally
through the middle third of the palates
of 15.5-day embryos. A is a bright-field
image and B.C.D are dark-field.
(A) The maturing palate (p). (B) TGF
betal probe hybridising to the areas of
ossification within the palate and around
the nasal processes (np). (C) Diffuse
hybridisation of the TGF beta2 probe to
the mesenchyme around the midline of
the palate. (D) Specific perichondrial
(pc) hybridisation of the TGF beta3
probe around the nasal septum and the
midline mesenchyma of the palate.
Scale bar represents 200 /tm.
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malformations in humans (Thompson and Thompson,
1986). From a clinical standpoint, it would therefore be
very important to understand the mechanisms control¬
ling mammalian palatogenesis at the cellular and mol¬
ecular level. The mouse represents a good model for
such a study since palatogenesis is almost identical to
that in the human, and the process can be disturbed in a
controlled manner by the administration of teratogens
(Morriss, 1973; Abbott et al. 1988). Furthermore,
several genetic lines of mice are available which show
increased susceptibility to this malformation (Fitch,
1957; Gasser et al. 1981).
The first evidence of the expression of members of
the TGF beta family during palatogenesis is the epi¬
thelial expression of TGF beta3 in the vertical palatal
shelves. TGF betal shows a similar pattern of ex¬
pression to that of TGF beta3 but apparently with lower
transcript prevalence. A comparison of relative tran¬
script levels of different genes by in situ hybridisation is
difficult to make, despite control over the size and
specific activity of the radioactive probe. However, one
conclusion that can be drawn regarding transcript
prevalence is that the medial edge epithelial cells are
the most abundant source of TGF beta3 RNA within
the murine embryo at this period of development.
In addition to the epithelial expression of TGF betal
and beta3, there is a distinct mesenchymal distribution
of TGF beta2 gene expression. The temporal and
spatial distribution of transcripts from these three genes
is summarised in Fig. 5.
As yet there are no published reports of the polypep¬
tide distributions of TGF beta2 or TGF beta3 during
murine embryogenesis, though the mesenchymal distri¬
bution of TGF betal polypeptide in the palate (Heine et
al. 1987) would be consistent with a paracrine mode of
action of epithelially derived TGF betal on the underly¬
ing mesenchyme, as previously suggested (Lehnert and
Akhurst, 1988; Akhurst et al. 1990b). From the similar
pattern of epithelial TGF beta 3 gene expression one
might speculate that this growth factor also has para¬
crine activities on the mesenchyme.
TGF betal (and beta3?) may act on the underlying
mesenchyme in a variety of ways. TGF betal is known
to stimulate proliferation and chemotaxis of cells of
mesenchymal origin (Moses et al. 1985; Postlethwaite et
al. 1987), though Sharpe and Ferguson (1988) have
claimed that, in the palate, it is inhibitory to mesenchy¬
mal cell growth. Both cell migration and proliferation
are essential features of palatal shelf development.
The action of TGF betal on the accumulation of
ECM components has been the subject of extensive
study. This growth factor induces synthesis of collagens
and fibronectin (Roberts et al. 1986; Ignotz and Massa-
gue, 1986), tenascin (Pearson et al. 1988) and
chondroitin/dermatan proteoglycans (Hiraki et al.
1988; Sharpe and Ferguson, 1988). Accumulation of the
latter class of molecules is thought to be important in
palatal shelf elevation by virtue of the rise in osmotic
pressure resulting from hydration of the proteoglycan
network (Pratt et al. 1973; Brinkley and Morris Wiman,
1987). In this respect it is interesting that high
f , ] TGF beta - 2 expression
[ : TGF beta - 1 & beta - 3 expression
Fig. 5. Diagrammatic representation of the role of the TGF
beta family in the developing palate. The line drawings
represent coronal sections through the midpalate at the
gestations (in days) indicated above the drawings. The
diagrams show the palatal shelves (ps) growing down beside
the tongue (to) and then elevating to fuse between the
tongue and nasal septum (ns). The filled black areas
illustrates TGF beta3 expression, diagonal striping for TGF
beta2 and stippled areas for the combined expression of
TGF betal and beta3.
levels of TGF beta3 RNA are observed 24 h prior to
palatal shelf elevation.
The distributions of many extracellular matrix pro¬
teins are fairly ubiquitous within the palatal mesen¬
chyme. Two significant exceptions are collagen IX and
tenascin. Collagen IX appears on the cell surface of
medial edge epithelial cells prior to shelf elevation
(Ferguson, 1988). Tenascin is localised beneath the
medial edge epithelium prior to and during palatal shelf
fusion (Sharpe and Ferguson, 1988). Since TGF betal is
known to induce synthesis of both of these proteins
(Sharpe and Ferguson, 1988; Pearson et al. 1988), it is a
reasonable supposition that these ECM molecules may
mediate some of the effects of TGF betas. The distri¬
bution of tenascin is particularly significant since the
embryonic distribution of this molecule is almost com¬
pletely correlated with the presence of epithelial TGF
betal RNA (Chiquet-Ehrismann et al. 1986; Lehnert
and Akhurst, 1988; Akhurst et al. 1990a\ Sharpe and
Ferguson, 1988).
Tenascin can disrupt epithelial sheet continuity by
breaking cell-cell and cell-substratum contacts (Chi¬
quet-Ehrismann et al. 1989). It also specifically pro¬
motes the mobility of neural crest cells in vitro (Halfter
et al. 1989). Both of these events would be necessary for
14.0 days 14.5 days
j£ TGF beta - 3 expression
12.5 days 13.5 days
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fusion along the mid-line seam, a time when the
epithelial sheet disrupts, epithelial cells transdifferen-
tiate to a mesenchymal cell phenotype and there is
much cell mixing.
Terminal differentiation, or 'programmed cell death',
plays an equally important role to transdifferentiation
in the disruption of the midline epithelial seam (Pratt
and Martin, 1975; Greene and Pratt, 1976). Cessation
of epithelial DNA synthesis occurs 24 h prior to fusion
(Pratt and Martin, 1975). It is accompanied by a down-
regulation in epidermal growth factor (EGF) receptors
(Abbott et al. 1988), and is not dependent on shelf
contact in vitro. This lethal differentiation is specific to
the medial edge epithelium, it is not seen in the oral or
nasal components (Pratt and Martin, 1975; Tyler and
Koch, 1975). The activation of TGF beta3 gene ex¬
pression occurs 24 to 36 h prior to fusion and could be
important in this growth inhibitory process.
TGFs betal, beta2 and beta3 are each known to be
growth inhibitory to epithelial cells, antagonising the
mitogenic activities of TGF alpha and epidermal growth
factor (EGF) (Massague, 1985; Like and Massague,
1986; Coffey et al. 1988; Grayar et al. 1989). It is,
however, unlikely that EGF receptor down-regulation
(Abbott et al. 1988) is directly initiated by TGF betas.
Although this is a mechanism of negative growth
regulation utilised by endothelial cells (Takehara et al.
1987), TGF beta acts distally to the EGF receptor in
growth inhibition of all epithelial cells that have been
examined (Massague, 1985; Like and Massague, 1986;
Coffey et al. 1988).
TGF beta2 RNA distribution during palatogenesis is
in marked contrast to that of TGFs betal and beta3. Its
predominant localisation in the mesenchyme would
agree with the observations of Pelton et al. (1989). It
was suggested by Pelton et al. that mesenchymal ex¬
pression of TGF beta2 might be important, not only in
modulating the mesenchyme per se, but in supporting
growth of the overlying epithelium via secondary events
such as induction of TGF alpha. In this context, it is
interesting that the TGF beta2 RNA distribution is
asymmetric with respect to the nasal and oral regions.
Differential concentrations of growth factors within the
mesenchyme could contribute to the generation of
regional heterogeneity of the overlying epithelium.
The localised high level expression of TGF beta2 in
the hyperplastic nodules of the early medial edge
epithelium is consistent with this growth factor acting as
an inducible homeostatic regulator of epithelial growth
and differentiation. Pelton et al. (1989) previously
observed the expression of this growth factor in the
suprabasal keratinocytes of the embryonic skin at a
time when the rate of keratinocyte cell division would
be slowing.
One point raised by these RNA localisation studies is
the question of why genes encoding proteins with such
similar in vitro biological activities should be expressed
in the same developing organ, in some cases with
overlapping but distinct patterns of expression, and in
other cases with quite disparate transcript localisations.
One explanation of the apparent temporal sequence of
expression (TGF beta3 followed by TGF betal and
beta2) would be the induction of one member of the
TGF beta family by another, to amplify specific profu¬
sion biological effects. It is known that TGF betal
positively regulates its own expression in normal and
transformed cells (Van Obberghen-Schilling et al. 1988)
but little is known about 'cross-talk' between these
individual genes. Clearly these different genes must
serve some disparate in vivo biological functions. This is
supported by the fact that some in vitro biological
activities reported for the TGF betas do show some
specificity in isoform requirement (Rosa et al. 1988;
Jennings et al. 1988).
We conclude from this study that all three TGF beta
isoforms must play an important role in mammalian
palatogenesis. It will be interesting to see how ex¬
pression of these genes is modified following treatment
with teratogens that cause cleft palate, and in mutant
mice with increased susceptibility to this deformity.
Thanks to Dr R. Derynck (Genentech) for the full length
murine TGF betal cDNA probe, to Dr G. Bell (Howard
Hughes Institute) for the human TGF betal cDNA. to Derek
Gatherer and Sigrid Lehnert for instruction and advice on the
in situ hybridisation technique and to D. Gatherer and F.
Millan for quotation of results prior to publication. Thanks to
Professor J.M. Connor for help and encouragement. DRF
was funded by the NHS. This work was supported by grants
from the MRC and the CRC.
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Type P transformating growthfactors (TGFfs) are members ofa large superfamily of
related proteins, each of which plays a pivotal role in embryonic processes. The TGFfs
per se are at least five in number, though only three isoforms have been identified in
mammals. Here we will review the evidence, taken from in vitro studies on bioactivity and
histochemical localization ofRNAs and encodedproteins in vivo, that TGFfl, f!2 and f}3
are involved in several mammalian developmental processes, including control ofgrowth,
differentiation, tissue inductions and morphogenesis.
Key words: Transforming growth factor y3, embryogenesis, cardiogenesis, epithelial-
mesenchymal interactions, morphogenesis, extracellular matrix.
INTRODUCTION
It has become widely accepted that growth factors are not only involved in the
regulation of cellular mitogenesis, but also in the modulation of a variety of biological
processes at the cellular and tissue organizational levels. The transforming growth
factor /2s (TGF/2) are an excellent example. These growth factors can influence cell
growth, differentiation, inductive interactions, transdifferentiation and cell lineage
pathways, as well as modulate the biosynthesis of the extracellular matrix, all of which
are of central importance in embryogenesis.
The in vitro biological activities ofTGF/2are variable, depending on cell type, culture
conditions and the presence of other growth factors. These have recently been
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extensively reviewed elsewhere [1-3], and thus will only be mentioned in the context of
their relevance to specific development processes.
THE TGF/3 SUPERFA.VIILY
TGF/31 was identified and isolated around a decade ago, on the basis of its ability to
induce anchorage-independent growth of non-transformed cells [4-6], The mature
growth factor was shown to be a 25 kDa homodimeric protein. Once the gene for
TGF/31 was cloned [7], it became clear that many molecules, from a diverse range of
species, were related to TGF/21. These include the Decapentaplegic (dpp) gene of
Drosophila, which is involved in dorso-ventral patterning of the fly [8] and the
amphibian mesoderm-inducing factors, Vgl and MIF-XTC (or activin B) [9,10] and
also the mammalian proteins; Mullerian inhibitory substance, which aids the
regression of male Mullerian duct during development [11], the inhibins and activins
[12,13], and the bone morphogenetic proteins (BMPs) [14], which include Vgr-1 [15]. A
striking observation is that each of these proteins serves a fundamental function(s) in
embryonic processes, which led researchers to investigate a potential role for TGF/3per
se in development of the embryo.
It is beyond the scope of this article to review the role of each of the superfamily
members in embryonic development. In the interest of brevity we will therefore restrict
ourselves to the function of the TGF/2s per se, and focus on their role in mammalian
development.
THE TGF/3FAMILY
All TGF/3s are translated as large precursor proteins which are subsequently
processed by the removal of an A-terminal signal sequence and cleavage of the larger
precursor domain (latency-associated peptide, LAP) from the adjacent C-terminal
active polypeptide. A dimer of LAP remains associated with the bioactive TGFp
homodimer, thus keeping it in a biologically latent form. Although factors capable of
activating TGF/3 in vitro have been identified, it remains unknown how TGF/3
activation occurs in vivo (see [2]).
To date, five members of the TGF/3 family have been reported. These are
characterized by sharing 70% amino acid identity within the bioactive C-terminal
portion of the polypeptide (in contrast, the superfamily members are only 30-40%
homologous). TGF/31, pi and pi have been isolated from various mammalian and
avian sources, but, as yet, no mammalian homologues of TGF/34 or fJ5 have been
found. The latter two have only been isolated from chick and frog, respectively [16,17],
In contrast to the intraspecies divergence of family members, the interspecies amino
acid sequence conservation ofany individual TGF/Igene is virtually complete. This has
raised the discussion ofwhether multiple TGF /fe have arisen to serve distinct biological
functions in vivo, or whether the purpose of the gene family is to provide expression of
proteins of identical function in diverse tissue contexts.
Comparative biological activity studies in vitro suggest that TGF/I1, pi and pi have
similar qualitative effects on keratinocytes, fibroblasts, osteoblasts and endothelial
cells, but that these activities vary quantitatively [18-20]. In yet other biological
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systems, the TGF@s clearly have distinct roles. As an example, mammalian TGF/2 can
induce the formation of mesoderm from Xenopus ectodermal explants. In contrast,
TGF/ff does not possess this bioactivity, but can synergize with fibroblast growth
factor (FGF) in this process [21], It thus appears more likely that theTGF/?s do indeed
possess functional specificity in vivo.
Since the bioactive coding portions of TGF/fe are so highly conserved, it is thought
that biological specificity may be conferred by the precursor region, either in
differential targeting of the latent complex to its site of action, binding to cell surface
receptors or activation of the latent forms. The precursor domains exhibit conservation
of certain structural moieties, but also possess distinct intermolecular differences.
TGF/2, for example, unlike other isoforms, lacks a potential integrin-binding site [2],
whereas TGF/34 lacks a signal peptide [16].
STUDIES ON MAMMALIAN EMBRYOS
As yet there is no definitive evidence that any of the TGF/3s are endogenous
regulators of mammalian embryonic processes. Most of the information implicating
TGF/3s as embryonic modulators comes from descriptive studies on a) the ability of
early embryos and embryonal stem (ES) cells to secrete bioactive TGF/3s, b)
immunohistochemical localization of TGF/fe in mouse sections, c) detection of TGF/3
RNAs by Northern blot or polymerase chain reaction (PCR) of total RNA, or by in
situ localization in embryo sections. From this data, together with the extensive
knowledge of the in vitro bioactivities of TGF/3s gained from cell or organ cultures,
various inferences may be made. Some elegant in vivo studies have also implicated
TGF/3 as important in morphogenesis of the mammary gland, but, as yet, it has not
been demonstrated that any of the TGFySs occur endogenously within this developing
organ [22],
Most of the published work relevant to the functions of TGFp in embryonic
processes has been gained from immunohistochemical protein localization studies
[23,24] and in situ RNA localization studies [25-31]. However, conclusions drawn from
these studies must be made with caution for a number of reasons. Firstly, the similarity
ofTGFyfiisoforms at both nucleic acid and polypeptide levels has made the preparation
of isoform-specific reagents exceedingly difficult. This is particularly true for the
generation ofantibodies. Cross-reactivity may not occur in one assay, but be extensive
in another. Furthermore, antibodies raised against identical peptides can recognize
different epitopes, possibly as a result of conformational changes in the protein
following its translation, secretion and activation [32,33],
The two most extensively utilized polyclonal antibodies against TGF/ft are the so
called LC and CC reagents. These were raised against the same 30 amino acid peptide,
yet show different staining patterns in immunolocalization studies, the former
recognizing intracellular TGF/31 and the latter staining extracellularly [32-34]. It has
been postulated that these antibodies recognize the precursor and mature forms of
TGF/J1, since tissues staining with the LC antibody are normally identical to, or in
close proximity to those staining with the CC antibody [33,34]. Discrepancies do,
however, occur, for example in the adult heart, intense LC staining is observed in the
myocardium whereas CC staining occurs only in the valve leaflets [34],
The design of gene probes for in situ hybridization studies is less of a problem, but a
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judicious choice of probes is warranted, since cross-reactivity can occur [26,31]. In
general, the results of TGF/I1 RNA localization studies are in agreement with the
immunolocalization of protein. Nevertheless, there are inconsistencies. The spleen, for
example, is know to be the richest source of TGF/ff RNA in the adult [35,36],
nevertheless, no protein can be detected with the LC or the CC antibodies [34], Also in
the heart, the intensity of LC staining of the myocardium does not correlate with RNA
levels determined by Northern blot or in situ hybridization [34,35,37]. These may
represent examples of extreme post-transcriptional control of protein production.
Finally, in the embryonic mouse lung, staining for pro-TGF/ff is observed in the early
bronchial epithelium [24], whereas no TGF/ff RNA is detectable by in situ
hybridization [26,31]. TGF/33 RNA is, however, detected in the early pulmonary
epithelium [31], opening up the possibility that the pro-TGF/31 antibody also detects
pro-TGF/£3.
Another limitation of descriptive studies is the inability to determine what
percentage RNA is translated and what portion of the immunohistochemically
detectable protein is biologically active and available to the responding cell. Although
the half-life of TGF/?in serum is exceedingly short (ri;, = 2.5min), TGF/fe can bind to
the extracellular matrix, which could either act as a pool of the latent growth factor,
readiness for future use, or as a sink for spent protein.
Finally, the presence of the growth factor does not necessarily imply that cells in its
vicinity can respond. Although it has been widely reported that TGF/3 receptors are
ubiquitous on normal cells [38], alterations in ligand-binding have been observed
during differentiation of cells in culture [39], A clear example of the differential
responsiveness of similar cell types to TGF/? in vivo comes from work on the mammary
gland. In this system, TGF/Limpregnated plastic implants potently inhibit DNA
synthesis in pubertal ductal epithelial cells of the growing end buds, but have no effect
on 'maintainence' DNA synthesis in lumenal epithelial cells nor on the rapidly growing
secretory alveolar epithelial cells of the pregnant animal [22].
TGF/fcIN PRE- AND PERI-IMPLANTATION EMBRYOS
Much of the evidence implicating TGFs as important in pre-implantation
development has come from the study of embryos per se, or of embryonal carcinoma
(EC) or embryonal stem (ES) cell lines, which are thought of as models of the pre-
implantation embryo [39-42]. Several years ago it was shown that EC cells release, but
do not respond to, TGFs, whereas their differentiated derivatives are TGF-responsive
[40]. This was correlated with the novel appearance of high affinity receptors of TGF/?
on the cells following induction of differentiation [39]. Extrapolating to the in vivo
situation, it has been predicted that TGF/1 might act in a paracrine manner, whereby
the undifferentiated cells of the inner cell mass are the source ofTGF/3which modulates
growth and/or differential of the endodermal derivatives. Indeed, TGF/ff is
synthesized by pre-implantation embryos, though with no obvious regional
distribution [42,43].
More recently it has been shown that TGFfil is also synthesized in pre-implantation
embryos, though in this case endodermal outgrowths of the blastocyst, rather than
undifferentiated inner cell mass cells, are the source of growth factor [41].
The exact function of the TGF/3s in peri-implantation development remains
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debatable. They could be involved in autocrine or paracrine control of cell growth,/
differentiation, elaboration of the extracellular matrices synthesized by the implanting
embryo [41] or in interactions with maternal tissue, for example in inducing
angiogenesis at the site of implantation [42].
HAEMATOPOIESIS
The first evidence of high concentrations of TGF/J1 RNA within the murine
conceptus occurs within the extraembryonic blood islands at 7 days post-coitum (p.c.)
[37], At this early stage it is impossible to distinguish between haematopoietic and
endothelial cell precursors, though we believe that both cell types express TGF/31. The
blood islands are the major sites of haematopoiesis in the early embryo. At later stages,
haematopoietic stem cells migrate to the liver, and finally populate the adult spleen and
bone marrow. In all of these organs, the haematopoietic progenitors are marked by
high levels of expression of TGFySl RNA. This is particularly pronounced in
proerythroid progenitors and megakaryocytes [26,27,30]. Since TGF/I1 is known to be
a potent inhibitor of haematopoiesis [44], it is likely that this growth factor acts as an
autocrine negative regulator of cell growth. Its presence at a time of rapid cell division
may be necessary for controlled proliferation and/or differentiation.
Neither TGF/72 or pi RNAs have been detected in haematopoietic tissue of mouse
or man [30,31].
VASCULARIZATION AND ANGIOGENESIS
TGFP elicits an angiogenic response in vivo when injected subcutaneously [45],
though it is not known whether this is a direct response of the endothelial cells, or
secondary to events initiated in other cell types, such as macrophages [46], Clearly, in
situ hybridization studies would suggest that TGF/J1 is not only an endogenous
autocrine regulator of vascularization and angiogenesis, but that this growth factor
may serve such a role prior to the appearance (and thus involvement) of other cell
types. Expression ofTGFp\ RNA is seen in endothelial cells of the blood islands as the
extraembryonic blood vessels are laid down, and in the cardiogenic plate of the embryo
proper at 7.5 days p.c. [37]. This expression is detectable very soon after the appearance
of the three definitive germ layers and before overt differentiation of cell types,
implicating this growth factor as a very early modulator of vascularization.
During vascularization and angiogenesis, endothelial cells perform several
functions, all of which may be modulated by TGF/?. These include cell proliferation,
tube formation, protease production and extracellular matrix production. Studies of
TGF/?1 bioactivity on endothelial cells in vitro have been confused, since the cellular
response depends on the precise culture conditions. In general, it can be summarized
that TGF/?1 inhibits endothelial cell proliferation in a 2 dimensional (2-d) but not in a
3-d culture system, suggesting that TGF/?1 is an endogenous autocrine negative
regulator of endothelial cell growth. In addition, in the 3-d culture system TGF/?1
promotes capillary-like tube formation [47,48].
The endothelial cell response to TGF/? is clearly isoform-specific in vitro. Though
TGF/?1 is a potent growth inhibitor of this cell type, at physiological concentrations,
TGFpi shows no such activity [49], In this respect, it is notable that, of the three TGF/?
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isoforms, only TGF/31 RNA is detectable in endothelial cells [30,31]. This may give
support to the theory that differential expression patterns within the embryo are related
to functional specificity in vitro.
CARDIAC DEVELOPMENT
Progenitor cells of the mammalian heart appear in the splanchnopleuric mesoderm
very early in embryogenesis, immediately following gastrulation. These cells become
organized into two primitive tissue types, the endocardial tube which is encapsulated
by the myocardial mantle. Initially, the endothelial and myocardial layers are
separated by an extensive acellular basement membrane, the cardiac jelly. However,
there is an early regional differentiation of the endothelium, such that some cells
overlying areas which will give rise to the future septae and valves undergo a
phenotypic transformation and infiltrate the cardiac jelly to form mesenchymal
cushion tissue.
The mechanism of endothelial-mesenchymal transformation in chicks has been
extensively studied by Markwald and his collaborators using an in vitro culture system
[50-52]. It has been shown that a signal, arising from the myocardium, induces the
overlying endothelium to undergo the transformation event. The inducing signal is
produced in a regional manner ie. only from the myocardium of the atrioventricular
(av) junction region and outflow tract. Furthermore, only the endothelia of the av
junction and outflow tract, but not the atrial or ventricular endothelia, are competent
to respond to this signal. Various lines of evidence suggest that TGF/3s may be central
to the events leading to the formation of mesenchymal cushion tissue and subsequent
cardiac morphogenesis.
Potts and Runyan [53] performed tissue recombination experiments with dissected
embryonic chick hearts. They demonstrated that, although ventricular myocardium
could not induce mesenchymal transformation of av endothelium, ifTGF/Iwas added
to the assay the transformation proceeded. Additionally, they showed that antibodies
which block the activity of TGF/3s could also prevent the in vitro transformation of av
endothelial cells induced by av myocardium. Thus, it appears that one of the TGF/Js
was, at least partly, involved in this regional transformation event.
Immunolocalization and in situ localization of murine TGF/I proteins and RNAs
has also shown that both TGF/31 and pi are localized within tissues which contribute
to endocardial cushion tissue formation [23,26, 31, 37] (summarized in Fig. 1). TGF/31
RNA is expressed ubiquitously in endocardial cells at early stages. This expression
subsequently becomes restricted to endocardial cells which overly cushion tissue, and
this restricted pattern persists in the cardiac valve leaflets until 1 week post-natally [37].
TGF/31 expression is not limited to the period of cushion tissue induction and is thus
unlikely to be involved in the inducing event per se. Its expression appears to be
correlated with morphogenetic movements of the endothelium and mesenchyme.
Endothelially-synthesized TGF/31 protein is mainly localized in the underlying cushion
tissue [23, 37], and this is correlated with the localization of extracellular matrix
proteins, such as tenascin [37]. the function of TGF/I1 may, therefore, be to regulate
growth of the endothelium in the vicinity of the heart valves, and to modulate
production of extracellular matrix in cardiac cushion tissue, thus favouring tissue
movements essential to remodelling of the heart.
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FIGURE 1. Schematic representation of the developing heart showing the pattern of expression of TGF p\ and
pi during atrioventricular valve (av) formation. As early as 9.5 days p.c., before overt appearance of
mesenchymal cushion tissue, there is a regionally restricted distribution of the TGF pi transcripts within the
myocardium underlying the av valve. TGF/tl transcripts are localized to the endothelium (part a). The peak of
cardiac TGFpi RNA occurs at 10.5 days p.c., with a clear spatial restriction pattern to myocardium underlying
mesenchymal cushion tissue (part b). By 14.5 days p.c. there is no expression of TGF/32 in the myocardium
surrounding the av valve, transcripts being restricted to the mesenchyme of the cushion tissue (part c). TGF/31
RNA is still expressed in the endothelium at this stage and up to at least one week after birth, a = atria; v =
ventricle.
In situ localization ofmurine TGF/J2 RNA, however, makes it a strong candidate for
a component of the inducing signal. This gene is expressed transiently, and in a
regionally-restricted manner, in the myocardium underlying the av junction and
outflow tract at the time of cushion tissue formation. To a lesser extent, it is also
expressed in the cushion tissue per se [31].
Since we have shown that av endothelium is a source of TGF/31, it is surprising that
there is a requirement for additional TGF/? in the bioassay used by Potts and Runyan
[53]. This might be explained by species differences between mammals and avians,
latency of the TGF/?1 protein, requirements for a certain threshold level of TGF/? or
requirements for specific isoforms and/or cross-induction of the different TGF/?s [2,
54].
c.
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SKELETAL DEVELOPMENT
TGF/J is known to have multiple biological effects on mesenchymal cells,
chondroblasts, osteoblasts and osteoclasts, affecting cell proliferation, movement,
differentiation, secretion of extracellular matrix molecules and even influencing
developmental fate of osteoblast progenitor cells [55-57], Furthermore, adult bone is
one of the richest sources of this growth factor. It is, therefore, not surprising that all
three TGF/? isoforms, plus the BMP family members [58], are expressed in areas of
chrondrification and ossification. Expression ofeach isoform is, however, very specific,
both with respect to the cell type, its state of differentiation and body site (see Table 1).
TABLE 1. Differential localization of RNAs encoding TGF pi, pi and p3 during murine
embryogenesis.
pv >S245 £34'5
Haematopoietic tissue + — —
Endothelia + — —




Whisker follicles + ■ ■
Salivary gland + +
Tooth bud + + -
Secondary palate2 + - +
Bronchial epithelium — + (s) + (c)
Optic epithelium — + -
Olfactory epithelium — + -
Lens epithelium — + -
Retina — + —
Hyperplastic nodules - + 2 -
Suprabasal keratinocytes - + 3 -
Cartilage and bone
Pre-cartilaginous blastema - + (limb) + (iv)
Growth zone of long bone - + —
Perichondria - +
Hypertrophic cartilage - -
Osteoblasts, osteoclasts • — —
Cardiac tissue
Pre-valvular endothelium + — -
Pre-valvular myocardium - + -
Neuronal tissue
Ventral spinal cord - + -
Ventral fore-brain — + —
Muscle - ( + )6 ( + )'
Mesothelia - +
Mesenchyme — + +
Notes; + denotes that RNA is abundant at some stage between 9.5 daysp.c and birth, though
expression may be transient. — is below the detection level of in situ hybridization.
' Data taken from [25-27].2 Data taken from [29].3 Data taken from [28].4,5 Data taken from
[30,31].6 Low levels of hybridization are seen in some muscular tissues at some stages, but this is
not abundant or ubiquitous,
c = cuboidal; s = squamous; iv = intervertebral disc anlagen.
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TGFpi and Pi appear to be involved in early stages of formation of the skeletal
system, including the condensation of mesenchymal cells to form cartilage precursors
[30,31]. For example, both of these genes are expressed in pre-cartilaginous blastemae;
TGF/32 RNA is seen in the limb buds, whereas TGF/J3 is expressed in the intervertebral
disc anlagen [30, 31], In this respect, it is interesting that both TGF/22 and, to a lesser
extent TGF/B, are expressed at mesenchymal sites involved in cell proliferation,
migration and condensation, such as facial and palatal mesenchyme [29-31]. TGF/? is
known to stimulate proliferation and chemotaxis of mesenchymal cells in culture [59,
60] and, indeed, TGF/?1 and pi were earlier isolated as factors that could induce the
formation of chondroblasts from muscle from muscle mesenchymal cells in culture
[61].
In contrast, TGF/?1 expression is associated with more overtly differentiated cell
types in areas of ossification, namely osteoblasts, osteocytes and osteoclasts [25, 26,
30]. It has been reported that TGF/?2 is also expressed in these cell types [28], though
this has been questioned by others [30, 31]. Unlike TGF/?2 and pi, TGF/?1 is, thus,
more likely to be involved in control of osteoblast/osteoclast function, including bone
remodelling which continues in the adult, and is influenced by osteotropic hormones
[62].
TGFpS IN EPITHELIA AND IN EPITHELIAL-MESENCHYMAL
INTERACTIONS
It has long been recognized that TGF/?1 is growth inhibitory to most epithelial cell
types in vitro and in vivo [22,63,64], This observation has now been extended to include
TGF/J2 and pi, which are, in fact, more potent negative regulators of epithelial cell
growth than TGF/?1 [18]. Additionally, some epithelial cell types are induced to
differentiate by TGF/?[65-67]. It is, therefore, an interesting observation that all three
TGF/? RNAs are expressed at high levels in various embryonic epithelia, often at times
of rapid epithelial cell growth (see Table 1) [26, 28-31]. This has raised the question of
whether epithelially-synthesized TGF/?s are involved in regulation of growth and/or
differentiation of the epithelium per se, or in paracrine modulation of the adjacent
stroma.
Epithelial-Mesenchymal Interactions
TGF/?1 was the first of the isoforms reported to be synthesized in epithelial cells in
vivo [68]. Surprisingly, the RNA is transiently detected, at high levels, in several
specialized epithelia at times of most rapid cell division. Two circumstantial lines of
evidence suggest, however, that the major function of the encoded protein is in
paracrine interactions with the adjacent mesenchyme. Firstly, the RNA is only seen in
epithelia that are actively involved in morphogenetic interactions with the adjacent
mesenchyme, such as the salivary gland, tooth bud, whisker follicle and secondary
palate [26, 29] (see Fig. 2). Secondly, in each of these situations the encoded protein is
localized in the adjacent mesenchyme [23],
Bearing in mind the caveats with interpretation of in situ localization and
immunolocalization data already discussed, bioactive TGF/?1 may act on the
underlying mesenchyme in a variety of ways. It can induce proliferation, differentiation
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FIGURE 2. Diagrammatic representation of the role of the TGF/? family in palatogenesis. The line drawings
represent coronal sections through the midpalate at the gestations (in days indicated above the drawings. The
diagrams show the palatal shelves (ps) growing down beside the tongue (to) and then elevating to fuse between
the tongue and nasal septum (ns). The filled black areas illustrate TGF/J3 expression, diagonal striping for
TGF/J2 and stippled areas for the combined expression of TGF/J1 and /33.
and chemotaxis of mesenchymal cells [56, 59, 60], each of which occurs during
morphogenesis. Secondly, it has a major effect on the elaboration of the extracellular
matrix (ECM) and on the synthesis of cell surface receptors for ECM components
(reviewed in [1]).
It is widely accepted that ECM composition can influence cell-cell and cell-
substratum interactions, resulting in differences in cell migration or stabilization of
organ structure. Studies in organ culture have emphasized the importance of ECM
composition on branching morphogenesis of lung and salivary gland. It has been
shown that collagen type III, for example, is essential to cleft formation in the
developing salivary gland [69, 70].
Subsequent to studies on TGF/31, it has been shown that, in each of the cases where
this gene is activated in embryonic epithelia, the RNA co-localizes with that ofTGFpi
and/or pi [29-31] (see Table 1). A good example is the transient epithelial expression of
TGF/J1 and pi during formation of the murine secondary palate [29] (Fig. 2.). Both of
these genes are transcribed in the medial edge epithelium of the palatal shelves, as they
form, elevate and fuse, and also in the epithelium of the anterior nasal septum, which is
destined to fuse with the palate. No information exists on the localization of the
corresponding TGF/I3 protein, but one might assume that the two isoforms serve
similar paracrine functions within the palatal mesenchyme, stimulating cell
proliferation and tissue migration [29].
As in the aforementioned cases (Table 1), epithelially-synthesized TGF/J1 protein
co-localizes in the mesenchyme with the ECM component, tenascin, which is one of the
many ECM-encoding genes which is transcriptionally up-regulated by TGF/J[71]. This
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bservation is particularly significant since tenascin is known to disrupt epithelial sheet
mtinuity [72] and to promote the mobility of neural crest-derived cells [73]. Each of
tese bioactivities is obviously important in morphogenesis of the palate, salivary
land, tooth and whisker follicle.
The Lung and Mammary Gland
The lung and mammary gland represent two further organs in which TGF/Js might
lay a central role in morphogenesis. Heine et al. [24], on finding co-localization of
xtracellular TGFp\ protein with collagens I and II III, fibronectin and proteoglycans
l the embryonic lung, have suggested that the ECM-directed branching of this organ
; controlled, in part, by epithelially-synthesized TGF/I1. Although TGF/% are most
irobably involved in lung morphogenesis, the cellular source of the growth factor(s)
nd the isoform involvement may be debatable.
No expression of TGF/ff RNA has been detected in bronchial epithelia, though
/idespread expression is seen in the stroma [26, 31]. In contrast, both TGFyS2 and
~GFpi RNAs are expressed in bronchial epithelia, albeit in different cell types (Fig. 3).
epresent sagittal sections through lungs from 12.5 days p.c. to 16.5 days p.c. TGF/J1 RNA is restricted to the
lesenchymal cells of the lung most notably at 14.5 days p.c. when the lung is not fully mature. TGF/33 RNA is
een submucosally in the trachea and proximal bronchi at 12.5 days p.c. Simultaneously, intense expression is
•en in the immature columnar epithelial cells of the growing bronchioles (a). As lung outgrowth proceeds,
GF/53 RNA expression remains restricted to the columnear epithelial cells of the proximal respiratory tree. No
GF/J3 expression is seen in the simple cuboidal epithelia of the growing terminal end buds (b). TGF/32 is
;stricted entirely to the simply cuboidal cells of the terminal end buds (b), and thus by 16.5 days p.c., expression
sems widespread due to the highly differentiated state of the lung (c). t = trachea; b = bronchiole; br =
ronchi; e = terminal end bud.
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TGF/B RNA expression is limited to the immature columnar epithelia cells of the
proximal respiratory tract in the early mammalian lung [30, 31]. In contrast, TGF/32 is
seen in the cuboidal epithelium of the growing terminal end buds and in the
differentiating alveolar epithelium [31].
Since TGF/J is a potent inducer of bronchial epithelial cell differentiation [66], it is
tempting to speculate that this is the endogenous role of TGF/32 in the differentiating
alveoli. However, each of the three isoforms might also be required for control of
epithelial growth or branching morphogenesis. At present, no protein localization data
exist for TGF/E or /J3, and no studies on embryonic pulmonary TGF/3 function have
been reported in vivo or in organ culture.
In the mammary gland, a different experimental approach has been taken. As
described earlier, using plastic implants impregnated with active TGFft in vivo, it has
been found that this growth factor has profound effects on terminal end bud growth,
which could not only affect extent of growth, but also the branching pattern of the
organ [22]. The response of the epithelial cell was dependent on the exact cell type and
position within the mammary gland. As yet, however, the endogenous isoform
distribution of TGF/i RNAs or proteins has not been mapped for this developing
organ.
Auto-Regulation ofEpithelial Growth and Differentiation
Several circumstantial lines of evidence suggest that TGF/2 might be endogenous
auto-regulator or epithelial growth and/or differentiation. Glick et al. [74] have
demonstrated that TGFpi levels are elevated in vitro and in vivo in keratinocytes
treated with retinoic acid or calcium ions, which induce growth arrest and
differentiation, respectively. Secondly, in the embryo, TGFffl RNA levels are very high
in the differentiating epithelial component of several established structures. These
include epithelia of the sense organs, lung alveolar epithelium [30, 31], hyperplastic
nodules (rugae) of palatal oral epithelia [29], and supra-basal keratinocytes [28] (see
Table 1). Furthermore, where it is possible to distinguish the differentiation and
dividing cell compartments, it appears that the differentiated cells are the source of this
growth factor. Bearing in mind the strong negative growth regulation exerted by
TGF/fe on epithelial cells, one might imagine a situation where TGF/32, produced from
differentiated epithelial cells, acts on the dividing cell compartment in a paracrine
feedback loop, as suggested previously for TGF/31 [68]. The localization of TGF/22
protein within the epithelium per se, following retinoic acid treatment of adult mouse
skin, would give support to this theory [74].
NEURONAL DEVELOPMENT
The presence of TGF/22 RNA within the sensory epithelia of the ear, eye and nose
(Table 1) could be correlated with differentiation of the epithelium, as discussed above,
or be associated with the innervation of the epithelium. It is interesting that TGF/I2
RNA is expressed transiently in the ventral nervous system of the early mammalian
embryo [30, 31], and that TGF/J2 and pi proteins have been detected immunohisto-
chemically in central and peripheral nervous systems [75]. Flanders et al [75] suggested
that these growth factors are important in the regulation ofneuronal cell migration and
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differentiation and of glial cell proliferation and differentiation.
CONCLUSIONS AND PROSPECTS
In summary, it can be stated that, in vitro, each of the mammalian TGF/fe possesses
quantitative, if not qualitative, functional specificity, and, in vivo, that each isoform has
a distinct temporal and spatial pattern of expression throughout mammalian
embryogenesis. The extreme amino acid sequence conservation of individual isoforms
between vertebrates, as compared with isoform variation with individual species,
coupled with the conservations ofembryonic expression patterns within mammals [30],
would suggest that, indeed, each isoform has a distinct function in vivo.
To test this proposition, it is essential that more functional studies are carried out,
for example using organ culture to examine epithelial-mesenchymal interactions, or
transgenic mice to manipulate isoform expression or isoform function.
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